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ABSTRACT

An abstract of the dissertation of John Patrick Fitzgerald for the Doctor of Philosophy
in Systems Science: Psychology presented April 10, 2007.

Title: A Multilevel Analysis of Individual and Organizational-Level Effects on Staff
Attitudes Towards Use of Medication in Substance Abuse Treatment

Studies consistently indicate a general lack of support for use of medications in
the treatment of substance abuse disorders by clinicians, patients, and other
stakeholders involved in treatment. Both individual and organizational factors have
been shown to influence attitudes towards medications, but the relative contribution of
each of these factors remains unclear. Whereas previous studies, by their very design,
have generated multilevel data structures, they nevertheless have employed analytic
strategies that ignore the multilevel dependencies inherent in such data sets.
To address these limitations, this study took a multilevel approach to
investigate the influence of individual and organizational factors on treatment staff.
Organizational survey data from the National Drug Abuse Treatment Clinical Trials
Network workforce surveys, including 1,421 workforce staff nested within 237
treatment units, were analyzed using hierarchical linear modeling.
Results of the present study suggest that attitudes towards addiction
medications are influenced by both individual and organizational factors
simultaneously, albeit the more significant determinants reside at the individual level.

In addition, this study found evidence that a unique blend of factors (individual and
organizational) exists for each medication, although two variables proved to be robust
predictors across all medications. Higher levels of academic education and support for
psychiatric medications were associated with more positive attitudes towards addiction
medications. Evidence was also found that staff attitudes towards addiction
medications varied significantly between treatment units.
The overall design of the present study was informed and guided by a systems
methodological framework, and in this setting, implications for increasing support for
addiction medications in practice were also considered and are discussed.
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Chapter 1: Introduction
Substance abuse is a persistent public health problem, affecting approximately
20 million people at any given time (Institute of Medicine, 2006; Substance Abuse and
Mental Health Services Administration, 2005), and costing the United States billions
of dollars annually (Institute of Medicine, 1998, 2006). Much of this expense can be
linked to crime, lost worker productivity, healthcare, and a wide range of other social
ills. But the costs are not just monetary. Those who abuse drugs risk losing intimate
relationships, self-esteem, and ultimately their life. The social damage is even more
staggering when considering the millions of children of substance abusers that must be
factored into the equation. Taken together, substance abuse ranks among the leading
causes of suffering in society. Of those who suffer with a substance abuse or
dependence disorder, only about 15% receive any kind of professional treatment
(Institute of Medicine, 2006; Substance Abuse and Mental Health Services
Administration, 2005). Unfortunately, the inability to treat a greater percentage of
those in need of help is not the only problem with the present substance abuse
treatment system.
In 1998, a report by the Institute of Medicine (IOM) revealed significant
deficiencies in the U.S. substance abuse treatment system (Institute of Medicine,
1998). Most notable were gaps in quality of care due in large part to a disconnect
between scientific knowledge and clinical practice. The report detailed how
interventions that had consistent empirical support, most commonly referred to as
evidence-based practices (EBPs), were significantly underutilized by the substance
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abuse treatment community. EBPs involve the “conscientious, explicit, and judicious
use of current best evidence in making decisions about care of individuals” (Sackett,
Richardson, Rosenberg, & Haynes, 1997, p. 2). In contrast, the IOM report provided
evidence that many substance abuse treatment providers relied instead on authoritybased practices, where interventions are based on anecdotal experience, opinions of
others, popularity, and unchecked intuition (Gambrill, 1999).
Since the publication of the IOM report, there has been a significant push from
government sponsored agencies such as the National Institute on Drug Abuse (NIDA),
the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the Center for
Substance Abuse Treatment (CSAT), and the Substance Abuse and Mental Health
Services Administration (SAMHSA) to bridge the gap between practice and research.
This dissertation documents many of those efforts, and suggests there is reason to
believe the gap is starting to close. Yet in spite of such progress, there remains a
consistent lack of support by clinicians and other treatment staff for use of EBPs in the
care of individuals with substance use disorders. Several reviews of EBPs specific to
substance abuse treatment have reported a wide range of interventions that improve
treatment outcomes (Institute of Medicine, 1998; Miller, Brown, Simpson, & et al.,
1995; Miller & Wilboume, 2002; Power, Nishimi, & Kizer, 2005). Further, the
reviews have shown that specific EBPs have consistently been linked to better
treatment outcomes, including brief interventions, specific psychosocial therapies
(e.g., community reinforcement approach, motivational enhancement, skills training),
and pharmacological interventions (Miller & Wilboume, 2002).
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Of the different EBPs, use of medications in the treatment of substance abuse
disorders represents one of the largest gaps between research and practice. The IOM
report illustrated how methadone maintenance therapy, considered among the most
effective of all addiction interventions, has struggled to gain widespread acceptance
due to stringent federal regulations, ideological barriers, and lack of funding.
Naltrexone, approved by the Food and Drug Administration (FDA) in 1994 for the
treatment of alcohol dependence, has consistently been shown to improve clinical
outcomes when used in conjunction with psychosocial interventions, yet it remains
significantly underutilized in practice. These medicines, in addition to many new
pharmaceutical agents currently in development, have the potential to help millions of
people, but only to the extent they become utilized and supported by the treatment
community.
As a practicing clinician treating primarily substance abuse disorders for over
eight years, it was not uncommon for me to see patients who had been in treatment
multiple times for alcoholism who had never even heard of naltrexone. Often, these
patients had received treatment at some of the most prestigious programs in the
country. Numerous times I witnessed how the addition of naltrexone to the patient’s
psychosocial therapy program significantly improved the clinical outcomes (i.e.,
relapse rates decreased, quality of life measures increased). In addition, I have
experienced first-hand many of the attitudes against using addiction medications while
traveling to conferences and presenting workshops to clinicians on good treatment
practices. Quite often I have been left frustrated as further discussion with clinicians
(
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revealed how little the attitudes are based on scientific knowledge, and how strongly
they are correlated with personal experience and myth. Based on empirical evidence
explored in detail in this dissertation, there are a number of addiction medicines that
when combined with psychosocial interventions, can improve clinical outcomes. I
believe patients should at the very minimum be told these medicines exist and be
given a choice whether to pursue the use of them in their treatments, particularly if
psychosocial interventions alone have historically failed. This belief in large part
motivates the present study.
This dissertation focuses on improving the understanding of attitudes towards
use of medication in substance abuse treatment. The intent here is not one of
promoting use of medications as the only useful EBP, nor is the intent to lessen the
credibility of existing psychosocial interventions. Rather, the focus is on discerning
and assessing variables that may inhibit and/or facilitate the appropriate use of
addiction medications. Such medications are known to consistently rate among the
most effective EBPs. Yet, they are also among the most underutilized in routine
clinical practice. In a recent review of interventions for alcohol use disorders, Miller
and Wilboume (2002) found that use of medications ranked third and fourth out of 46
different treatment interventions (higher ranking indicating better treatment outcomes
from clinical trials). Yet as the literature review in this dissertation illustrates, there is
a consistent lack of support for appropriate use of addiction medications in practice
despite the evidence o f their effectiveness.
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As a step toward providing a balanced perspective, this dissertation also
provides material related to the potential downsides of increasing medication use.
Studies related to medication errors are reviewed in Section 3.1.1, and Section 7.4
explores potential unintended consequences that can arise from medication use. Such
consequences include: (a) an over-reliance on use of medications; (b) without buy-in
from impacted stakeholders, well-intended policy decisions may lead to adverse
outcomes; (c) unbalanced consideration of the benefits, risks, and costs; (d) abuse and
diversion of opioid medications; and (e) complex dosing may lead to non-adherence
and increased likelihood of relapse. Such issues must be considered among the
possibilities when attempting to optimize patient outcomes.
Existing research suggests that both individual staff characteristics and
organizational attributes play a role in attitudes towards medication, but the relative
contribution of these factors remains unclear. To better understand these factors and
leam why new treatment technologies, including medications, have not become more
widely adopted, researchers have employed the notion of diffusion process, and have
put forth conceptual models specific to substance abuse treatment (Simpson, 2002;
Thomas, Wallack, Lee, McCarty, & Swift, 2003). These models draw heavily on
diffusion theory (Rogers, 1995, 2003), and attempt to illustrate the dynamics involved
in technology transfer. The models include both individual and organizational factors,
but fall short of indicating the degree to which specific factors play a role in the
overall diffusion process.

5
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This dissertation advances these models and fills a gap in the literature by
using a multilevel framework to examine the degree to which individual and
organization-level factors influence treatment-staff attitudes toward addiction
medications. Although past studies have examined treatment-staff attitudes (Forman,
Bovasso, & Woody, 2001; Fuller, Rieckmann, McCarty, Smith, & Levine, 2005;
Knudsen, Ducharme, Roman, & Link, 2005; Mark, Kranzler, Poole et al., 2003; Mark,
Kranzler, & Song, 2003; Mark, Kranzler, Song et al., 2003; Thomas et al., 2003), there
is reason to question the validity of these findings. Most researchers have focused their
investigations at either the individual or organizational level, ignoring the
relationships that exist between levels. As a result, the methods employed in those
studies were based on assumptions that fail to account for the inter-level dependencies
that exist in the real world (i.e., individuals nested within organizations nested within
geographic regions). The present study addressed these problems by examining both
individual and organizational-level factors simultaneously.
Because these multilevel relationships have received little consideration in past
studies, a key objective of this study was to identify, hypothesize, and test
relationships that have some basis of support in the current literature. To accomplish
the above described objectives, this dissertation employed a systems approach to
examine complex problems involving variables at different levels of analysis
(Lendaris, 1986; Senge, 1990; Sterman, 2000). Further, sophisticated multilevel
modeling methods (e.g., hierarchical linear modeling) that appropriately address
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dependencies inherent in multilevel data were utilized (Bryk, Raudenbush, &
Congdon, 2005; Hox, 2002; Raudenbush & Bryk, 2002).
Collection of data related to substance abuse treatment programs in the
National Drug Abuse Treatment Clinical Trials Network (CTN) provided an ideal
resource to model the multilevel determinants of treatment staff attitudes towards
medication. The CTN is an alliance of 120 community treatment programs and 17
research centers whose purpose is to test emerging substance abuse interventions. Data
were collected at the individual, treatment unit, and program levels, but only
individual (N = 1,421) and treatment unit (N= 237) data were used in the present
study. The program-level data was not included, due to the fact that only one variable
of interest existed in that data (primary service setting), and the ability to
accommodate this single factor within a two-level model. Initial analyses of staff
characteristics and attitudes towards use of medication in substance abuse treatment
suggested that treatment staff, in general, were not overly supportive of addiction
medications (McCarty et al., 2007).
Based on the literature review, six individual-level factors (prescriber status,
academic education, addiction continuing education units, job category, and support
for psychiatric medications) and five organizational-level factors (treatment model,
use of methadone, primary care on-site, percent of staff in recovery, and service
setting) were identified as having strong empirical support for predicting medication
attitudes and were tested within a multilevel framework. As hypothesized, this study
provided empirical support for the following:
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1. Individual and organizational factors simultaneously influence attitudes
towards addiction medications. Results indicated that attitudes towards
naltrexone were least influenced by organizational determinants
(8.6%), while more than a third of attitudes towards methadone were
explained at the organizational-level (34.5%), with buprenorphine in
the middle (21.5%). These findings also suggest that the primary
determinants of medication attitudes are individual-level factors.
2. The determinants of medication attitudes are not consistent across
medications. The findings suggest that a unique blend of individual and
organizational factors exist for each medication, although some specific
factors are robust predictors of attitudes across all medications. This
would also suggest that no one intervention to increase support for
pharmacotherapy would be successful across all medications.
3. Higher levels of academic education and support for use of psychiatric
medications are among the most important factors influencing attitudes
supportive of addiction medications. Many of the payees of addiction
treatment services have also recognized that graduate-trained
counselors are better trained to deliver EBPs, including treatment of
mental health disorders, and provide the best cost-benefit outcome for
their expenditures. As a result, contracts for services are increasingly
requiring that services be delivered by graduate-trained clinicians. The
present study provides further support for this latter trend.
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4. Staff attitudes towards addiction medications vary between treatment
units. Findings pointed to some of the variability between treatment
units for naltrexone and methadone being explained by differences in
academic education and attitudes towards psychiatric medications, but
additional research is needed to further understand the variability
between treatment units.
5. Existing models illustrating the factors and processes involved in the
adoption of addiction medications could be improved by incorporating
factors and processes that more carefully operationalize the
relationships between variables, and take into consideration the unique
attributes of each medication.
6. A systems approach offers the best framework for examining the
complex nature of attitudes towards addiction medications, and for the
development of interventions to increase support for addiction
medications.
The following chapters begin with an exploration of what is meant by a
systems approach (Chapter 2). The limitations of existing literature are discussed in
more detail, and the lack-of-support-for-addiction-medications problem is defined
more precisely within a systems framework. The contributions of a systems approach
to problem solving and intervention development are also presented. The formal
literature review (Chapter 3) then examines studies relevant to the context in which the
problem being studied is found, and additionally, reviews the current FDA approved
f
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medications to treat substance abuse disorders. Central to Chapter 3 is a review of
existing studies that have examined treatment staffs lack of support for addiction
medicines, and a discussion of diffusion theory that is inherent in that body of
research. The chapter concludes with an overview of the origin of the data set used in
the present study. The dissertation continues with a formal problem statement
(Chapter 4), overview of the method employed (Chapter 5), and results (Chapter 6).
Finally, the discussion (Chapter 7) summarizes the contribution of the findings, and
what they say about how best to increase appropriate use of addiction medications.
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Chapter 2: The Systems Approach
The systems approach is a way of thinking about complex problems and a
methodology for developing optimal solutions to those problems. It involves a special
type of thinking, often referred to as systems thinking, that makes use of several tools
to gain powerful insights into the nature of a problem (Richmond, 2001). In essence, it
does this by examining the system in which a problem occurs, identifying the core
parts of the system, and how they work together to manifest the attributes of the
system. Thus, knowledge of a system is both a prerequisite and an ongoing
requirement critical to systems methodology, which broadly involves the design,
construction, implementation, and optimization of an effective solution to a problem
(Hall, 1989). Such an approach is most appropriate for problems that are complex,
meaning they involve multiple variables that interact over time in ways that can be
challenging to predict. Examples include living systems, social systems, and the
problem of underuse of addiction medications in substance abuse treatment examined
in this study. The more that is known about a system, the easier it is to decide how to
intervene. Before elaborating on the systems approach and how it guides the present
study, it is first useful to consider why such an approach may be necessary.
2.1 The Need for a Systems Approach
Efforts to study treatment staffs lack of support for use of addiction
medications in substance abuse treatment programs have relied almost exclusively on
survey research methodologies. The approach has led most researchers to focus their
efforts at the individual level, or the level where prescribers of medication or other
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individuals who may influence prescribing decisions reside (e.g., physicians,
counselors, program administrators). Questionnaires have commonly been used to
learn about attitudes and behaviors related to medication use, and typically the results
are analyzed without regard to dependencies that exist in the populations surveyed
(Forman et al., 2001; Fuller et al., 2005; Mark, Kranzler, Song et al., 2003; Thomas et
al., 2003). Although this approach has led to a list of reasons why medications are
underutilized in practice, it also has suffered from a number of methodological
limitations that have hindered further understanding of this issue and the development
of interventions to increase support for medication use.
The overemphasis on individual-level variables has resulted in few studies that
have investigated the contextual or group-level effects that exist within organizations,
and that may also influence prescribing attitudes and behaviors. Existing studies
provide evidence that factors such as size (Fuller et al., 2005), funding source (Fuller
et al., 2005; Thomas et al., 2003), and patient population of the treatment organization
(Roman & Johnson, 2002) can influence usage of medication. But the failure to study
the problem from both an individual and organizational perspective simultaneously
has resulted in study outcomes that do not account for the relationships that exist
between levels or the real-world complexity of the problem. This issue has been raised
by Kozlowski and Klein (2000) who have argued that organizational research has
commonly approached problems either from a micro (individual level) or macro
(group/organizational level) perspective, when neither approach adequately accounts
for organizational behavior. More specifically:

Chapter 2: The Systems Approach

13

The macro perspective neglects the means by which individual behavior,
perceptions, affects, and interactions give rise to higher-level phenomena.
There is a danger of superficiality and triviality inherent in
anthropomorphization. Organizations do not behave; people do. In contrast,
the micro perspective has been guilty of neglecting contextual factors that can
significantly constrain the effects of individual differences that lead to
collective responses, which ultimately constitute macro phenomena
(Kozlowski & Klein, 2000, p. 7).
A consequence of ignoring the multilevel framework in which substance abuse
treatment organizations exist is that the relationships or dynamics that occur between
variables at different levels have received little attention. In part, this is related to the
challenges of disentangling the separate and joint effects of predictor variables at
different levels. Only in the past decade have sophisticated multilevel modeling
programs with the ability to more accurately separate out individual and group-level
effects in multilevel data found their way into organizational research (Raudenbush &
Bryk, 2002). With the ability to model both individual and group (or organizational)
level predictors simultaneously, it is now possible to gain a clearer understanding of
how variables at different levels influence individual attitudes about medication. Even
more, such an approach provides valuable insight into the degree to which specific
variables contribute to attitude outcomes. Such knowledge can then be used to design
more effective interventions aimed at increasing support for use of medications in
substance abuse treatment.
Before reviewing the current literature specific to addiction medications in the
next chapter, it is important to understand why outcomes from these prior studies may
be misleading and the approach offered here is necessary. As mentioned above,
previous studies have relied almost exclusively on statistical methodologies that
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assume independence o f observations. This assumption means that, for any two
observations within a sample population (i.e., individuals, treatment units, or
programs), knowing how one of these observations stands relative to the sample
population mean tells us nothing about the other observation (Howell, 2002). In other
words, knowing the score of a survey from one individual gives you no information
about any other individual’s survey score. But the referenced prior studies have relied
almost exclusively on survey data of individuals and organizations that have inherent
dependencies. For example, it is often true that more than one individual from an
organization is included in a study population; clearly, by nature of working in the
same program, the experience of those individuals are likely to have a relationship.
Thus, the independence of their responses should be suspect. Likewise, programs
existing in one state may be very similar to each other (e.g., because of legislative
policies dictating medication practices, similar funding mechanisms) compared to
programs that were randomly sampled from all 50 states. By ignoring these
differences and treating all individuals or organizations in a data set as independent,
estimates of the standard errors of conventional statistical tests are much too small,
leading to a higher probability of rejection of the null hypothesis (Raudenbush &
Bryk, 2002).
Nevertheless, researchers have analyzed, and continue to analyze multilevel
data sets using traditional multivariate regression techniques. In such cases, analyses
are accomplished by either aggregating the individual level data up to the group level
using a metric like the statistical average, or disaggregating the group level data down
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to the individual level in a similar manner (i.e., all individuals would receive the same
average score for a group predictor variable). However, neither approach accurately
represents the data, because aggregation results in the potential loss of meaningful
variability in individual data, while disaggregation violates a number of statistical
assumptions and yet makes inferences about higher level variables based on lower
level data (Griffin & Hofmann, 1997; Raudenbush & Bryk, 2002). Multilevel
modeling was developed to overcome the above issues, and to accurately model both
individual and organizational predictors simultaneously. The power of multilevel
modeling is that it not only attempts to explain the differences between groups, but at
the same time attempts to explain the differences that exist within groups.
This study advances the present literature by using multilevel modeling to
investigate the variance both within and between treatment units by testing
relationships between multilevel variables. A central hypothesis is that the degree to
which individual-level variables accurately predict attitudes about addiction
medications depends on specific organizational factors. In other words, the importance
of education, professional discipline, and addiction-specific education (i.e., all
individual-level predictors) depends on whether a treatment program is part of a
hospital or medical clinic, has on-site primary care, and the general intervention
approach used by treatment staff.
In addition to ignoring the relationships between multilevel variables and the
statistical implications of multilevel data, prior studies focusing on lack of support for
addiction medications have given scant attention to the additional challenges inherent
/

Chapter 2: The Systems Approach

16

in designing effective intervention strategies aimed at increasing support for use of
addiction medicines. Even with a clearer understanding of the factors that most
influence attitudes, knowing how to intervene, be it an individual, treatment program,
or group of programs, is not so simple. Sterman (2000) has pointed out how even well
designed interventions often have unintentional side effects or consequences when it is
difficult to foresee how a change in one part of a system impacts other parts of the
system. For example, a newly hired and well-meaning treatment director may take
steps to increase use of addiction medications by hiring a part-time prescriber,
conducting staff trainings on the benefits of medication use, and issuing a clinic policy
requiring that addiction medications be considered as a core component of treatment.
Months later, the director may be perplexed when staff turnover doubles and patient
dropout rates increase.
Quite often such outcomes arise when those directly impacted by a policy
decision are not included in decision-making processes that affect them. Whether it is
the counselors or the patients, without a clear understanding of how these two groups
(or parts of the system) feel about addiction medications, any sole decision by a
director is likely to result in unintended consequences. It may be that counselors (and
patients) historically have opposed medications in favor of spiritual interventions (e.g.,
12-step approach), but the point of this example is that changes in one part of a system
often have unanticipated effects for the entire system. The late biologist Lewis
Thomas wrote:
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When you are confronted by any complex social system, such as an urban
center or a hamster, with things about it that you’re dissatisfied with and
anxious to fix, you cannot just step in and set about fixing with much hope of
helping. This realization is one of the sore discouragements of our
century... You cannot meddle with one part of a complex system from the
outside without an almost certain risk of setting off disastrous events that you
hadn’t counted on in other, remote parts. If you want to fix something you are
first obligated to understand.. .the whole system.. .Intervening is a way of
causing trouble (Thomas, 1974, p. 90).
If we are to follow the wisdom of Dr. Thomas, a systems approach is critical
for a number of reasons. First, the problem of lack of treatment staff support for
addiction medications is complex. It involves relationships between patients,
prescribers, organizations, and the larger health care system, all existing at different
levels of analysis. It also includes a technology (medication) that has its own inherent
complexities related to costs, benefits, and risks. Further, all these variables may be
constantly changing, resulting in what Sterman (2000) describes as dynamic
complexity. Problems that are dynamically complex involve many variables that
change simultaneously, resulting in behavior that is challenging to predict. A systems
approach is also necessary to overcome the limitations of traditional research
methodologies, such as: (a) focusing on either the individual or organizational level;
(b) use of statistical techniques that require independence of observations when the
data contain inherent dependencies; and (c) and ignoring the dynamic complexity
inherent in social problems. Finally, a systems approach also offers perhaps the best
available framework for the development of successful interventions.
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2.2 The Systems Approach to Defining the Problem
Central to the systems approach is a need to gain an understanding of the
system in which a problem occurs. Such an understanding is aided by a check-list type
definition of system. For example, a system can be defined as a unit with certain
attributes perceived relative to its external environment, and the unit contains within it
subunits that operate together to manifest the perceived attributes of the unit (Lendaris,
1986). It is important to realize that this definition is observer-dependent, meaning
that whatever system is being defined is based on the perception of the person defining
it. In the present study, I am the one who defines the system in which lack of support
for addiction medication occurs. While there is individual latitude and creativity in the
system-defining process, ideally the defined system is based on empirical research.
Also, important in the definition is the notion of multiple perspectives. Different
people may look upon a system (or problem) differently depending on whether they
are focusing on the parts of the system, the entire system, or the system as it relates to
its defined external environment. It is precisely by examining a problem or system
from different perspectives that a greater understanding of its complexity is attained.
Also, the above definition makes explicit that it is the behavior of the subunits or parts
of a system, that when operating together, manifest the perceived attributes of a
system. This means that a system cannot be understood simply by examining its
individual parts. Imagine understanding how a watch “tells time” if all you were given
was a collection of gears and a small spring. While knowledge of the parts is needed,
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it is even more important to understand how the parts dynamically interact to manifest
the attributes of the defined system.
The above definition also specifies that a system must be defined relative to its
external environment, meaning that the beholder of the system must place some
boundaries around the system. Although the environment is generally defined to be
everything outside of a system, when problem solving, the environment is more
appropriately defined as the relevant environment, or context, in which the problem
occurs (Lendaris, 1986). Previously, the term multilevel was introduced to describe
how researchers have traditionally viewed a phenomenon either from an individual
(micro) or organizational (macro) level. It is now more specifically defined as the
different levels chosen to represent the relevant environment or context of a problem.
Here again, selection of the levels is observer-dependent, meaning that I choose which
levels to include in my relevant environment based on my perception o f the problem,
influenced by the research literature. Variables at each level to be included in the
analytic models will be called multilevel predictors, and the effects those predictor
variables have on each other and the outcome variables will be called multilevel
effects.
Inherent in a multilevel approach is that the levels are organized
hierarchically. This means that lower levels are embedded in higher levels, and that
what is perceived at the higher level emerges through the interaction and dynamics of
the lower-level elements (Kozlowski & Klein, 2000). Put another way, for every level
the defined system has a suprasystem, a system in the above level of which the defined
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system is considered a subunit {subsystem) (Lendaris, 1986). A set of data that
contains information collected at different levels that are hierarchically organized is
defined as a hierarchical data set. Such data are also commonly referred to as
multilevel data or nested data, particularly in the language of multilevel modeling.
In summary, the process of using a systems approach to define a problem
includes: (a) the observer (or researcher) of a problem first drafts what he/she believes
to be the system in which the problem occurs, including the relevant
environment/context; (b) the perceived system and its subunits emerge from a
combination of sources that include: empirical research, theoretical constructs,
commonly held attitudes and beliefs, and the creativity employed by the beholder of
the system; (c) the system is then examined from multiple perspectives, ideally both
by the beholder of the system, and others who have knowledge of the problem/system;
and (d) these efforts occur over time and result in modifications to the perceived
system by the beholder as he or she gains greater knowledge of the system.
In the present study, the system of interest is illustrated in Figure 1:
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Supra-levels Influencing Treatment Staff Attitudes
(Relevant Environment/Context)
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Figure 1. Levels influencing treatment staff attitudes toward use of addiction
medications
Although there are numerous systems embedded within the different levels, the
one that is most pertinent to the present study is the system related to treatment staff
attitudes. The term focal level refers to the system that I, the beholder, am choosing to
focus on in the study, and the system defining the problem of interest. At this level,
attitudes are perceived at the unit-level, while the subunits of that system are found in
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the level below (i.e., sub-level). Eagly and Chaiken (1993) suggested that attitudes
emerge from the combined interaction of affective, behavioral, and cognitive subunits,
and characteristically last for a period of time. The primary attributes of the attitude
system pertinent to this study (also called focal attributes) include evaluating objects
(e.g., value of addiction medications) and influencing behavior. Treatment staff
attitudes also are the dependent variable of interest in the present study, meaning that
an attempt is made to understand what other (independent) variables predict treatment
staff attitudes, specifically the attitudes that do not support use of addiction
medications.
As mentioned previously, the current literature on attitudes toward addiction
medications tends to use research designs that focus on one level of analysis, typically
the individual or organizational-level. Such single-level designs are common in the
literature, but suffer from the limitations discussed earlier. In this study, treatment staff
attitudes are predicted from multiple independent variables occurring on two supralevels: treatment staff and substance abuse treatment units. This top-down, cross-level
research design facilitates the investigation of how higher-level factors may directly
or indirectly affect treatment-staff attitudes (Kozlowski & Klein, 2000). This research
design is well supported by the existing CTN data set described in Chapter 1.
In Figure 1, the relevant environment not only includes the system of interest
and the levels associated with the data set that influence the system of interest, but it
also includes two further supra-levels: the U.S. substance abuse treatment system and
the U.S. health care system. Although no data are analyzed in this dissertation related
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to either of these levels, they nevertheless indirectly influence the study in a number of
ways, and provide a context that significantly contributes to understanding why there
exists a lack of support for addiction medications. In the next chapter, the literature
review begins by detailing how the U.S. health care and substance abuse treatment
systems both struggle with problems related to quality of patient care and the
implementation of EBPs that very much influence attitudes of those working within
these systems.
2.3 The Systems Approach to Problem Solving
Although the primary objective of this research is to gain greater knowledge
about the general lack of support for addiction medications by treatment staff, a
second objective is to explore how the study results can influence the development of
effective interventions to improve this situation. Here, a systems approach refers to the
methodology utilized to achieve an optimal solution to the defined problem.
Expanding on the above definition, a systems methodology refers to all the steps
involved in taking knowledge about a system and applying it to the process of
optimizing a solution. A useful characterization of this process is given as a set of
seven logical steps (Hall, 1989):
1) Problem definition'. Encompasses all the efforts necessary to gain an accurate
picture of the problem, including: defining the system and its life cycle,
identifying the relevant environment, collecting information about costs, risks
and benefits related to stakeholders, and quantifying and clarifying the need
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that creates the problem. In essence, this step answers the question: “Where are
we now?”
2) Value system design'. Involves defining the set of objectives and goals that will
guide the process of identifying options for solving the problem. It involves
defining a vision of the ideal system or solution, and the values that will be
used to guide the process used to reach that optimal solution. This step answers
the questions: “Where do we want to be, what values will guide us in the
process of getting there, and how do we measure attainment of the
objective(s)?”
3) Systems synthesis: Requires exploring different alternatives for reaching a
solution and applies a decision criterion to whether an alternative is viable. It
answers the question: “What are the possible options for solving the problem?”
4) Systems analysis'. Examines the various alternatives delineated in the previous
step by applying the values, goals, and objectives outlined in the second step.
Options are reduced, and the process answers the question: “What are the best
alternatives or options for solving the problem based on where we want to be?”
5) Optimization-. Involves fine-tuning the most viable options for problem
solving, and entails interaction of the previous four steps. This step answers the
question: “How can we optimize the alternative solutions so that each is the
best it can be?”
6) Decision making: Involves evaluating the alternatives as refined in Step 5 and
selecting a solution. Key to this step is the use of decision criteria (defined in

Chapter 2: The Systems Approach

25

Step 2) that allows for all alternatives to be evaluated in the same way. It
answers the question: “What is the ideal solution to the problem?”
7) Planning fo r action: Encompasses all the tasks involved in communicating the
chosen solution to those who will implement it, including allocating the
necessary resources and determining how to monitor the outcomes. It answers
the question: “How best can we implement the solution?”
These steps provide a logical framework for understanding a problem and how to go
about solving it. In the present study, the above steps provide a useful framework for
examining interventions specific to addiction medications (cf. Section 7.3).
Thus far, an assumption has been made that if a problem is understood
sufficiently by using a systems approach, and the above systems methodology is
applied, it is possible to arrive at a useful intervention or solution to that problem. But
consider the words o f Linstone:
When we talk about a “problem” we assume a solution exists. We have been
brainwashed in school: a textbook presents a problem only if there is a
solution (often in the back of the book). Such books do not point out that in
the living world every new solution provided by a technology creates new
problems. Public health measures cut the death rate; but this result, in turn,
fueled a global population explosion. The introduction of European
agriculture techniques in Africa produces food in the short term and
desertification in the long term. It would be more nearly correct to state that
we shift problems rather than solve them (Linstone, 1999, p. 13-14).
Although the intention is not to create more problems by finding ways to increase
support for addiction medications, it would be foolish to not at least consider the
possibility that such an outcome may have some undesirable side effects. As suggested
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above, perhaps the best way to address this issue is by using the systems approach, and
examining the related issues from multiple perspectives.
2.4 Multiple Perspectives
As discussed in Lendaris (1986), the definition of system provided in Section
2.2 entails the need to adopt a variety of perspectives - both vertically and horizontally
- as well as a variety of consciously selected perceptual filters by the
observer/perceiver, to enable a fuller definition and/or understanding of the system of
his/her focus. A particular set of perspectives (really, perceptual filters) for the study
of socio-technical systems were proposed by Linstone (1999), and are among the most
effective tools for examining such systems, and for considering how various
interventions would be received by those they impact. Linstone (1999) suggested that
complex problems exist within dynamic, socio-technical systems, and can be usefully
viewed through three different perceptual filters', (a) technical perspective, (b)
organizational perspective, and (c) personal perspective (abbreviated as TOP
approach). Here, the term perceptual filter is used interchangeably with perspective,
and defined as one lens, among many, that an individual uses to make sense of the
world. Each perspective is unique, offering insights not possible with the other
perspectives. Imagine the difference between seeing an object three-dimensionally
(3D) versus two-dimensionally. A (single) photograph of Mt. Everest provides
significantly less information compared to what would be available if one were
physically in the presence of the world’s highest mountain (particularly if in an
aircraft). It is by integrating the three different perspectives that a clearer
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understanding of lack of treatment staff support for addiction medications emerges,
and Aristotle’s famous words, “the whole is more than the sum of its parts; the part is
more than a fraction of the whole” ring true. In using the TOP approach, a balance is
sought among the perspectives so that one particular perceptual filter does not result in
gross imbalances that impede the ability to see a problem, system, or solution as
clearly as possible.
The technical perspective (T) represents the traditional way of viewing the
world through the lens of rationality and the scientific method. The focus is on
understanding through logic, quantification, mathematics, and by maintaining
objectivity. What cannot be measured is assumed to be not important or to exist at all.
It is a perspective that is reductionist, making the assumption that the sum of the parts
is the whole, and that it is possible to split a system into subunits that can be studied
individually to gain knowledge of the entire system. Decisions made through the T
perspective often use cost-benefit analysis, statistics, and probability theory to arrive at
the best solution to a problem. The T perspective is a dominant theme running
throughout this study, following closely the scientific method.
The T perspective has received a great amount of attention in the addiction
field as a result of recognizing that a significant gap exists between what is known
from scientific research and the approaches used most often in clinical practice
(Institute of Medicine, 1998, 2001). Studies have indicated that clinicians have for
years avoided interventions with significant empirical support, choosing instead to
employ treatments that often have little foundation in science (Institute of Medicine,
/
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1998). Although the gap between research and practice has focused considerably on
understanding why the treatment field has largely ignored evidence-based treatment
interventions, it is clear that the behavior of clinicians cannot be solely understood by
a T perspective and another perspective is necessary.
The organizational perspective (O) represents the social aspects of a system
or problem, typically from the perspective of a group or organization. Behavior is
understood through the actions of the group, and problems are most often solved to
protect the stability of the group or organization. The O perspective examines the
structure of an organization and how that structure operates to maintain stability and
control of the people within it. Problems are often viewed as short-term and solved
through interventions that maintain the best interests of those in power. Among the
best illustrations of this perspective is the political arena, where decisions about
complex problems are often based on doing what will result in reelection instead of
what may benefit society in the long-term.
The O perspective plays a critical role in the present study, both in
understanding the problem and in the development of interventions. A limited number
o f studies (Fuller et al., 2005; Roman & Johnson, 2002; Thomas et al., 2003),
reviewed in detail in the next chapter, have shown that lack of clinician support for
medications may in part be explained by organizational characteristics, including
culture, size, and structure (i.e., in this case, services offered). Perhaps among the most
predictive is the case where the organizational culture adheres strongly to a 12-step
treatment orientation, an approach rooted in the long-standing self-help group
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Alcoholics Anonymous (AA). Historically, A A understands addiction to be a spiritual
problem, thereby requiring a spiritual solution. Within this treatment approach, there is
little need for medications, and in fact, medications may be viewed as distractions
getting in the way o f the spiritual transformation that is necessary for recovery. Thus,
interventions to successfully increase support for medication use have to consider the
many organizational factors that influence the use of medications in treatment,
including: (a) organizational culture and climate, (b) costs associated with the delivery
of medications, (c) patient populations, and (d) organizational risks inherent in using
medications. Interestingly, despite the control, structure, and status quo behavior of
organizations and groups, one individual can change everything, resulting in the need
for the third perceptual filter.
The personal perspective (P) is represented through the eyes of the individual
and his or her own thoughts, feelings, and behaviors. The goal of using this perceptual
filter is to understand individuals’ self-interests, intuition, and power within sociotechnical systems. It also helps explain how and why decisions are made under a wide
range of conditions including: (a) crisis situations, (b) development of policies where
there is significant variability in individual beliefs, and (c) times when there exists an
overload of information. History is rich with examples where understanding an event
necessitates taking a P perspective. For example, the liberation of India from British
rule would be ill understood if the actions of Mahatma Gandhi were not taken into
account. Also, the avoidance of nuclear war during the Cuban Missile Crisis can only

Chapter 2: The Systems Approach

30

be appreciated by examining the actions of President John F. Kennedy. Thus, the P
perspective is a powerful filter that augments the other two perspectives.
Much of the current research devoted to understanding lack of support for use
of addiction medications focuses on attitudes of individual treatment staff. Studies
reviewed in the next chapter reveal that individual differences in education, clinical
experience, and job role can indeed account for some of the variability in attitudes
related to addiction medications. There is also evidence that when a treatment director
supports use of medication it is more likely that staff counselors will follow suit. Later
in this dissertation, diffusion of innovation theory is reviewed, which provides a
framework for understanding how and why particular innovations spread through a
social system. Within diffusion theory, there is evidence that influential individuals
can come from any level of an organization. Such individuals are commonly referred
to as opinion or thought leaders, and often they are among the early adopters o f a new
innovation. In the present study, the individual or P perspective is critical, but only
when balanced with the other two perspectives.
Summarizing this section, the TOP approach offers a powerful set of lenses to
investigate complex issues in socio-technical systems, and at the same time it offers
useful insights when employing a systems methodology for problem solving. In the
end, understanding lack of treatment staff support for addiction medications ideally
emerges from the integration of the three perspectives.
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This chapter provided an overview of the systems approach, and highlighted
some of the limitations of prior studies. It also served as an introduction to many of the
terms used in a systems approach, and suggested definitions that will be used
throughout this dissertation. In the next chapter, the literature review serves to fill in
many of the details regarding what is known about medications to treat substance
abuse disorders within the framework outlined in Figure 1. That discussion begins by
reviewing studies about the U.S. health care and substance abuse treatment systems,
and then proceeds to explore the details of current addiction medicines and what is
known about the barriers to their use.
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Chapter 3: Literature Review
In keeping with a systems approach, this chapter begins by reviewing the
literature that helps define the relevant environment or context in which the perceived
problem (lack of treatment staff support for addiction medications) occurs. It first
considers the role o f the U.S. health care system, since addiction treatment programs
are embedded in this larger system. Recent reports about the U.S. health care system
indicate there are significant deficits in quality of care and several issues surrounding
the use of medications in general. These findings help provide a frame for a more
detailed discussion of quality related to substance abuse treatment. The second section
of this chapter reviews medications specific to the treatment of substance abuse
disorders, and concludes there is significant evidence that a number of medicines,
when used in conjunction with psychosocial therapies, improve patient outcomes.
Despite the evidence of improved patient outcomes, medications to treat
substance abuse disorders remain underutilized in practice, the topic of the third
section in this, review. Studies suggest multiple barriers, but as pointed out in the
previous chapter, most have ignored the hierarchical nature of the data and have given
little attention to the relationships between individual and organizational factors.
Inherent in all these studies, however, is the theory behind why some technologies
become widely adopted, while others fail to gain an audience. The fourth section
tackles this topic by reviewing diffusion of innovation theory and how it pertains to
addiction medications. Finally, the review concludes with a discussion of the National
Drug Abuse Clinical Trials Network. The latter research, funded by NIDA is an
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attempt to bridge the gap between practice and research in the addiction field. It is also
the source of the data for the present study.
3.1 The Treatment System
3.1.1 Quality o f Health Care in the United States
To better understand the present state of the substance abuse treatment system,
it is first useful to recognize that it is but one component of a much larger health care
system, one that in recent years has been under considerable scrutiny. A brief review
of the quality of health care in the United States helps frame a more detailed
discussion that follows on quality related to substance abuse treatment and medication.
In 1999, the Institute of Medicine published its first of three reports on the
quality of health care delivered to Americans. To Err Is Human: Building a Safer
Health System, focused specifically on patient safety. The report delivered a scathing
critique of how patient safety is significantly jeopardized as a result of medical errors
that on the whole are preventable. The authors concluded that “tens of thousands of
Americans die each year from errors in their care, and hundreds of thousands suffer or
barely escape from nonfatal injuries that a truly high-quality care system would
largely prevent” (Institute of Medicine, 2001, p. 2).
Studies investigating the incidence and prevalence of errors fall into two
categories: general studies of patients’ experiencing adverse events that may include
medication-related events, and studies related more specifically to errors in use of
medication. Adverse events are those in which the patient injury is caused by an error
in medical management rather than the underlying condition of the patient. Most

r
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studies on adverse events focus on hospitalized patients, the most extensive being the
Harvard Medical Practice Study conducted in 1984 (Brennan et al., 1991; Leape et al.,
1991). In a review of over 30,000 randomly selected patient discharges from 51
randomly selected hospitals in New York State, adverse events occurred in 3.7% of
hospitalizations. Adverse events included: drug complications (19%), wound
infections (14%), and technical complications (13%). In 13.6% of the cases, the error
resulted in death, and in 2.6% of the cases the error led to a permanent disabling
injury. The errors were considered preventable in 58% of the cases.
Results from the above study were further corroborated in 1992 when a similar
review process was applied to 14,732 randomly selected discharges from 28 hospitals
in Colorado and Utah (Thomas et al., 1999). Adverse events occurred in 2.9% of
hospitalizations, with one out of every five events occurring prior to admission in a
non-hospital setting (e.g., physician’s office, patient’s home). The reviewers detected
459 adverse events costing in total, $661,889,000 (health care costs, lost wages, lost
household production). Of this, $348,081,000 was attributable to health care costs. Of
these adverse events, 256 were considered preventable (53%) and their prevention
would have yielded a total cost savings of $308,382,000 ($159,245,000 from health
care). Adverse events were classified into several categories including: operative
(35%), drug related (32%), diagnostic or therapeutic (17%), procedure related (9%)
and other (6%).
When the results from these two large studies are extrapolated to the 33 million
hospital admissions in 1997, the national costs of adverse events exceeds $37 billion
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and implies that as many as 98,000 patients die each year as a result of preventable
medical errors (Institute of Medicine, 2000). Although medication errors were among
the most common adverse events in the above two studies, the majority of these errors
did not result in death or serious injury (Institute of Medicine, 2000). Successfully
increasing use o f addiction medications will necessitate balancing effectively the
benefits and risks, and finding mechanisms to protect patients from adverse drug
events (cf. Section 7.4).
Studies focused specifically on errors in use of medication are quite common
in the U.S. due to the vast numbers of people affected by medications, the prevalence
of medication errors, and the costs involved. A study that reviewed U.S. death
certificates in 1983 and 1993 found that 7,391 people died as a result of medication
errors in 1993, compared to 2,876 deaths in 1983 (Phillips, Christenfeld, & Glynn,
1998). This represents an 8.48-fold increase in outpatient deaths and a 2.37-fold
increase in inpatient deaths during the 10-year period. In another study that analyzed
289,411 medication orders written at a teaching hospital during a one-year time
period, the overall error rate was estimated to be 3.13 errors for every 1000 orders
written (Lesar, Briceland, & Stein, 1997). In a meta-analysis of 39 prospective studies
from U.S. hospitals investigating the incidence of adverse drug reactions (ADRs)
between 1966 and 1996, the overall incidence of serious ADRs was 6.7% and the
incident of fatal ADRs was .32%. The authors estimated that in 1994 about 106,000
hospital patients died due to ADRs and that fatal ADRs rank somewhere between the
fourth and sixth leading cause of death in the U.S., a finding that has remained stable
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for the last 30 years. In a more recent study of ADRs, Gurwitz et al. (2005) followed
all residents in two long-term care facilities (i.e., nursing homes) from 2000 to 2001
and found that the rate of adverse drug events was 9.8 per 100 resident-months. The
rate for preventable adverse drug events was 4.1 per 100 resident-months. If these
findings are extrapolated to the 1.6 million residents in U.S. nursing homes, the
authors concluded that about 1.9 million ADRs may occur each year, of which
approximately 40% are preventable (Gurwitz et al., 2005).
Perhaps the most important finding from the IOM report To Err Is Human:
Building a Safer Health System was that the results from the above studies on adverse
events and medication errors were primarily a function of the system in which they
occurred rather than the fault of any one person or group of people. In most cases,
when errors occur, “it is due to multiple faults that occur together in an unanticipated
interaction, creating a chain of events in which the faults grow and evolve (Institute of
Medicine, 2000, p. 52).” Consequently, the report called for a national effort to
improve patient safety and outlined several recommendations to accomplish this goal.
But in a critique of the progress made in the five years since the report’s publication,
Leape and Berwick (2005) concluded that in spite of some improvements, the overall
health care system is not demonstrably or measurably safer. The authors suggested
that the primary barriers to progress include: (a) difficulties in changing complex
medical systems; (b) professional fragmentation; (c) a culture of medicine that
promotes individualistic, hierarchical authority structure, and diffuse accountability;
(d) individual habits and belief systems; and (e) organizational leadership.
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The second report published by the IOM, Crossing the Quality Chasm: A New
Health System fo r the 21st Century (2001), provides an even broader framework for
understanding the context of lack of use of medications in the addiction field. Unlike
the first IOM report that focused narrowly on patient safety, this report examined the
quality of health care using a much wider lens. Central to the report was a review of
over 70 peer-reviewed journal articles published from 1987 to 1998 on studies specific
to health care quality across a broad range of medical domains including the field of
addiction. In summary:
The dominant finding of our review is that there are large gaps between the
care people should receive and the care they do receive. This is true for
preventive, acute, and chronic care, whether one goes for a checkup, a sore
throat, or diabetic care. It is true whether one looks at overuse, underuse, or
misuse. It is true in different types of health care facilities and for different
types of health insurance. It is true for all age groups, from children to the
elderly. And it is true whether one is looking at the whole country or a single
city (Institute o f Medicine, 2001, p. 236).
Despite the increasing attention to the quality of the system, only one study
examined issues related to addiction. Regier and colleagues (1993) reviewed
prevalence rates of mental and addictive disorders and subsequent treatment
utilization. The authors concluded that a huge gap exists between the number of
people needing treatment and those actually receiving it. They found that less than
one third of those identified with a mental or addictive disorder received any kind of
treatment in the year prior to being interviewed, and less than a quarter of those with
substance abuse disorders received any care (Regier et al., 1993). In fact, of the total
population in need of substance abuse treatment, Epstein & Gfroerer (1998) found
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that only about 20% received any kind of care in a given year, a trend that continued
throughout the 1990s in spite of increased treatment needs.
Although underutilization of medications in substance abuse treatment was not
mentioned specifically in the report (Institute of Medicine, 2001), other examples of
both underuse and misuse of medications across a broad range of medical conditions
were documented. The reasons behind these and other gaps in health care quality,
came down to four key factors: (a) growing complexity of science and technology; (b)
increases in the number of chronic conditions; (c) poorly organized delivery system;
and (d) constraints on exploiting the revolution in information technology. These four
factors do not operate independently, but are best understood from a systems
perspective, where each factor may exacerbate the effects of the others.
Not surprisingly, the report called for a redesign of the health care system to
address the identified problems, and it outlined several recommendations to improve
quality of care. Among them was the need to incorporate systematically scientific
knowledge into clinical practice (Institute of Medicine, 2001). The report pointed out
that it takes an average of 17 years before new knowledge generated by randomized
controlled trials is incorporated into practice, and even then adoption rates vary
considerably among users (Balas & Boren, 2000). The gap between scientific evidence
and clinical practice in large part reflects the failure of dissemination efforts to reach
clinicians and patients.
Recognizing that health care for mental and substance use conditions have
unique characteristics (e.g., coercion into treatment, inconsistent delivery systems and
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infrastructure, and universal quality measures), the IOM published a third report titled
Improving the Quality o f Health Care fo r Mental Health and Substance-Use
Conditions: Quality o f Chasm Series (Institute of Medicine, 2006). The report offered
a more comprehensive examination of the quality of services specific to mental health
and substance abuse treatment compared to the previous IOM publications. The report
documented that every year about 33 million Americans seek treatment for mental
health and substance abuse problems, and that millions more report that they could
benefit from treatment but do not receive it. Across the many diverse illnesses,
diagnoses, and conditions for which people seek help, the report provides significant
empirical evidence that effective treatments are available.
The results of research to date have revealed our lifelong ability to influence
the structure and functioning of our brains through manipulation of
environmental and behavioral factors (our brains’ “plasticity”) and have
enabled the development of improved psychotherapies (“talk” therapies), drug
therapies, and psychosocial services. Effective mental health interventions
range from the use of specific medications (such as clozapine) to treat
schizophrenia better in some people to the application of specific models for
treating depression in primary care and providing supported housing for
homeless persons with mental illness. Those and other mental health
interventions have been demonstrated to be cost-effective (Institute of
Medicine, 2006, p. 4).
Further, the report documented the range of effective psychosocial and
pharmacological interventions to treat substance abuse disorders. Medications
including naltrexone, buprenorphine, and methadone - all of which are examined in
the present study, are provided as examples of effective treatments that are
underutilized in practice.
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In a review of studies published from 1992 to 2000 assessing the quality of
care for those suffering from a wide range of mental health or substance use disorders,
it was found that about 75% of the treatment did not adhere to established clinical
practice guidelines (Bauer, 2002). A number of other review studies outlined in the
IOM report provided further evidence that, across the spectrum of mental health and
addiction problems, more often than not, the care individuals receive is not consistent
with the best known treatments available (Institute of Medicine, 2006). The report
further details how such gaps in quality of care have significant consequences for the
nation.
Consequences are felt directly in the workplace; in the education, welfare, and
justice systems; and in the nation’s economy as a whole. Together, unipolar
major depression and drug and alcohol use and dependence are the leading
cause of death and disability among American women and the second highest
among men (behind heart disease) (Institute of Medicine, 2006, p. 6).
The report concluded by providing evidence that the framework for improving
quality across the general healthcare system, outlined in the previous two Quality of
Chasm reports, can also be used to effectively improve care for mental and substance
use disorders.
In summary, findings from the IOM reports on quality of health care in the
U.S. suggest that: (a) adverse medical events and errors in medication use are quite
common, often preventable, and in numerous cases lead to death; (b) despite
initiatives to improve patient safety, little has been accomplished; (c) there exist
significant gaps in health care quality across a broad range of medical domains
including the field of addiction; (d) scientific knowledge is slow to be, or often not
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incorporated into clinical practice; and (e) there is a need to redesign the health care
system to improve patient safety and overall quality of health care. Taken together,
these findings not only represent challenges for the entire U.S. health care system, but
they also reflect many of the problems currently existing in the substance abuse
treatment industry.
3.1.2 The Practice-to-Research Gap in Substance Abuse Treatment
In 1998, the Institute of Medicine published Bridging the Gap Between
Practice and Research: Forging Partnerships with Community-Based Drug and
Alcohol Treatment, a review focusing on the quality of care in substance abuse
treatment. Although predating the IOM reports on health care quality, the findings
were remarkably similar in many respects, highlighting significant deficiencies in
quality, fragmentation of stakeholders, and the need for improvement in many areas of
delivered care. The central message was that gaps in quality were in large part the
result of a disconnect between scientific knowledge and clinical practice (Institute of
Medicine, 1998). The IOM committee charged with investigating the gaps held
numerous discussions with treatment providers, researchers, policy makers, and a host
of other stakeholders. Among the first lessons learned was that each of these groups
operate from a different mental model, or deeply held set of beliefs and assumptions
about how the world, and specifically substance abuse treatment, work. Consequently,
these groups made little use of each other’s knowledge base, resulting in a
community-based treatment system that has largely ignored scientific advancements in
addiction treatment during the past 30 years (Rawson, Marinelli-Casey, & Ling,
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2002). Evidence for the gaps between practice and research were outlined in the
report and included five critical areas.
Different perspectives: Researchers value the scientific process and live in a
world of data, statistics, and randomized clinical trials. Truth is based on ^-values and
the replication of results over time. They often become frustrated by clinicians’ lack
of support for EBPs and believe clinicians to be naive and ignorant about the
necessity for empirical principles in substance abuse treatment. Clinicians, on the
other hand, place significant value on personal experiences, mentoring relationships,
experiential processes, and ideological positions. They see researchers as mechanistic
since they have never sat with a client in a therapy session and are unable to
appreciate the real-world challenges of diverse patient populations (Rawson et al.,
2002). Policy makers provide a third perspective. They complain that the information
they need to make good decisions is often buried in volumes of journal articles and
written in a language that does not provide clear guidance for practice. Further, they
say that research findings are often published long after they could be of value.
Finally, consumers o f substance abuse treatment services come from a position that
seeks knowledge about the most effective treatment interventions. Yet, unlike other
chronic medical conditions for which there is a vast amount of popular literature,
relatively few publications exist for the general public about substance abuse
treatment incorporating current scientific knowledge.
Underutilized research findings in practice: The IOM report (Institute of
Medicine, 1998) identified numerous examples where effective interventions
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developed from research were generally not utilized or underutilized in practice.
These EBPs included both psychosocial and pharmacological approaches to
treatment. Among the most researched and supported of the psychosocial
interventions is contingency management, an intervention that involves the use of
positive reinforcements to increase desired behaviors such as abstinence from illicit
substances (Higgins et al., 1994). Despite evidence of its effectiveness in both
laboratory and clinical settings in multiple clinical trials, the IOM report documented
that it has not been widely adopted in practice. Another example is the underuse of the
community reinforcement approach (Hunt & Azrin, 1973; Smith, Meyers, & Miller,
2001). This intervention, now over 30 years old, has consistently been rated among
the most effective psychosocial treatments for alcoholism in multiple meta-analytic
reviews (Finney & Monahan, 1996; Holder, Longabaugh, & Miller, 1991; Miller et
al., 1995), yet it remains practically unknown to most clinicians. Most significant to
the present study was the lack of support by treatment staff for use of medications to
treat opioid and alcohol dependence. Details of the medications and evidence for their
underutilization are considered in detail in the sections that follow. Although the
present study focuses on understanding attitudes related to the lack of support for use
of addiction medications, the need to examine why other psychosocial EBPs are
underutilized remain equally important. In the end, if substance abuse treatment
outcomes are to be optimized, treatment providers will need to use a wide range of
EBPs that will include both psychosocial and pharmacological interventions.
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Service delivery approaches'. Because many who struggle with substance
abuse also suffer from physical, emotional, social, and economic hardships, programs
recognize the necessity to offer supplementary services in their treatment approaches.
Such services include case management, tailored interventions for women and
children, and so called “wrap-around” services that include medical care, legal
assistance, and career counseling. Although the benefits of such interventions have
been documented (McLellan, Alterman, Metzger, Woody, & O'Brien, 1993), the IOM
report called for increased research to assess more fully the role such services play in
outcomes across a variety of treatment settings.
Treatment approaches understudied in research: Just as treatment providers
have underutilized research findings, researchers have failed to investigate many
current treatment practices. Underscoring this point is the abundance of efficacy
research and the lack o f effectiveness research (cf. Section 3.2) (Institute of Medicine,
1998). In a comprehensive review of the treatment outcome literature, the IOM report
concluded that there is a significant lack of effectiveness research. Many studies have
purposely excluded important classes of patients who are common in communitybased treatment programs, often because such patients make it more difficult to study
an intervention under controlled conditions. Researchers have also studied
interventions requiring resources that are not realistic in the current treatment
environment, assuming that if the interventions are successful the resources can be
found.
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Policies that impede treatment'. A final gap involves the barriers created by
state and federal legislation that hinder successful adoption o f EBPs. For example,
methadone is the most regulated medication in the nation, requiring patients and
providers to adhere to a long list of federal requirements (discussed later in this
chapter) and limiting its wide spread adoption by those who could benefit (Institute of
Medicine, 1998). Another barrier is the need for states to amend individually their
narcotic regulations to incorporate new medications, a time-consuming process that
has significantly hindered the implementation of beneficial treatments. There are also
financial, paperwork, and treatment policies that the IOM report suggested needs
reexamination.
Taken together, these issues present significant challenges to the substance
abuse treatment system. Similar to the IOM findings on quality of health care in the
U.S. (2001; 2000), use of scientific knowledge is lacking throughout the substance
abuse treatment industry, and efforts are needed to redesign the system to improve
patient access and overall quality of care. However, such an undertaking will require
addressing numerous barriers that hinder closing the gaps between practice and
research. The IOM report (1998) identified six broad barriers to improve substance
abuse treatment that may impede communication and cooperation among researchers,
clinicians, and policy makers.
Structure: The typical treatment program is a small organization, employing
fewer than 30 staff, and most often reliant upon state and federal funding to remain in
business. Such programs face substantial challenges to find the resources necessary to
f
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improve “wrap-around” services, hire medical staff to prescribe and dispense
medications, or train clinicians on new EBPs.
Financing-. Most treatment programs rely on a combination of public funds
through block grants, Medicaid, and state funding sources. Each financial stream
comes with a unique set of rules and policies that must be followed, often resulting in
a paperwork overload for treatment providers. Further, many funding sources refuse
to pay for new treatments, including medications.
Education and training: Staff working in substance abuse treatment
programs are far from homogeneous. Differences in formal academic education,
recovery status, and licensure and certifications, all lead to very different perspectives
about treatment and the need to use EBPs. For example, clinicians in recovery from
alcohol dependence who achieved sobriety by utilizing the 12-steps of AA may be
less likely to embrace EBPs. They may feel there is little need for EBPs when the
active ingredient of change from their perspective is the acceptance of a higher power.
Stigma: Ignorance and prejudice about addiction remain commonplace
throughout society. These problems are in part related to deficits in addiction
education in medical and graduate schools, citizens supporting treatment but not
wanting the programs located in their communities, and decreased funding for
treatment technologies.
Lack o f knowledge about technology transfer: Despite the long history of
diffusion research (Rogers, 1995, 2003), few studies have examined diffusion of
substance abuse treatment technologies. Absent a clear, systematic approach to
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implementing new technologies into practice, researchers and clinicians will likely
remain frustrated with clinical outcomes. Recent diffusion models specific to
addiction treatment offer hope and are reviewed later in this proposal (Simpson, 2002;
Thomas et al., 2003).
Policy barriers: Local, state and federal policies can significantly impact who
gets treatment and the quality of care. Treatment funding often is a function of the
degree to which policy makers believe it is cheaper than putting substance abusers
behind bars, rather than acknowledgement that addiction is a treatable condition
(Institute of Medicine, 1998).
Perhaps the most significant contribution of the IOM report (1998) was that it
provided solid recommendations for how to improve the substance abuse treatment
system. Soon after publication, both NIDA and CSAT released funding initiatives
aimed at bringing researchers and clinicians together to address collaboratively the
“gaps.” In January 1999, NIDA introduced the National Drug Abuse Clinical Trials
Network (CTN) that partnered university-based research centers with community
treatment programs. What started as five nodes has now grown to 17 nationwide, an
indication that the CTN has shown it is possible to bridge the cultural divide between
researchers and clinicians. In addition, the NIDA Clinical Toolbox: Science-based
Materials fo r Drug Abuse Treatment was disseminated to nearly 12,000 programs
nationwide (Rawson et al., 2002). At the same time, CSAT aggressively increased
efforts to close the gaps through a number of initiatives that included: (a) publishing
The Change Book: A Blueprint fo r Technology Transfer (Addiction Technology
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Transfer Centers, 2000); (b) funding 14 Community-Based Practice Improvement
Collaboratives (PICs) nationwide to foster knowledge exchange among key
community stakeholders; and (c) publishing 38 Treatment Improvement Protocols
(TIPs) designed to be best-practice guidelines for a wide range of topics related to
substance abuse (free publications available to treatment providers).
In summary, many positive changes are occurring within the treatment field,
but as one researcher put it, “It is clear that researchers and practitioners are beginning
to dance together, but it is unclear if the dance will look like a waltz or like the funky
chicken” (Rawson et al., 2002, p. 948). At the center of the dance is the need to bring
EBPs, including the use of effective medications, to the forefront of treatment. Yet
studies consistently indicate that when it comes to use of addiction medications,
clinicians have not been overly supportive. Before delving into why this is so, it is first
useful to understand a bit about the medications that have been approved for the
treatment of substance use disorders, the topic of the next section.
3.2 Medications to Treat Substance Use Disorders
Significant advances in understanding the neurobiology of addictive disease
have occurred during the past couple of decades, yet these discoveries have resulted in
just a handful of medications that have successfully been brought to market (Institute
of Medicine, 1998; Yocci, 2003a, 2003b). Currently, FDA approved drugs exist for
the treatment of alcohol and opioid dependence, yet none have achieved widespread
acceptance, a topic reviewed hereafter. Considering that 16 million Americans abuse
alcohol and 19 million abuse illicit drugs (U.S. Department of Health and Human
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Services, 2005), the stakes remain high for increasing use of currently approved drugs
and developing new medications for the treatment of addiction. This section reviews
FDA approved medications specific to the treatment of substance abuse disorders, and
provides a brief overview of what the future holds. Attention is focused on naltrexone,
methadone, and buprenorphine, the three medications involved in the present study.
Studies conducted to test medication effects generally fall into two categories.
Efficacy research refers to those studies that test the impact of a medication under
controlled experimental conditions. The primary advantage of such studies is that they
demonstrate the degree to which an outcome can be attributed to the effect of the
medication (i.e., they maximize internal validity). This in part is accomplished by
selecting study participants that meet specific criteria aimed at screening out
extraneous factors that may confound the treatment effects. For example, participants
in a study to test a medication for alcohol dependence might be required to have no
other mental health diagnoses and no recent history of any other substance abuse.
Such restrictions improve the internal validity of the study, but decrease the external
validity of the results since study populations are often not representative of the
populations of people who seek treatment.
Studies conducted under more realistic, real-world treatment conditions are
often referred to as effectiveness studies. Medications are tested in various treatment
settings (e.g., residential, outpatient), during particular times of treatment (e.g.,
beginning, middle, or end of treatment), and often with patients that have multiple co
occurring disorders. When treatment effects are found, such studies indicate the degree
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in which a medication can be generalized to other settings, times and conditions. The
downside of such studies is that findings can often be hard to interpret when
confounding variables are present. Where efficacy studies maximize internal validity
at the expense of external validity, effectiveness studies have the opposite effect; they
maximize external validity at the expense of internal validity. It is also worth noting
that randomized controlled trials (RCTs) are often associated with efficacy research,
but effectiveness studies can also be RCTs as well. Approved FDA medications to
treat substance abuse disorders have all been subjected to both efficacy and
effectiveness research to some degree, however efficacy studies are generally more
common.
3.2.1 Medications to Treat Alcohol-Use Disorders
Currently, there exist three FDA approved medications to treat alcohol abuse
disorders: disulfiram, naltrexone, and acamprostate. Disulfiram (Antabuse®) has been
used for over 50 years and is available in both oral and implant forms. It impacts the
metabolism of alcohol, resulting in unpleasant symptoms (e.g., nausea, vomiting,
flushing) when even small amounts of alcohol are ingested. More than 135 studies
have investigated its efficacy and effectiveness, yet only a handful of these have been
RCTs (Garbutt, West, Carey, Lohr, & Crews, 1999). In spite of widely-held beliefs by
counselors that disulfiram reduces drinking and deters relapse, the evidence suggests
strongly that disulfiram has only moderate effects on alcohol consumption, and
virtually no impact on abstinence rates (Garbutt et al., 1999).
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Naltrexone (ReVia™), an opiate antagonist available since the 1980s to treat
opioid dependence, was approved in 1994 as an adjunct to psychosocial treatments of
alcoholism. Currently available in oral and injectable forms, naltrexone is believed to
reduce drinking cravings by blocking the release of endogenous opioids associated
with the rewarding effects of alcohol (Weinrieb & O'Brien, 1997). Initial RCTs
showed naltrexone to be efficacious in reducing drinking frequency and the incidence
of relapse (O'Malley et al., 1992; Volpicelli, Alterman, Hayashida, & O'Brien, 1992).
Since that time, at least 20 published RCTs have provided additional support that
naltrexone is an efficacious, safe, and useful adjunct to psychosocial interventions for
reducing drinking behavior and the frequency of relapse (Carmen, Angeles, Munoz, &
Jose Maria, 2004; Kranzler & Van Kirk, 2001). However, a few studies have
challenged these finding by reporting that naltrexone was found to be no better than
placebo (Chick et al., 2000; Krystal, Cramer, Krol, Kirk, & Rosenheck, 2001).
Although shown to be efficacious in well-controlled clinical trials, naltrexone’s
effectiveness in community-based treatment settings with heterogeneous populations
has been mixed. In a recent study of alcohol dependent patients in a rural community
treatment setting, Killeen et al. (2004) found support for use of naltrexone in patients
continuing to drink in the early stages of treatment, but found no differences on
drinking outcome measures at 12 week follow-up. This finding suggests that it may be
more useful in the early stages of treatment to reduce drinking behavior or help
patients gain initial abstinence, but not as useful in the long-term management of
addiction. The authors suggest that marginal medication adherence, psychosocial
f
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instability, and polysubstance abuse all contributed to the poor outcomes in this study,
and further effectiveness research in community-based settings is needed.
In July of 2004 the FDA approved acamprosate (Campral®) as a third
alternative for the treatment of alcoholism. Also available in oral form, acamprosate is
believed to exert its effect by restoring normal activity of glutamatergic
neurotransmission adversely affected by chronic alcohol exposure, but the specific
mechanism of action is still not well understood (Mason, 2005). It has been used
extensively for the past 15 years, primarily in Europe, and been subject to many RCTs
that have found it to be a safe, effective, and efficacious medication for reducing
alcohol consumption (Carmen et al., 2004; Kranzler & Van Kirk, 2001; Mason, 2005).
Some evidence suggests that acamprosate may be more useful for patients targeting
long-term abstinence, whereas naltrexone may be more beneficial in programs focused
on reduced or controlled consumption (Carmen et al., 2004).
There is recent evidence that combining acamprosate with naltrexone is more
effective than either medication alone when used with cognitive behavioral therapy
(Feeney, Connor, Young, Tucker, & McPherson, 2006). The study matched 236
patients across gender, age group, and alcohol dependence severity, and allowed
patients to self-select one of three treatment options: (a) naltrexone with therapy, (b)
acamprosate with therapy, or (c) naltrexone and acamprosate with therapy. Three
groups of 59 patients were assessed over a 12-week period, in addition to a group of
patients that chose therapy without any medication. On all outcome measures (e.g.,
attendance, abstinence rate, and relapse rate) a trend favored the combined medication
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and therapy approach, but the results never achieved statistical significance. As an
effectiveness study, the authors point out the results are low on internal validity since
patients were able to self-select their treatments. Further, issues related to medication
compliance and differences between patients who take medications, and those who
choose not to, need further investigation.
In summary, disulfiram, naltrexone and acamprosate provide three different
pharmacological alternatives to the treatment of alcoholism. Efforts to increase
support for use have primarily focused on naltrexone, but acamprosate will likely be a
target of future efforts. Both have been subject to multiple RCTs and shown to be safe,
efficacious, and beneficial when used concurrently with psychosocial interventions.
Other medications have also been tested in the treatment of alcoholism (e.g.,
nalfemene, SSRIs, lithium, etc.), but results have yet to support their use (Garbutt et
al., 1999). One recent innovation to enhance patient compliance is the development of
a long-acting injectable naltrexone (Vivitrol™) that became available to patients in
late 2006. A recent RCT found it to be well tolerated and effective at reducing
drinking days, but its benefit over oral naltrexone has yet to be determined (Garbutt et
al., 2005).
3.2.2 Medications to Treat Opioid Dependence
Currently, there are four FDA approved medications for the treatment of
opioid dependence: methadone, buprenorphine, levo-alpha-acetymethadol (LAAM),
and naltrexone. The most widely prescribed, methadone, was first introduced as a
potential treatment against a backdrop of escalating heroin use in the 1960s. Dole and
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Nyswander (1965; 1967) are credited with first using methadone as a legal opioid
substitution therapy. By acting on the same receptor sites as heroin, methadone
satiates addictive cravings, while suppressing withdrawal symptoms for up to 24 hours
(i.e., once daily dosing). At the same time, it does not produce sedation or a dulling of
consciousness, and is thus unattractive as a drug of abuse (National Institute of Health,
1997). It currently is available in tablet, wafer, and liquid form, and used in 1,105
methadone clinics in 44 states nationwide (American Association for the Treatment of
Opioid Dependence, 2004). It is estimated that of the approximate 810,000 heroin
addicts in the U.S., about 20% receive treatment in methadone maintenance programs
(American Methadone Treatment Association, 1998). Since its introduction as a
therapeutic agent for opiate dependence, numerous RCTs have shown a consistent,
statistically significant relationship between use of methadone and reductions in illicit
opiate use, mortality, crime, and HIV risk behaviors, as well as improved rates of
treatment retention and quality of life (Amato et al., 2005; Gossop, Marsden, Stewart,
& Treacy, 2001; Marsch, 1998; National Institute of Health, 1997).
. Despite being among the most effective evidence-based treatments available
(National Consensus Development Panel on Effective Treatment of Opiate Addiction,
1998), its use has historically been plagued by numerous barriers. Many working in
substance abuse treatment and the criminal justice system are philosophically opposed
to nonabstinence-based interventions, and believe that ongoing use of a prescribed
narcotic is immoral and fundamentally opposed to the goals of rehabilitation (U.S.
Department of Health and Human Services, 1994). Methadone is also the most
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regulated pharmaceutical agent in the nation, requiring providers and patients to
follow stringent guidelines that many consider aversive and unnecessary. The NIH
consensus statement on methadone treatment went so far as to say “we know of no
other area where the Federal government intrudes so deeply and coercively into the
practice o f medicine” (National Consensus Development Panel on Effective Treatment
of Opiate Addiction, p 1940). Although diversion of methadone has been noted (e.g.,
street trade, theft, etc.), it frequently is the result of patients attempting to selfmedicate outside of professional treatment (Cicero, Inciardi, & Munoz, 2005). Finally,
lack of physicians trained in addiction interventions and limited funding have inhibited
access to treatment (National Consensus Development Panel on Effective Treatment
of Opiate Addiction, 1998).
Among the recommendations from the National Consensus Developmental
Panel was the need for federal legislative change to improve substance abusing
patients’ access to opiate medications. Soon after, the Drug Addiction Treatment Act
o f 2000 (DATA 2000) was passed, allowing qualified physicians to use Schedule III,
IV, or V narcotics approved for treatment of opiate dependence. In 2002,
buprenorphine became the first schedule III medication approved by the FDA to meet
the criteria, heralding in a long awaited alternative to the often demeaning structure
surrounding use o f methadone. Patients could now receive treatment in a physician’s
office, although the Act limited physicians’ prescribing to 30 patients at any given
time. The limitation was enacted primarily to prevent physician practices from
becoming too dependent on buprenorphine prescriptions, and did not apply to group
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medical practices or treatment programs. Buprenorphine is a partial agonist, exerting a
ceiling effect at higher doses that makes it particularly safe in the treatment of opioid
dependence, but that limits its usefulness in patients requiring higher levels of full
agonist activity for treatment success (U.S. Department of Health and Human
Services, 2004). Further, its long duration of action, minimal withdrawal symptoms
upon cessation, and low level of physical dependence add to its favorable profile (Ling
& Smith, 2002). Currently it is available in two sublingual tablet forms (Subutex® and
Suboxone®), but Suboxone® has become the preferred medication because is contains
naloxone, an opioid antagonist that helps deter diversion and misuse. Multiple RCTs
have shown buprenorphine to be an efficacious treatment for opioid dependence
(Amass et al., 2004; Johnson et al., 2000; Ling et al., 2005; Ling et al., 1998; Pani,
Maremmani, Pirastu, Tagliamonte, & Gessa, 2000). Similar support is found for the
buprenorphine-naloxone combination (Amass, Kamien, & Mikulich, 2000, 2001).
Similar to methadone, there is evidence of improved outcomes in combination with
psychosocial services (Law & Nutt, 2003).
Two other medications for opiate dependence treatment deserve mention.
LAAM was approved by the FDA in 1993 after numerous RCTs showed it to be a safe
and efficacious treatment (Fudala, Vocci, Montgomery, & Trachtenberg, 1997; Judson
& Goldstein, 1983; Ling, Klett, & Gillis, 1978). It was hailed to quickly overtake
methadone as the treatment of choice for opiate dependence, but instead became a
lesson in all that can go wrong when attempting to implement a new innovation into
practice (Ling, Rawson, & Anglin, 2003). Almost eight years after its approval, fewer
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than 2% of opiate dependent patients in the U.S. were using LAAM (Rawson, Hasson,
Huber, McCann, & Ling, 1998). A combination of limited marketing, state and federal
regulatory hurdles, and the lack of a powerful advocate championing its use all
contributed to its failure. Currently, it remains an approved medication by the FDA,
but it is not being manufactured by any pharmaceutical company for patient use and is
unavailable in pharmacies.
Finally, naltrexone gained FDA approval in 1985 for the treatment of opiate
dependence. It is a complete antagonist, blocking the mu opioid receptors and taking
away the effect of opiate drugs. It has been primarily used to maintain abstinence
following detoxification, but a recent review of RCTs found insufficient evidence to
justify its use in maintenance treatment (Kirchmayer et al., 2002). There is some
evidence that when naltrexone is used in combination with benzodiazepines, it may
improve a patient’s ability to maintain abstinence from opiates (Stella et al., 2005).
In summary, methadone has been used successfully for over 35 years as an
effective therapeutic agent for the treatment of opioid dependence, and is considered
by many to be among the most effective of all addiction treatment interventions. But
as successful as it may be, it remains a controversial agent that is used by only 20% of
those in need, and has yet to gamer consistent support from the treatment community.
As an alternative, buprenorphine shows great promise in overcoming many of the
methadone hurdles; but as the next section on medication barriers reveals, it remains
largely unknown to many in the treatment industry two years after approval. Those

/
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pushing for its adoption need only look to the failure of LA AM to realize that bridging
the gap between research and practice can be a daunting task.
3.2.3 Future Directions
The current arsenal of addiction medications may be limited, but significant
effort is currently underway to discover new pharmacological agents. There are two
primary approaches to the development of new medicines. The first, known as a topdown approach, occurs when researchers test whether a medication already on the
market for a health issue other than addiction, may have some benefit for those
struggling with addiction (Vocci, 2003a). One example is rimonabant, a drug that
blocks cannabinoid-1 (CB1) receptors in the brain and used in the management of
obesity. It is now being tested as a potential treatment for alcohol dependence since
animals studies indicate that blocking CB1 receptors results in animals consuming less
alcohol (National Institutes of Health Clinical Trials Center, 2006). Another example
is baclofen, a decades-old medication approved for the treatment of muscle spasms
and cramps in patients suffering from multiple sclerosis or spinal problems. A recent
RCT demonstrated that baclofen may be effective in reducing cocaine use when used
concurrently with psychosocial interventions (Shoptaw et al., 2003). At present, there
is no approved medication for the treatment of cocaine dependence, but NIDA is
currently using a top-down approach to test 21 medicines already on the market as
possible options (Vocci, 2003b). Disulfiram (Antabuse) used for alcohol treatment
was also recently shown to be an effective pharmacological agent for treating cocaine
dependence when used with cognitive-behavioral therapy (Carroll et a l, 2004). A
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number of the SSRIs, including fluoxetine and venlafaxine, are also current
candidates.
Development of new medications also occurs from what is known as a bottomup approach, where new medicines result from scientific discoveries in the laboratory.
Numerous drugs are now being assessed for possible treatments for cocaine (e.g.,
GBR 12909, NMD A modulators, CRF antagonists, etc.), and methamphetamine
dependence (e.g. Loeline) (Vocci, 2003a). Taken together, significant resources are
currently being devoted to pharmacological treatments for substance abuse disorders.
Whether these investments will result in widespread benefit depends largely on their
effectiveness, and on attitudes patients, providers, and the public have towards them.
The above review points to the important role medications can play in the
treatment of substance abuse disorders. Naltrexone, buprenorphine, and methadone
have all been used successfully to reduce addictive behavior and improve clinical
outcomes, but none have become widely adopted in practice. Each medication has
benefits and risks, and the best that can be said about their effectiveness is that they
have all been shown to have moderate effect sizes in RCTs, a finding often used to
justify their underuse. But as Orford (2001) points out, experts have searched long and
hard for the best treatment for addiction, and in the process, have developed numerous
psychosocial interventions that have all resulted in moderate effect sizes as well. In the
absence of a gold standard, patients and providers benefit from a menu of options that
include both psychosocial and pharmacological interventions, often used concurrently
for the best outcomes.
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3.3 Barriers to Use of Medication in Substance Abuse Treatment
Despite the empirical evidence that medications can significantly improve
clinical outcomes for those struggling with substance abuse disorders, research
consistently points to their underutilization in practice. Numerous studies have been
done to learn more about this phenonenon, the majority of which have relied on survey
methodologies of those who prescribe medication, or who are in a position to
influence whether medications may be used (e.g., counselors, program administrators,
etc.). These individual-level studies provide evidence that there are multiple barriers at
work. Also, as mentioned in the previous chapter, a few studies have investigated
barriers to medication use at the organizational level. This section reviews those
studies, the majority of which have focused on barriers to adoption (or use) of
naltrexone in alcohol dependent patients. The limitations of the studies are then
summarized, and how these limitations can be overcome using a multilevel approach
is explored.
Among the most recent studies was an investigation examining organizationallevel influences on the adoption of naltrexone in six northeastern states (Fuller et al.,
2005). Surveys were conducted in outpatient substance abuse treatment programs in
1997, 1999, and 2001, and structural equation modeling was used to assess the degree
to which organizational variables, including size, type of clinic, medication services
offered, funding streams, and staff characteristics impacted the adoption of naltrexone.
During the five-year time span of the study, the percent of programs reporting that
they use naltrexone went from 14% in 1997 to 25% in 2001. Most significant was the
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finding that organizational variables did not directly influence the use of naltrexone
during this time period, but rather their effects were mediated by whether a treatment
program offered psychiatric medications for mental health disorders. The authors
suggested that when a treatment program has already invested in the infrastructure
necessary to prescribe psychiatric medications, then it is not such a leap to make
available addiction medications. The study also found that larger organizations, with
more diverse funding streams and more highly educated counselors, were more likely
to adopt use of naltrexone. Programs that offered substance abuse treatment only were
less likely to adopt naltrexone.
In a mail survey to 135 physicians with substance abuse specialization (63%
response rate) and 1,116 certified addiction counselors (65% response rate) in
Massachusetts, Tennessee, and Washington state, limited support for use of naltrexone
was found (Thomas et al., 2003). As expected, physicians were more supportive of use
than counselors, with 80% reporting current or past experience prescribing naltrexone.
However, only 15% indicated prescribing it often or fo r almost all clients, while the
majority (45%) said they used it occasionally and the remaining indicated rare
(20.2%) or no experience (18.6%) (Thomas et al., 2003). In comparison, over half of
all counselors said they never suggested using naltrexone to their patients, and less
than 5% indicated recommending it often or almost all the time. To better understand
these findings, the investigators utilized logistic regression to examine the barriers to
adoption for both groups.
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For physicians, being involved in an organization that supported use of
medications for substance abuse disorders (odds ratio [ratio of the odds of an event
occurring in the physician group to the odds of it occurring in the counselor group] =
11.6) and having some experience with research (odds ratio = 19.7) increased the
likelihood that they would prescribe naltrexone. However, physicians in recovery (i.e.,
they were “in recovery” from their own addiction and were assumed to be abstinent)
(odds ratio = .2) and with multiple academic degrees (odds ratio = .1) were found to be
less likely to prescribe naltrexone. No explanation was given to explain these findings.
The authors also noted adoption may be hindered by a physician’s skepticism
regarding the evidence of naltrexone’s effectiveness. For counselors, programs that
organizationally supported use of naltrexone (odds ratio = 7.9) and who received
marketing information (odds ratio = 3.2) were more likely to recommend it to patients.
Additionally, counselors were more likely to encourage use of naltrexone if patients
had insurance coverage (Medicaid) (odds ratio = 2.0) or worked in the state of
Washington, which promoted use of the medication (odds ratio = 1.5), but less likely
to suggest its use if patients were self-pay or funded through block grants. In sum,
there appear to be multiple factors influencing use of medication in substance abuse
treatment programs, the strongest predictors being organizational support, financing
mechanisms, and state policies.
Focus groups have been used to leam more about the barriers to the use of
naltrexone. Mark, Kranzler, Poole et al. (2003) conducted two focus groups, one with
11 alcoholic patients and the other with 11 physicians who had treated alcohol
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dependent patients. Both patients and physicians were asked to rank barriers to use.
Patients’ responses in order of most salient to least were: (1) lack of education about
naltrexone, (2) side effects, (3) cost, (4) mode of administration, and (5) Alcoholics
Anonymous philosophy. Physicians offered their responses but did not agree on any
rank order: (1) insufficient research, (2) lack of perceived effectiveness on both the
part of patient and the physician, (3) lack of marketing, and (4) cost. For both groups,
the most significant barrier to use was lack of education about naltrexone. To examine
this finding further, the investigators reviewed the degree to which information about
the medication was being disseminated in research literature, at professional meetings,
and through pharmaceutical marketing efforts. Their conclusion was that, compared to
other psychotropic medications, there appeared to be less information disseminated
about naltrexone. They noted however, that if use of naltrexone was to increase, both
patients and physicians needed to be convinced that the benefits outweigh the side
effect risks.
In another study about physicians’ opinions about medications to treat
alcoholism, Mark, Kranzler, and Song (2003) surveyed 1,388 physicians (65%
response rate) from two specialty medical societies with expertise in addiction, the
American Society of Addiction Medicine (ASAM) and the American Academy of
Addiction Psychiatry (AAAP). Physicians belonging to both groups received only one
survey. On average, physicians indicated prescribing naltrexone to only 13% of their
alcohol dependent patients. Self-reported reasons for not prescribing naltrexone to
more patients included: Failure to comply with treatment (23.2%), cost (21%), patients
/
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not in a formal treatment program (14.8%), small effect on drinking relative to side
effects (11.6%), and concerns about side effects (10.3%). Other noted reasons
included lack of time to monitor use, naltrexone not being a medication paid for by
insurance, and an effect size in the small to medium range. When asked what actions
would lead to increased prescribing of medications for the treatment of alcohol
dependence, physicians indicated a need for more research to develop new
medications (33%), increased education about existing medications like naltrexone
(17%), and greater involvement of physicians in the treatment of alcoholism (17%).
Taken together, these findings suggest that physician attitudes, patient behavior,
economic factors, and medication characteristics all contribute to the low rate of
naltrexone prescribing.
In a study investigating organizational influences on the adoption of
naltrexone, Roman and Johnson (2002) found that 44.1% of a national sample of 400
private substance abuse treatment programs reported use of naltrexone. However,
actual usage in alcoholic patients was low (13.2% of the caseload), as was usage
among opiate dependent patients (11.3%). Using logistic regression, the authors
examined the degree to which treatment center structure, leadership, and caseload
characteristics influenced the adoption and implementation of naltrexone. Increased
probability of use was found in: older programs, led by administrators with longer
tenure in the field, that employed a higher percentage of master’s level counselors, and
with caseloads having a higher percentage of HMO/PPO patients and relapsers
(Roman & Johnson, 2002). With the exception of center age, no other structural
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characteristics including size, placement in a hospital, or availability of physician time
i

were significant predictors of naltrexone use. This finding suggests that an expanded
resource base may not be necessary in the adoption of naltrexone, and that other
variables play a more significant role in whether it is incorporated into routine
practice. Specifically, administrative experience in the field, counselor education, and
caseload characteristics appear to be the primary drivers.
In one of the first surveys to characterize attitudes about addiction treatment
and medication use in community-based treatment programs in the U.S., Forman,
Bovasso and Woody (2001) surveyed 317 substance abuse treatment staff members
(57% response rate) from three northeastern states. Survey participants came from a
broad cross-section of addiction treatment professionals working in a variety of
treatment settings and funding structures. Although over 80% of the respondents
supported increased research-based practice, only 39% supported the use of
naltrexone, and only 34% favored methadone maintenance. Many were unsure about
the use of naltrexone (46%) and over 40% disagreed that methadone maintenance
should be used more. In regards to naltrexone, the authors noted that it is unclear
whether the lack of support is due to a belief that it is not effective or the result of
insufficient knowledge about the medication (Forman et al., 2001). Consistent with
previous studies, support for medication use was highest for physicians and
psychiatrists, as well as those with advanced education. It is also worth noting that
support for psychiatric medications for mental health disorders ranked highest (52%)
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among all respondents, but the authors did not investigate whether this finding
predicted support for use of addiction medication as in the Fuller et al. (2005) study.
In a similar study in Ontario, Canada, 663 treatment staff (44% response rate)
from 227 specialized addiction treatment programs were surveyed about their attitudes
related to 53 different treatment processes including the use of medication (Ogbome,
Wild, Braun, & Newton-Taylor, 1998). Factor analysis identified three interpretable
dimensions of beliefs: (a) cognitive-behavioral, (b) disease, and (c) medication. The
cognitive-behavioral factor had high loadings for items related to coping skills,
identifying relapse triggers, and information on community resources frequently used
by cognitive-behavioral therapists. The second factor, disease, had high loadings for
items associated with 12-step programs and the disease concept of addiction. The final
factor had the highest loadings for items related to use of medication in preventing
relapse. Although there was overwhelming support for cognitive-behavioral
interventions, processes related to the disease concept of addiction received mixed
ratings. However, respondents overwhelmingly rated medications (antabuse,
methadone, opiate antagonists, and medications to control alcohol craving), on
average, as detrimental. The authors suggested this finding may reflect a general
ideological opposition to the use of medications in addiction treatment. Support for
medication use was only found for staff with masters or doctoral degrees, and those
working in assessment/referral services.
In the first comprehensive survey assessing attitudes related to the use of
buprenorphine in the treatment of opioid dependence, little support for use of the
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medication was found (Knudsen et al., 2005). More than two-thirds of the substance
abuse treatment counselors (N= 1972) selected a “don’t know” response when asked
about their perception of the effectiveness of buprenorphine based on their knowledge
and experience with the medication. Among counselors who provided ratings of
effectiveness ( N - 660), the mean score was 4.0 on a seven-point scale (SD = 1.66),
with no significant change in this outcome during the time of the study. Despite the
low rate of adoption overall, in the two years of data collection (June 2002 - July
2004), there was some evidence of increased counselor knowledge about
buprenorphine over time (note: different counselors surveyed during the study period).
Variables that predicted increased knowledge about perceived effectiveness included:
receiving buprenorphine specific training, increased education (at least a master’s
degree), and working in a treatment program that promoted use of the medication. The
authors also noted that counselors in recovery were more likely to know about and
accept use of buprenorphine, while those with a 12-step treatment orientation had the
opposite response. This finding suggests that personal recovery is not synonymous
with a 12-step orientation to treatment. Overall, these results show that lack of use of
medication in addiction treatment is not limited to naltrexone.
3.3.1 Influence o f the Above Findings on the Present Study
Summarizing the above, these studies collectively offer significant evidence of
the consistent lack of support for medication use in addiction treatment. They also
provide insight into the many barriers that play a role in why such medications are not
used more frequently. Perhaps most telling is the replication of findings related to both
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positive and negative influences on prescribing attitudes. Consistent positive
predictors from multiple studies included:
•

Increased education

•

Working in a treatment program that supports use of medications

• Patients having access to insurance to pay for medications
• Having received training or marketing materials related to medications
Being in a position to prescribe medications (physician, psychiatrist, etc.)
•

Experience with psychiatric medications

Consistent negative predictors were:
•

Having a 12-step orientation to treatment

•

Beliefs about the characteristics of the medications such as:
o

Cost

o

Side effects

o

Low to moderate effect

Although other predictors such as clinician recovery status (i.e., whether a clinician is
in recovery from his or her own addiction versus no personal experience with
addiction), organizational size and age, and caseload characteristics showed less
convergence among the study outcomes, they add to the complexity in understanding
why medications are underutilized in substance abuse treatment. What becomes
apparent when considering the above findings is that attitudes about medication are
influenced by a host of factors. What is not clear from the previous studies is the
specific role each of these factors plays in treatment staffs’ lack of support for
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medication use, as well as potential interactions among them. Also, as highlighted in
the previous chapter, these studies suffer from a number of methodological limitations
that include: 1) focusing on either individual or organizational level effects when both
need to be considered simultaneously; and 2) using analytic techniques that assume
independence of observations when the data have inherent dependencies.
In the above studies, some of the researchers chose to focus on individual-level
effects (Forman et al., 2001; Knudsen et al., 2005; Mark, Kranzler, Poole et al., 2003;
Mark, Kranzler, & Song, 2003; Mark, Kranzler, Song et al., 2003; Ogbome et al.,
1998; Thomas et al., 2003), whereas others examined outcomes based primarily on
organizational predictors (Fuller et al., 2005; Roman & Johnson, 2002). To date,
investigators have not studied the impact of both individual and organizational-level
factors simultaneously. The present study hypothesized there are a number of
important relationships between these multilevel variables that should be examined.
The specific relationships are detailed in Chapter 4, but they are based upon variables
at both the individual and organizational levels that have already been shown to be
significant predictors of medication attitudes. The key point is that when variables
from different levels of analysis are examined simultaneously, it is hypothesized that
important differences between treatment units will emerge, motivating the need for
different types of interventions to increase support for appropriate use of addiction
medications.
In addition to ignoring the relationships between variables at different levels of
analysis, a significant shortcoming of the above studies summarized above is their
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disregard of the dependencies that exist in the surveyed populations. This issue was
introduced in the previous chapter, and with the exception of Knudsen et al. (2005)
who corrected for the effects of clustered data, none of the other studies mention the
complexities involved in analyzing hierarchical data sets. By not accounting for the
dependencies that result from nested data (i.e., counselors nested in treatment
programs nested in geographic locations), outcomes from the above studies may not
be accurate. For example, in the Thomas et al. (2003) study, it was found that
counselors working in the state of Washington were more likely to recommend use of
naltrexone relative to counselors in Massachusetts and Tennessee as a result of state
policy differences. As a result, treatment programs in the state of Washington shared a
relationship that did not exist in the other states, illustrating how treatment programs
in the total sample are not all truly independent.
In summary, to gain a greater understanding of the factors influencing attitudes
towards use of medication in substance abuse treatment, it is necessary to consider
both individual and organizational predictors simultaneously. Multilevel modeling can
be used to examine such relationships, and offers a number of advantages including:
(a) improved estimation of the individual effects since multilevel models take into
consideration inherent dependencies in the data; (b) the ability to model cross-level
effects (i.e., interactions between individual and organizational factors); and (c) the
ability to partition the variance and covariance components among the levels, helping
to assess which predictors are most important (Raudenbush & Bryk, 2002). It is also
helpful to consider the theory behind why particular innovations become widely

Chapter 3: Literature Review

71

adopted, and others like addiction medications, fail to diffuse. All the above studies
provide pieces to the puzzle, but what connects the dots is diffusion o f innovation
theory, the focus of the next section.
3.4 Diffusion of Innovation
3.4.1 Theory and Models
Recent studies investigating barriers to medication use (Fuller et al., 2005;
Knudsen et al., 2005; Roman & Johnson, 2002; Thomas & McCarty, 2004; Thomas et
al., 2003) have all made reference to classical diffusion theory (Rogers, 1995, 2003).
Pioneered by Everett Rogers, the field of diffusion theory provides a framework for
understanding how and why particular innovations spread through a social system,
while others languish or are minimally adopted if at all. The theory offers a
generalizable model for piecing together findings from the previously reviewed
studies, ultimately paving the way for diffusion models specific to the field of
substance abuse treatment reviewed hereafter. The primary factors in the diffusion of
new ideas are: (a) an innovation (b) that is communicated through certain channels (c)
over time (d) among members of a social system (Rogers, 1995, 2003).
To a large degree, diffusion depends on attributes o f the innovation, which
help explain different rates of adoption (Meyer & Goes, 1988; Rogers, 2003). Among
the most important attributes are: relative advantage, compatibility, complexity,
trialability, and observabilty (Rogers, 2003). Taken together, these factors account for
up to 87% of the variance in whether an innovation is likely to be adopted, and offer
further insight into why medications used in substance abuse treatment have been
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underutilized (Rogers, 1995, 2003). To further illustrate this point, consider the role
these factors play in the diffusion of naltrexone.
Relative advantage refers to the degree to which an innovation is perceived as
being better than what is currently available, or what essentially boils down to a costbenefit analysis. Working against the diffusion of naltrexone is that it has not been
shown to be superior to other pharmacological or psychosocial treatments for alcohol
dependence. Further, naltrexone can be cost prohibitive for some patients, can
produce adverse side effects, and requires physician time to monitor. However, since
it does have a moderate effect, for some patients it is a useful intervention.
Compatibility refers to the degree in which the innovation is perceived as
being consistent with the values, experiences, and needs of potential users. For
clinicians and programs with a 12-step orientation to treatment, medications like
naltrexone serve little purpose, because recovery from alcoholism is based on
embracing a higher power (i.e., God or some other spiritual source of power). On the
other hand, treatment programs that have prescribers on staff and administrative
support for using addiction medications are more likely to adopt use of naltrexone.
Complexity is the degree to which the end user believes the innovation is hard
to use. Increased education and training are associated with greater levels of support.
This suggests that the more clinicians know about naltrexone (i.e., both about the
medication and steps necessary to have it prescribed to a patient) its perceived
complexity o f use is reduced. However, physicians have noted that use can be
complicated by noncompliance of patients and the need for increased monitoring
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(e.g., more appointments to address intended drug effects, side effects, compliance
issues). Other complexities may include dealing with insurance, finding referral
sources, and patient selection.
Trialability refers to the degree to which an innovation can be tested on a
limited basis without significant risk or commitment. All medications, including
naltrexone, are essentially prescribed on a trial basis until there is evidence of the
desired outcome without significant side effects. For this to happen, a patient must
first have access to naltrexone, which can be hindered by barriers including cost,
access to insurance, and prescriber availability. As a side note, free samples of
naltrexone were never offered (Mark, Kranzler, Song et al., 2003).
Observability is the degree to which the results of an innovation are visible to
others. For clinicians and their patients, observability most often translates into the
clinical outcome of fewer drinking days since this is often a primary goal of treatment.
But determining if this outcome is directly the result of naltrexone can be challenging
when patients receive concurrent psychosocial interventions and may also attend selfhelp support groups.
In addition to the above factors, the diffusion process is influenced by the
communication channels by which an innovation becomes known. Rogers (2003)
proposes that mass media channels (e.g., radio, internet, television, newspaper) are the
most rapid and efficient means of informing a population of potential adopters about a
new innovation. Although such channels potentially can change weakly held attitudes,
their primary role in the diffusion process is to inform individuals, who by their
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influencing power, persuade others to adopt an innovation. Individuals with persuasive
powers have been termed opinion leaders. During the persuasion stage, diffusion
occurs primarily through interpersonal channels that involve face-to-face interactions,
often with opinion leaders. These exchanges are more effective in forming and
changing attitudes toward a new idea, because they usually involve the transfer of
subjective information from a person who has tried the innovation to a potential new
adopter (Klein & Sorra, 1996; Meyer & Goes, 1988; Rogers, 2003). Thus, scientific
research may create awareness-knowledge of an innovation, but rarely does it
persuade a person to adopt an innovation to the same degree as a recommendation
from a trusted peer. Rogers (2003) also points out that although communication is
more effective among homophilous peers (similar in certain attributes), some degree
of heterophily (differences in attributes between individuals) is necessary for
successful diffusion to occur. Whereas homophily accelerates the diffusion process
among like individuals, heterophily communication links diverse groups of people,
thus expanding the spread of diffusion.
Communication channels play an important role in the diffusion of addiction
medications. Awareness-knowledge of medications like naltrexone and buprenorphine
first becomes known through mass media channels including scientific literature,
professional meetings, and trainings. Adoption decisions most often then occur
through face-to-face interaction with colleagues, opinion leaders in the addiction field,
and representatives from pharmaceutical manufacturers. However, marketing of
addiction medications by drug companies has historically played a smaller role, as
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manufacturers have spent little on promotion and have been cautious to avoid the
perception of selling a “miracle pill” (Mark, Kranzler, Song et al., 2003; Thomas et
al., 2003). Survey studies on the barriers to medication use have also revealed the
heterophilous nature o f the substance abuse treatment industry. Although there are
characteristic differences between physicians, counselors, and treatment
administrators, even wider gaps exist between researchers, clinicians, policy makers,
and the general public (Institute of Medicine, 1998). Although it may be easier for
addiction psychiatrists to convince other physicians of the effectiveness of addiction
medications, for adoption to become wide spread, communication between the various
heterophilous stakeholders is essential.
Diffusion of an innovation takes time. Diffusion research conceptualizes this
process into five steps: (1) knowledge (2) persuasion (3) decision (4) implementation,
and (5) confirmation (Rogers, 2003). From the time when a person first learns about
an innovation to his or her confirmation that adopting was the right thing to do, there
are inherent risks that an innovation may fail. Individuals will naturally seek
information throughout the diffusion process in order to reduce uncertainty about an
innovation’s expected outcome. Because individuals differ in their degree of risktaking, there is variability in adoption rates of an innovation across any given social
system. Significant research has been devoted to innovativeness, or the degree to
which an individual is relatively earlier at adopting an innovation over his or her peers.
This has led to adopter categories based on the S-shaped growth curve of successful
innovations. Since this growth curve approaches normality when plotted over time,
/

'

Chapter 3: Literature Review

76

five adopter categories have been conveniently established using the mean and
standard deviation as dividing lines: innovators (2.5%); early adopters (13.5%); early
majority (34%); late majority (34%); and laggards (16%) (Rogers, 2003).
Most research on adopter categories has focused on the socioeconomic,
personality, and communication traits of early adopters compared to the other groups.
To summarize, early adopters tend to have: (a) more formal education, (b) higher
social and economic status, (c) greater rationality and intelligence, (d) favorable
attitudes toward science and research, (e) higher status occupations, (f) more socially
outgoing personalities with larger interpersonal networks, (g) greater exposure to mass
media and interpersonal channels, and (h) increased knowledge of innovations
(Rogers, 2003). The ability to characterize differences between the groups has led to a
variety of market segmentation strategies utilizing different communication channels
to reach each subaudience.
Addiction treatment providers are not a homogeneous lot. Not only do
functional differences exist between programs (e.g., outpatient, inpatient, hospital), but
there is a range of attitudes toward medication use among treatment administrators and
staff. In general, the traits of early adopters resemble the traits found in individuals
who tend to support use of addiction medications. More favorable attitudes are
associated with higher levels of formal education, higher status occupations (e.g.,
psychiatrists/physicians vs. counselors), and greater acceptance of scientific research
(Fuller et al., 2005; Roman & Johnson, 2002; Thomas et al., 2003). The heterogeneity
of the substance abuse treatment industry is one reason why addiction medications
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have not been as quickly adopted as other pharmaceutical innovations. For example,
new arthritis and gastrointestinal disease medications have been shown to be widely
adopted within one year (Thomas & Ritter, 2000), whereas naltrexone has been
available since 1994 and still has limited usage, primarily by early adopters. It
becomes clear that if effective interventions are to be developed to increase support for
use of medications in substance abuse treatment, it will be necessary to better
understand the different groups or adopter categories within the addiction field.
Finally, diffusion of new ideas occurs within a social system, or group of
interrelated units (e.g., individuals, groups, organizations) that come together to solve
a common goal (Rogers, 2003). Although each unit may have its own individual
attributes, it is the shared objective between the units that defines the system. As
previously illustrated, underutilization of addiction medications is manifested within a
multilevel social system. The focal unit for understanding lack of pharmaceutical
diffusion in this study is the attitudes of staff, nested within substance abuse treatment
units, further influenced by the treatment industry and the national health care system.
Different factors from each level influence staff attitudes towards medication use,
ultimately impacting the entire diffusion process. Also, within each level there is a
defined structure that gives stability and regularity to how the units within that level
operate. For instance, staff working in treatment programs are subject to the policies
and working guidelines established by management. At the same time, every treatment
program must follow specific state practice policies or risk closure.
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Other important predictors of successful diffusion related to social systems
include norms, opinion leaders, and change agents (Rogers, 2003). Norms are the
established behavior patterns considered typical for a particular group. They define the
range of tolerable behavior and serve as guides to what is expected of each member
within a group. Norms can become a barrier to diffusion, particularly in the case of
addiction medications. The majority of treatment programs in the country embrace a
12-step ideology that resists medication use (Roman & Blum, 1997), resulting in a
norm among clinicians that significantly hinders adoption of new pharmacological
agents. However, such barriers may become weakened due to the influence of opinion
leaders and change agents.
Opinion leaders act as catalysts within an organization, using their influence in
informal ways to convince others of the benefits of a new innovation. They tend to be
at the center of interpersonal communication networks, and often are respected by
others for their technical competence and adherence to the system’s norms. In
substance abuse treatment programs, opinion leaders are at the forefront of bridging
the gap between practice and research. Whether functioning as a treating clinician or
administrative supervisor, these individuals embrace scientific research and work to
promote evidence-based practices within their organizations. They typically stay
current with new treatment innovations, attend workshops specific to new treatment
technologies, and network with others who maintain similar positions. Although
opinion leaders maintain significant influence in the diffusion process, often
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organizations will employ an external change agent with expertise in the diffusion
process.
Within the substance abuse treatment industry, change agents are most often
associated with academic research institutions (e.g., National Drug Abuse Treatment
Clinical Trials Network), government agencies (e.g., SAMHSA, CSAT, NIDA), or
private consulting firms. Change agents often make use of the influence of opinion
leaders, as well as offer structured interventions to guide the diffusion process within
an organization. As an example, change agents may utilize strategies from The
Change Book, a resource published by the Addiction Technology Transfer Centers
(2000) suggesting 10 steps that facilitate organizational change specific to the
adoption of new treatment technologies.
Lastly, when considering the many factors within a social system influencing
the diffusion of new innovations in substance abuse treatment organizations, it can be
useful to view a treatment program as an open system (Katz & Kahn, 1978). Figure 2,
illustrates the essential elements of a substance abuse treatment organization as an
open system:
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Figure 2. Substance abuse treatment organization as an open system.
To function, treatment programs require inputs from the external environment
including: qualified staff, population of patients needing treatment, financial support
from managed care organizations, and a location in which to offer services. These
resources are then transformed within the organization into outputs that ideally consist
o f patients with improved functioning. Outputs may also include decreased crime
within the local community, increased patient productivity, and reductions in
aggregate health care expenses (McLellan, Lewis, O'Brien, & Kleber, 2000).
Feedback in the system occurs in many forms, including patients returning to
treatment who have relapsed (Hubbard, Flynn, Craddock, & Fletcher, 2001),
counselors who are former patients, and changes in service delivery due to economic
or patient population conditions. Further, the dynamics between a treatment program
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and the external environment are often changing, making it more difficult to sort out
the many factors influencing diffusion of new technologies.
3.4.2 Diffusion Models in Substance Abuse Treatment
Recently, diffusion theory has played a role in the development of conceptual
models of technology adoption specific to substance abuse treatment. Simpson (2002)
has proposed a process model of program change built around major stages of
organizational change and factors that promote or hinder successful adoption of an
innovation (Figure 3):
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Figure 3. Texas Christian University Program Change Model (Simpson, 2002).
At the core o f the model are four steps that parallel closely those in general diffusion
theory: exposure, adoption, implementation and practice.
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Exposure to a new technology occurs through both mass media (lecture,
workshop) and interpersonal (consultant) communication channels. For exposure to
have an impact, treatment staff and administrative leaders need motivation to change
the status quo or a reason to consider a new innovation. Additionally, resources must
be available to support learning about the new technology such as training time and
educational materials.
Adoption combines Rogers’ (1995; 2003) persuasion and decision steps and
can be initiated on either an individual or group level. After attending a workshop, a
clinician or group of counselors may wish to adopt a new treatment intervention.
Likewise, a treatment director may decide to incorporate a new technology on behalf
of the organization. In these cases, the diffusion process is influenced by reception
and perceived utility of the innovation by counselors and treatment administrators,
which depend largely on the innovation attributes discussed previously (e.g., relative
advantage, compatibility), whether staff are properly trained, and the degree to which
the new innovation fits into the organizational culture (Morgenstern, Morgan,
McCrady, Keller, & Carroll, 2001).
Implementation involves the activities required to gain the targeted
organizational members’ appropriate and committed use of an innovation (Klein &
Sorra, 1996). In large part, this depends on the innovation’s fit with the current
climate fo r change within the organization, and the institutional supports (e.g.,
staffing, facilities, training, and equipment) necessary to initiate and sustain use of the
new technology. During this stage, users are likely to experience uncertainty and have
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questions related to putting a new innovation into practice (Rogers, 1995, 2003).
Andrzej ewski, Kirby, Morral, and Iguchi (2001) have shown that monitoring,
feedback, and positive reinforcement all can influence successful implementation.
Practice is the stage at which an innovation evolves into routine use. Simpson
(2002) stresses the importance of staff attributes (e.g., professional growth, efficacy,
influence, and adaptability) on successful adoption, while Rogers (1995,2003)
provides evidence that it largely depends on a confirmation process. Even after a new
innovation is in use, adopters and decision makers may continue to seek
reinforcement for the adoption-decision and may reverse it if there is sufficient
evidence that the new technology is not working as expected (although this feedback
mechanism is not illustrated in Simpson’s model).
In summary, this 4-stage process model offered by Simpson (2002) provides a
tool for better understanding the variables influencing successful diffusion of new
technologies specific to substance abuse treatment programs. Further, it identifies
targets for treatment program interventions that could occur at any of the four stages
and has been used as a framework for developing numerous organizational
questionnaires and surveys to support the diffusion process (Simpson, 2002). Most
useful is the TCU Organizational Readiness for Change (ORC) assessment used to
collect data from both staff and program directors on four domains related to the
process model: motivation for change, adequacy of resources, staff attributes, and
organizational climate (Lehman, Greener, & Simpson, 2002).
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Thomas et al. (2003) proposed an alternative model of technology diffusion
(Figure 4).

ClinicianCharacteristics
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Treatmentorientation
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Figure 4. Conceptual model for adoption of new substance abuse pharmaceutical
technologies (Thomas & McCarty, 2004)
First developed specifically to illustrate the factors affecting adoption of naltrexone, it
was later refined into a general model for adoption of new substance abuse
pharmaceutical technologies (Thomas & McCarty, 2004). As with the Simpson model,
this model incorporates many of the elements of standard diffusion theory including:
an innovation (Technology Characteristics), that is adopted by an individual
(Clinician Characteristics), in a social system (Organizational and System

Chapter 3: Literature Review

85

Characteristics). Unlike the Simpson model, which focused specifically on change
within a substance treatment program, Thomas et al. (2003) incorporate factors from
multiple levels (clinician, organization, larger treatment system) that interact to
influence adoption and implementation of a new pharmaceutical innovation. Further,
routine use of a new medication is dependent on patient acceptance, which is
influenced by patient attitudes and characteristics. The model is particularly useful for
identifying potential barriers to adoption of addiction medications, but it falls short of
illustrating the degree to which different variables contribute to the end goal.
Both models offer a framework for understanding the role treatment staff
attitudes play in use of medications in substance abuse treatment. In particular,
Simpson (2002) stresses the need for clinicians to have some degree of motivation for
considering use of medications, such as a caseload of high-relapsing alcoholics or the
need to manage opiate dependent patients without the use of methadone. In addition,
clinicians’ attitudes are influenced by the degree to which they are exposed to new
innovations, often a function of the training opportunities provided by treatment
administrators. Further, staff attitudes are influenced by the organizational climate,
resource availability, and personal attributes (e.g., education, recovery status,
theoretical orientation). The Thomas et al. (2003) model also illustrates that clinician
attitudes can be influenced by factors outside the treatment organization, including
financing of treatment, public policy, service capacity, and market factors. Finally, in
the case o f adoption of addiction medications, there is the need for organizational
acceptance prior to provider/patient acceptance. In sum, clinician attitudes about
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medication use are best understood from multiple perspectives as discussed in the
previous chapter.
Although these models offer insight into the diffusion of addiction
technologies, if they are to be widely used in practice, they will ultimately need to
articulate more clearly the relationships that exist between variables. The present study
does not attempt to provide all the answers, but it moves research in the right direction
by beginning to examine how some of the variables are related and to what degree. To
accomplish this goal, individual and organizational factors specific to attitudes about
addiction medications are studied using a hierarchical data set. The next section
reviews the history behind the National Drug Abuse Clinical Trials Network, the
source of the data used in the present study.
3.5 National Drug Abuse Clinical Trials Network
As identified in the IOM report Bridging the Gap Between Practice and
Research (1998), many evidence-based treatments developed by researchers for
substance abuse disorders, including the use of medication, have been significantly
underutilized in practice. The efficacy of these treatments, although demonstrated in
specialized research settings with homogeneous populations, generally have not been
tested in heterogeneous groups under contemporary treatment conditions. To address
this issue, the IOM report recommended that NIDA and CSAT develop a national
infrastructure of practitioners, investigators, and policymakers to facilitate research
within community-based treatment programs, similar to the National Cancer
Institute’s Community Clinical Oncology Program networks (Institute of Medicine,
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1998). The result was the National Drug Abuse Treatment Clinical Trials Network
(CTN).
In 1999 NIDA funded five nodes, each consisting of a regional research and
training center and 5-10 community treatment programs (CTPs). Since that time, the
CTN has evolved to a network that includes 17 nodes and more than 120 CTP
partners. The core mission of the CTN is twofold:
(1) Conduct studies of behavioral, pharmacological, and integrated behavioral
and pharmacological treatment interventions of therapeutic effect in rigorous,
multisite clinical trials to determine effectiveness across a broad range of
community-based treatment settings and diversified patient populations; and
(2) Transfer the research results to physicians, providers, and their patients to
improve the quality of drug abuse treatment throughout the country using
science as a vehicle (NIDA, 2002, p. 2).
Key to the success of the CTN has been the active participation of CTPs in the
research design, implementation, and analysis of data from clinical trials. Their
involvement also assures that researchers are appropriately informed about the
complexities involved in treating diverse patient populations with limited funding and
a diversely educated workforce.
The initial clinical trials tested buprenorphine detoxification, motivational
interviewing (MI) and motivational enhancement therapy, and low cost incentives for
methadone and outpatient programs. Results from the studies have only recently been
published. Two studies investigated buprenorphine-naloxone for short-term opioid
detoxification in both outpatient and residential settings (Amass et al., 2004; Ling et
al., 2005). Findings across twelve diverse CTPs revealed the medication to be safe,
efficacious, and effective, even for those patients receiving services from a CTP with
f
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minimal experience providing medical detoxification for opioid dependence.
Integrating motivational interviewing (MI) into the initial assessment in five CTPs
found that participants randomized to MI had significantly better retention rates
through the 28-day follow-up than those receiving the standard evaluation (Carroll et
al., 2005). However, no differences were found in use patterns at either the 28-day or
84-day follow-up, suggesting that MI is most useful in promoting patient retention
early in treatment. Lastly, the efficacy of an abstinence-based contingency
management intervention was tested across multiple methadone and outpatient CTPs
(Peirce et al., 2005; Petry et al., 2005). Patients in the treatment condition received
prizes for submitting substance-free urine samples, with the chances of winning
increasing with continuous abstinence. The intervention led to significantly more
stimulant and alcohol free drug samples, better retention rates, and statistically
significant abstinence outcomes over standard treatment.
These initial results suggest that researchers and clinicians can collaboratively
work together to test new treatment technologies and develop mechanisms for
successful adoption into practice. But diffusion theory, and the previously reviewed
diffusion models specific to substance abuse treatment, revealed that bridging the gap
between practice and research requires more than clinical trials in CTPs. Successful
adoption of evidence-based practices hinges on multiple factors including clinician
and organizational characteristics. Although a number of substance abuse treatment
workforce surveys have investigated these two critical factors (Brown, 1997; Forman
et al., 2001; Gallon, Gabriel, & Knudsen, 2003; Mulligan, McCarty, Potter, &
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Krakow, 1989; The Lewin Group, 2001), the CTN recognized the need to further
characterize attributes of participants in the CTPs to guide further clinical trials and
gain a better understanding of factors influencing study outcomes. The Oregon Node
coordinated data collection, analysis, and dissemination of results of the CTP,
treatment unit, and clinical workforce surveys.
Results from the surveys were summarized in two studies; one focusing on the
individual staff attributes (Level-1 in the present study), the other on the
organizational attributes (Levels 2 in the present study). Data from the Level-1
Workforce Survey (N= 3,786) focused on individual demographics, education,
certification and licensure, and attitudes towards use of specific EBPs including use of
medications to treat substance abuse disorders (McCarty et al., 2007). Results from the
Level-2 Treatment Unit Survey (N = 348) revealed: types of care offered, ancillary
services, patient demographics, patient drug use, and prevalence of co-occurring
disorders (i.e., patients having both a substance abuse and mental health disorder)
(McCarty et al., under review). When compared to the 2003 National Survey of
Substance Abuse Treatment Services, the findings suggested CTPs reflect the national
treatment system but tend to be more often located in medical settings and less likely
to offer mental health services (Substance Abuse and Mental Health Services
Administration, 2002).
As in the previously reviewed studies on barriers to medication use, the Level1 individual Workforce Survey (focus on individuals) found that across all job
categories, support for addiction medications was modest. About 35% of respondents
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supported increased use of methadone for heroin dependence, 29% supported
increased use o f naltrexone for alcohol dependence, and 28% indicated buprenorphine
is an effective treatment for opiate dependence (McCarty et al., 2007). Not
surprisingly (based on the previously cited results), higher levels of education and
ability to prescribe were associated with greater levels of support for medication use.
3.5.1 CTN Data as Basis fo r Present Study
The present study expands on these initial descriptive results and prior studies
cited above by investigating the degree to which individual and organizational
variables jointly help predict staff attitudes towards addiction medications. The CTN
surveys provide an ideal data set for this study for a number of reasons.
The first, and potentially most important, reason is that the surveys involved
data collection at three nested levels of analysis: 1) Individual, 2) Treatment Unit, and
3) Program. Data for the Individual level included attitudes towards the most
commonly used addiction medications (e.g., naltrexone, methadone, and
buprenorphine), and in addition, many individual-level factors previously shown to be
significant predictors of attitudes, including primary job function, highest educational
degree, and whether staff members received addiction-specific education and training.
Data collection for levels 2 and 3 (Treatment Unit and Program) was motivated by the
fact that treatment programs often operate multiple treatment units, where each unit
specializes in a particular aspect of treatment (e.g., detoxification, residential,
outpatient). As such, treatment units within one program may vary significantly in
terms of staff characteristics, models of treatment utilized, and patient populations
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(Roman & Blum, 1997). Program-level surveys focused more on the corporate
structure of the organization, its primary service setting (e.g., free-standing substance
abuse clinic, part of a hospital or medical facility), and funding sources. For the
present study, only service setting (from Level-3) was included in the analysis, and for
reasons to be described in Chapter 5, it was included as a Level-2 predictor. In this
way, program-level data, per se, were not employed in the present study.
The second attribute of the CTN survey data important to the present study is
that it allows a number of relationships to be examined within a multilevel framework.
Because differences exist between treatment units, the present study hypothesized that
these differences will impact the significance of individual-level factors on attitudes
about use of addiction medications in some predictable ways. For example, staff
working in treatment units whose service setting is connected to a hospital or medical
clinic, have a medication provider on staff, and already use pharmacotherapy to treat
psychiatric disorders, will be more likely to support of use of addiction medications,
regardless of their level of education or personal recovery status.
A third attribute of the CTN survey data important for the present study is its
form and format, which allows analysis using multilevel modeling that accounts for
the natural dependencies existing in such hierarchical data sets. Prior studies have used
similar multilevel data sets, but have analyzed the data using traditional regression
techniques, where the latter methods fail to account for the dependencies (cf. Section
2.1). The main thrust o f the present study was to employ multilevel modeling tools to
analyze the CTN data. This allowed development of more precise and nonbiased
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estimates of the predictors of attitudes towards addiction medications (i.e., technical
advantage over prior studies). Also, since the multilevel modeling methodology is
designed to examine individual and organizational variables simultaneously, it
provides a more real-world understanding of the predictors of medication attitudes
(i.e., conceptual advantage over prior studies).
Finally, the CTN survey data involved a large enough sample to meet the
requirements of a multilevel analysis that is focused on cross-level interactions and
exploration of variance across levels. Hox (2002) suggests that these analyses need to
meet the 100/10 rule, which means that the sample includes a minimum of 100 groups
with about 10 individuals per group. In the final sample following listwise deletion,
1,421 treatment staff are nested within 237 treatment units (cf. Section 6.1). In
addition, the CTN workforce survey is based on a national sample of communitybased treatment programs that generally reflects the national substance abuse
treatment system, strengthening the external validity of the study (Roman & Blum,
1997).
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Chapter 4: Problem Statement, Study Aims,
and Research Hypotheses
Motivation for the present study was presented in the previous chapter, and is
summarized here:
1. There exist several FDA approved medications for the treatment of substance
abuse disorders, yet support for use of these medicines by treatment staff
remains moderate at best (cf. Sections 3.2 and 3.3).
2. Understanding of attitudes related to use of addiction medications has
traditionally been gained via research methodologies that have not taken into
consideration the systemic nature of the variables, nor the hierarchical nested
structure inherent in treatment settings. This has resulted in outcomes that may
not only be inaccurate, but add little understanding of how variables at
different levels of analysis interact with each other (cf. Sections 2.1 and 3.3).
3. Diffusion models of technology adoption specific to the field of substance
abuse treatment have been proposed to help identify variables central to the
diffusion process. These models provide an underlying structure upon which
interventions can be developed. However, these models, by themselves,
articulate little about the dynamic relationships between variables, or the
degree in which specific variables play a role (cf. Section 3.4.1).
With the above as backdrop, the aims of the present study may be stated as follows:
Aim 1: Examine the relationship between individual-level (Level-1) variables
and attitudes about use of addiction medications, while controlling for other Level-1
/
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variables and organizational-level (Level-2) factors. The importance of this aim is to
assess whether individual-level variables that have been shown in prior studies to be
predictive o f medication attitudes remain significant when higher level variables are
included in the model. There are four hypotheses specific to Aim 1:
Hypothesis 1. Treatment staff members with a professional license to prescribe
addiction medications will be more supportive o f use o f addiction medications than
staff without a license to prescribe addiction medications, when controlling fo r other
individual and organizational factors. Prior research suggests that treatment staff who
are licensed to prescribe medications (e.g., physicians, psychiatrists, nurse
practitioners) are more supportive of use of addiction medications than staff who have
no authority to prescribe medications (Forman et al., 2001; Knudsen et al., 2005;
Thomas et al., 2003). Although a consistent finding, what has not been examined is
the degree to which being a prescriber versus a nonprescriber influences medication
attitudes when controlling for other multilevel variables.
Hypothesis 2. Higher levels o f education will be associated with greater levels
o f support fo r use o f addiction medications when controlling fo r other individual and
organizational-level factors. A consistent finding across several studies is that higher
levels of formal academic education are associated with greater levels of support for
use of addiction medications (Forman et al., 2001; Fuller et al., 2005; Roman &
Johnson, 2002). With increased education, the assumption is that treatment staff are
exposed to new ways of thinking about problems, become more open to various
treatment options, and are more apt to be exposed to research findings that support use
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of addiction medications. In the U.S., 98% of mental health treatment programs
require incoming treatment staff to have a minimum of a master’s degree, while only
10% of substance abuse treatment programs have the same requirement (Kerwin,
Walker-Smith, & Kirby, 2006). If education remains a significant predictor within a
multilevel framework as hypothesized, the challenge will be how to increase support
for use of addiction medications by less educated treatment staff.
Prior reviewed studies have also found that addiction-specific education (e.g.,
continuing education, pharmaceutical marketing materials, addiction-specific trainings
and workshops) is positively associated with increased support for use of addiction
medications (Knudsen et al., 2005; Thomas et al., 2003). Independent of academic
education, there is evidence that if treatment staff receive some kind of training
specific to the use of addiction medications, their level of support for the medications
increases. Because both academic and addiction-specific education are included in the
same model and tested under hypothesis 2, it is possible to assess the degree to which
each of these types of education are predictive of medication attitudes.
Hypothesis 3. Primary job category will predict attitudes about use o f
addiction medication, when controlling fo r other individual and organizational-level
factors, such that medical sta ff will be more supportive o f addiction medications than
managers/supervisors, counselors, and support staff. Whereas hypothesis 1
categorized treatment staff into two groups by professional licensure (i.e., those who
can prescribe versus those who cannot), this hypothesis assesses the degree to which
job category (e.g., counselors, medical staff, managers/supervisors, support staff)
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differentiates support for use of addiction medications. In essence, it provides another
test of hypothesis 1, where medical staff are assumed to be more supportive than all
other treatment staff. But it also examines the degree to which managers/supervisors
and support staff contribute to medication attitude outcomes within a multilevel
framework. Initial analyses of the CTN workforce surveys indicated that
managers/supervisors tended to be most supportive of evidence-based practices
(McCarty et al., 2007). Therefore, it is hypothesized that managers/supervisors will be
positively associated with use of addiction medications even more than counselors
because their job position likely involves staying current on EBPs. Support staff are
included in the analysis because they very often have direct patient contact and may
influence in subtle, or not so subtle, ways the use of addiction medications. For
example, a patient who is ambivalent about taking naltrexone for alcohol dependence
and shares this with a receptionist may hear something like “you probably don’t really
need it, most clients here just go to a few extra AA meetings.” To what degree this
factor plays a role when compared to other individual-level variables and
organizational predictors has not been previously investigated.
Hypothesis 4. Treatment staff indicating greater levels o f support fo r use o f
psychiatric medications will be more likely to support use o f addiction medications
when controlling fo r other individual and organizational-level factors. Although prior
studies have not examined this relationship directly, Fuller et al. (2005) found that use
of psychiatric medications in substance abuse treatment programs mediated the
relationship between other organizational variables (e.g., size, services offered,
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funding streams) and adoption of naltrexone. Further, Forman et al. (2001) found high
levels of support for use of psychiatric medications among a survey of substance abuse
treatment staff. Taken together, these studies suggest that the association between
psychiatric and addiction medications may depend on both individual and
organizational factors.
Aim 2: Examine to what degree treatment unit variables (Level-2) explain
variance at Level-1 that is not explained by Level-1 predictor variables, and explore
how significant Level-2 variables moderate relationships between Level-1 variables
and attitudes about use of addiction medications. Although previous studies have
shown that Level-2 predictor variables can significantly influence attitudes about
addiction medications, their relationship to Level-1 variables has not been
investigated. Therefore, this study tests four additional hypotheses specific to the
relationships that exist between individual and organizational factors.
Hypothesis 5. Treatment unit predictor variables (Level-2), taken together,
will account fo r a significant amount o f the variance in individual treatment staff
attitudes about the use o f addiction medications. This hypothesis, in large part,
addresses the major underlying motivation of the present study, because it says that an
accurate understanding of individual staff attitudes towards use of addiction
medications depends on both individual and organizational factors. Whereas the Aim1 hypotheses focus on testing Level-1 predictor variables in a multilevel framework,
this hypothesis tests whether Level-2 variables taken together represent a significant
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amount of variance that is not explained at the individual-level, while controlling for
Level-1 variables.
Five Level-2 variables that have been shown in prior research to be
significantly associated with medication attitudes are used to test this hypothesis. The
first is based on several studies that have shown organizational treatment models are
likely to explain some of the variance in individual staff attitudes (Knudsen et al.,
2005; Mark, Kranzler, Poole et al., 2003; Ogbome et al., 1998). Kaskutas et al. (1998)
has suggested that treatment units or programs can be classified as adhering either to a
social or medical model of treatment. Staff working in programs supportive of the
social model tend to utilize the philosophy promoted in the 12-step approach of AA
and believe that a higher power is the most significant ingredient associated with
behavior change. In essence, if recovery is the result of turning an addiction over to
God, then medications serve little purpose. Alternatively, those working in programs
supportive of a medical model (i.e., conceptualize addiction as a brain disease) are far
more likely to be supportive of use of medications that work to reverse or prevent
further brain changes resulting from continued substance abuse. The second selected
Level-2 variable is staff recovery status. This variable represents the estimated percent
of treatment staff that are in personal recovery within a given treatment unit. Prior
studies suggest a mixed relationship between this variable and support for addiction
medications (Knudsen et al., 2005; Thomas et al., 2003). By including this variable in
the multilevel models, the goal is to show that it plays a significant role in medication
attitudes, and to clarify its relationship with Level-1 variables and the DVs. The third
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selected Level-2 variable assesses whether a treatment unit’s primary intervention is
use of methadone. The assumption tested is that if a treatment unit already uses an
addiction medication, it should have a positive influence on individual staff attitudes.
The fourth selected Level-2 variable measures whether a treatment unit offers primary
medical care. Treatment units that are integrated in some way with primary care
medicine are assumed to be more supportive of addiction medications. The final
selected Level-2 variable, primary treatment setting, is a disaggregated Level-3
variable that is being tested in this study in a manner to determine whether it warrants
consideration in a full three-level model. If predictive in the two-level model, it would
suggest significant variability may exit between programs, and a more complex threelevel model would be indicated. This variable essentially measures whether a program
is a free-standing substance abuse clinic, or part of a larger healthcare service setting
(e.g., hospital, mental health center). The assumption is that programs attached to any
healthcare setting already routinely using medications would likely have a positive
influence on staff attitudes towards addiction medications. Taken together, these five
organizational variables are hypothesized to significantly explain variability in
treatment staff attitudes towards use of addiction medications.
Hypothesis 6. The relationship between staff education and attitudes towards
use o f addiction medications will be moderated by treatment model such that
education will play less o f a role when organizations adhere more to a social model o f
care. As previously reviewed studies have shown, higher levels of both academic and
addiction-specific education are associated with greater levels of support for addiction
f
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medications. However, it is hypothesized here that this relationship is not independent
of organizational effects, and that the treatment model used within a treatment unit
significantly influences the impact of education on individual medication attitudes.
The mechanism by which this occurs is in large part explained by organizational
culture. Schein (1992) has stated that organizational culture is:
A pattern of shared basic assumptions that the group learned as it solved its
problems of external adaptation and internal integration that has worked well
enough to be considered valid and, therefore, to be taught to new members as
the correct way to perceive, think, and feel in relation to those problems (p.
12).

Although treatment staff may have differing levels of education, the group-level effect
of organizational culture powerfully shapes the assumptions and attitudes about how
best to treat substance abuse disorders. This is particularly true when newer staff
members interact with staff that have worked in the field for many years and have
strong opinions about the “right way to work with clients.” As reviewed in Section
3.1.2, a significant challenge in the substance abuse treatment field is that many
treatment programs have long-adhered to a specific culture that has resisted use of
evidence-based practices including medications in favor of more social models of care
(i.e., 12-step philosophy of treatment). Therefore, when treatment model is allowed to
vary across treatment units, this study hypothesizes that this variation will
significantly explain Level-1 variability in the relationship between education and
attitudes about addiction medications.
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Hypothesis 7. The relationship between support for psychiatric medications
and attitudes towards use o f addiction medications will be moderated by whether a
treatment unit has on-site primary medical care, such that support fo r psychiatric
medications will be greater fo r treatment units offering medical care on-site. Prior
studies suggest there is reason to believe that a positive association exists between
attitudes about psychiatric medications and support for use of addiction medicines
(Forman et al., 2001; Fuller et al., 2005). Treatment staff that support medications for
mental health disorders and witness clients benefiting from psychiatric medications
are likely to be more supportive of addiction medications than staff that have no
experience with medications at all. But to a large extent, use of psychiatric
medications in substance abuse treatment programs depends on access to prescribers.
Therefore, it is hypothesized that the strength of the relationship between support of
psychiatric medications and attitudes about addiction medications will be depend on
whether a treatment unit has the necessary infrastructure to prescribe medications (i.e.,
on-site medical care). Staff working in treatment units that do have prescribers should
show greater levels of support for addiction medicines.
Hypothesis 8. The relationship between primary job and attitudes towards use
o f addiction medications will be moderated by whether a treatment unit is licensed to
dispense methadone, such that across all job categories, support o f addiction
medications will be higher in treatment units that currently use methadone. The
mechanism that best explains this moderating effect is Bern’s (1972) self-perception
theory that attitudes are often inferred from our behavior and the context in which the

Chapter 4: Problem, Aims, and Hypotheses

102

behavior occurs (i.e., it is behavior that causes attitudes). Therefore, regardless of job
position, if a treatment unit dispenses methadone it is hypothesized that staff behaviors
associated with this service will, over time, result in more positive attitudes towards
use of addiction medications. Further, as reviewed in Section 3.2.2, methadone
treatment for opioid dependence is among the most effective substance abuse
interventions currently available. Staff that are unsure or ambivalent in their attitudes
towards addiction medications are likely to develop more positive attitudes towards
these medicines if they witness positive outcomes for clients on methadone. It is also
the case that the organizational culture supporting methadone as a treatment
intervention positively influences attitudes about addiction medications in similar
ways as psychiatric medications.
Aim 3: Explore how results from the multilevel analyses might refine the
present diffusion models specific to substance abuse treatment, and motivate
interventions to increase support of appropriate use of addiction medications.
As a summary, Figure 5 illustrates: (a) the two levels of the study; (b) the
selected predictor variables at each level; (c) the hypothesized relationships each
variable has with attitudes about use of addiction medications; and (d) the three
dependent variables representative of attitudes about use of addiction medicines (i.e.,
naltrexone, methadone, and buprenorphine).
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TREATMENT UNIT (Level-2)
(1) Treatment Model
a. Social model (-)
b. Medical model (+)
(2) Methadone (i.e., Unit uses methadone)
a. Yes (+)
b. No (-)

ATTITUDE ABOUT
USE OF (Dependent
Variable):

(3) Primary Care On-site (+)
/

(4) Percent of Staff in Personal Recovery (-)

/
/

(5) Primary Service Setting
a. Free-standing AOD (-)
b. Medical/Mental/Social/Other (+)

(1) Naltrexone
(2)Methadone
(3) Buprenorphine

±
INDIVIDUAL fLevel-1)
(1) P rescriber statu s
a. P rescriber (+)
b. N on-prescriber (-)

/

LEGEND

Influences
Dynamically
Interact

(2)A cadem ic Education (+)
(3)Addiction Minor (+)
(4) Addiction CEUs (+)
(5) Jo b C ategory
a. C ounselor (-)
b. Medical staff (+)
c. M anagers/Supervisors (-)
d. S upport staff (-)

(+)

Hypothesized
positive relationship
with the DVs

(-)

Hypothesized
negative relationship
with the DVs

(6) S upport for Psychiatric M edications (+)

Figure 5. Multilevel predictors influencing attitudes about appropriate use of addiction
medications
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5.1 Study Participants and Procedure
This study analyzed existing data from the National Drug Abuse Treatment
Clinical Trials Network Workforce Surveys discussed in section 3.5. The data were
collected by the Oregon Node of the CTN between March 25, 2002 and August 24,
2004. Community-based treatment programs participating in the CTN were invited to
participate in the workforce study by completing three surveys: (1) Organizational, (2)
Treatment Unit, and (3) Staff. Of the 112 eligible community treatment programs in
the CTN, 106 completed the Organizational Survey (95% response rate). Treatment
Unit Surveys were obtained from 348 out of a possible 384 treatment units (91%
response rate), and Staff Surveys were collected from 3,786 workforce members (71%
response rate).
The workforce sample included 1,757 counselors, 522 managers/supervisors,
511 medical personnel, and 908 support staff. Missing data on job category from 88
respondents resulted in a total N of 3,698. Sixty-six percent of the workforce staff
were female, with the majority occupying support (74%) and medical (71%) positions,
rather than counselor (62%) and manager/supervisor (61%) roles (McCarty et al.,
2007). The workforce was ethnically diverse: 24% African-American, 11%
Latino/Hispanic, 3% multi-racial, 1% Asian/Pacific Islander and 1% American Indian
(60% were Caucasian). Most survey participants were full-time workers (i.e., 35 or
more hours per week) (84%), with the exception of medical staff (67%), who were
more likely to work part-time. Professional licensure was most common among
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medical staff (93%), and less so among managers (57%) and counselors (42%).
Seventy-two percent of the workforce had a college degree (associates degree or
higher), while managers (58%) and counselors (42%) were more likely to hold
advanced degrees (masters or doctoral degree).
To help facilitate data collection, the Oregon Node enlisted the help of a
protocol coordinator for each of the 17 CTN nodes. The coordinator distributed
surveys to their (respective) local CTPs, monitored response rates, and encouraged
participation in the study. All data by protocol coordinators were submitted to the
Oregon Node, which served as the data management center. Organizational and
Treatment Unit Surveys were primarily administered through a secure website and
completed online by Executive Directors and Treatment Unit Managers. In some
cases, paper and pencil versions were used when web access was hindered. The
Treatment Unit Survey also requested a listing of all staff employees; individual
workforce surveys were then provided to each person on the list through local CTN
protocol coordinators.
Because programs within the CTN varied in their opinions about participant
compensation, each node made its own participation compensation decisions.
Confidentiality for both the web-based and paper version surveys was maintained
using passwords and sealed envelopes. Quality assurance for the web-based forms
included checks for range, logic, and skip patterns, thus minimizing entry error.
Summaries of data for the Organizational and Treatment Unit Surveys were sent to
Executive Directors who made corrections for missing or incorrect values. The
/
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Oregon Health Science University (OHSU) Institutional Review Board (IRB)
reviewed and approved the study procedures. Because the survey was evaluated as low
risk, the OHSU IRB authorized use of an information sheet rather than a formal
consent process. Some nodes had their own IRB reviews with a few requiring a signed
consent form.
5.2 Measures
The three surveys described above were all developed by the Oregon Node of
the CTN for the purpose of collecting information on the attributes of participating
treatment organizations, treatment units, and workforce staff providing care. Items for
the surveys were constructed from the National Survey of Substance Abuse Treatment
Services (Substance Abuse and Mental Health Services Administration, 2002), prior
literature (Kaskutas et al., 1998; Simpson, 2002), or were developed specifically for
the surveys to assess beliefs and opinions about practices and treatment technologies
being tested or potentially being tested in the CTN. The Staff Survey included a 115item Organizational Readiness to Change Scale (Simpson, 2002), but no data from the
scale was used in the present study.
The Treatment Unit Survey included a 33-item Social Model Philosophy Scale
(SMPS) that was filled out by one supervisor for each treatment unit. The SMPS
classifies the extent to which treatment units follow a social model approach to
treatment (Kaskutas et al., 1998). Programs adhering to a social model approach rely
heavily on the principles of AA and often utilize staff who are in personal recovery
(Borkman, 1990). The scale is based on six domains (physical environment, staff role,
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authority base, view of substance abuse problems, governance, and community
orientation), where higher scores reflect greater use of the social model. Overall,
internal reliability of the SMPS was high (a = .92), with alphas for each of the six
subscales ranging from .57 to .79. Additionally, correlations between an overall scale
score and individual subscales ranged from .61 to .84, suggesting a moderate to strong
relationship between subscales and the scale’s total score. Validity testing was also
done by having three experienced substance abuse program administrators rank order
15 known programs in terms of the degree to which they felt the programs adhered to
a social model o f treatment. Rankings were then compared to results from the SMPS
with an overall correlation of .6 6 . The authors concluded that the SMPS accurately
measures a treatment unit’s adherence to the social model approach to treatment
across time, administrators, and respondents. The scale has also been shown to reliably
differentiate social model programs from those that adhere more to a medical model of
treatment (Kaskutas et al., 1998), and is used as an organizational predictor in the
present study.
Three dependent variables (DVs) were used in the study. All were from the
Staff Survey and based on answers given when CTN workforce members were asked
to assess the degree to which they disagree or agree (1-5 Likert scale, where higher
numbers reflect greater agreement) with the following statements: (a) Methadone
maintenance should be used more to treat heroin dependence; (b) Naltrexone should
be used more in the treatment of alcohol dependence; and (c) Buprenorphine is an
effective treatment for opiate dependence. Selection of the independent variables (IVs)
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was based on: (a) findings from previously reviewed studies; (b) key variables
identified by diffusion theory; and (c) their perceived (or face-value) usefulness in
explaining staff attitudes towards addiction medications within a multilevel framework
(cf. Section 4.1).
Six IVs from the Staff Survey were used to predict staff attitudes toward
addiction medication. Prescriber is a dichotomous variable where treatment staff have
been categorized by professional license into those with an ability to prescribe
medications (e.g., physicians, psychiatrists, nurse practitioners) and those clinicians
who are not licensed to prescribe medicines (e.g., counselors, social workers, clergy).
Academic Education is a dichotomous variable comparing staff members with a
graduate-level education (e.g., masters degree, doctoral degree, medical degree) to
those with less than a graduate education (e.g., no high school diploma, high school
diploma, associates degree, bachelors degree). Addiction Minor is a dichotomous
variable indicating whether a staff member has a minor degree in an addiction related
field. Addiction CEUs is measured by the number of substance abuse related
continuing education units (CEUs) taken during the last year. The variable Job
Category is a dummy-coded variable, where medical staff are the reference category,
compared against counselors, managers, and support staff. The final individual-level
variable, Psychiatric Medications, was measured by the question “Psychiatric
medications should be used more in addiction treatment” and scored on a 5-point scale
that ranged from 1 (strongly disagree) to 5 (strongly agree).
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Five IVs from the Treatment Unit Survey were used as Level-2 predictor
variables. Treatment Model were measured by the SMPS, where a total possible score
of 100 represents the ideal type of a pure social program. Lower scores reflect
treatment units more accepting of a medical treatment model. Methadone is a
dichotomous predictor variable indicating whether a treatment unit provides
methadone maintenance therapy as a primary component of treatment. The variable
was operationalized as units treating 10 or more patients with methadone. The
variable, Primary Care On-site, is also dichotomous and indicates whether a treatment
unit offers primary medical care on-site. Staff in Recovery is the percent of staff
estimated to be in personal recovery from substance abuse disorders. Finally, Service
Setting is a dichotomous variable and indicates whether a treatment unit is a free
standing substance abuse treatment program, or associated with a larger healthcare or
social service organization.
5.3 Analysis Strategy
The research questions examined in this study are hierarchical, in that their
goal was to help understand how individual-level and organizational-level
characteristics influence individual staff attitudes towards appropriate use of addiction
medications. Therefore, the associated hypotheses were analyzed using random
coefficient modeling (RCM) that allows for the investigation of both within and
between group effects on individual-level dependent variables (Raudenbush & Bryk,
2002; Snijders & Bosker, 1999). Currently, there exist a number of software packages
that can analyze multilevel models. For this study, Hierarchical Linear Modeling
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(HLM 6.0) software (Bryk et al., 2005) was used to estimate the random coefficient
models. The analyses followed the outline suggested by Hox (2002) that involves
specifying the simplest possible model, and then adding parameters step by step to
improve the overall model fit.
Before reviewing the steps that were used to develop the models in the study, it
is important to know how the models were estimated and compared, and the criteria
that were used to assess the significance of parameter estimates. The method most
commonly used to estimate regression coefficients and variance components in
random coefficient models is the Maximum Likelihood (ML) method (Raudenbush &
Bryk, 2002). ML essentially is an iterative process accomplished by multilevel
software that first generates estimates for all parameters. It then uses a computational
procedure to improve on the parameter estimates until the program converges, or
reaches a point where the estimates cannot be improved any further. A full discussion
of the estimation procedure is beyond the scope of this dissertation; the reader is
referred to Snijders & Bosker (1999) for a more detailed discussion.
With large samples such as those used in this study, ML estimates are
generally robust and protective against minor violations of the assumptions, including
non-normal errors (Hox, 2002). The HLM program produces /^-values (normally set to
.05 significance level) and confidence intervals that guide the selection of which
variables to keep in a model. An advantage of using the ML method is that a deviance
statistic can be computed to determine how well a particular model fits the data, and
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how it compares to other models. In general, lower deviance scores reflect better
fitting models. Hox (2002) explains:
The deviance is defined as -2xLN{Likelihood), where Likelihood is the value
of the Likelihood function at convergence, and LN is the natural
logarithm.. .the difference of the deviances for two nested models has a chisquare distribution, with degrees of freedom equal to the difference in the
number of parameters estimated in the two models. This can be used to
perform a formal chi-square test to test whether the more general model fits
significantly better than the simpler model (pp. 43-44).
Because all models tested in this study are nested models (i.e., two models are
equivalent with the exception that one model contains a subset of parameters not
shared by the other model), they can be compared statistically using their deviances. If
a significant difference is found between two models, it means that the model
estimating more parameters has a better fit to the data than the more parsimonious
model. However, if the chi-square test is not significant, estimating the additional
parameters has no benefit over the more parsimonious model and the simpler model is
retained.
The first step in model development is to analyze the simplest model, known
as the intercept-only model (i.e., also known as the empty model, constant-only model,
or null model) in which there are no explanatory variables. The model is represented
by the equation:
Yij = yoo + Uoj + Rij

The model contains only random groups (treatment units) and random variation within
groups. Y represents one of the DVs and is the sum of: (a) a general mean, yoo; (b) a
random effect at the group level, Uoj; and (c) a random effect at the individual level,
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Ry. The subscript i is for individual treatment staff within each treatment unit (i = 1
[first individual within a particular treatment unit j ] .. .i [last individual in treatment
unit j]) and the subscript j is for the treatment units (j = 1 [first treatment unit in
sample].. .j [last treatment unit in sample]). In the above case, yoo represents the mean
of all treatment unit means, and Uoj and Ry represent the unexplained variance at the
treatment unit and individual treatment staff levels. The intercept-only model is useful
because it provides an estimate of the intraclass correlation, or the proportion of
variance explained by having treatment staff grouped into treatment units. By
definition, the intraclass correlation is the proportion of variance at the group level
compared to the total variance (Snijders & Bosker, 1999). It is the expected correlation
of any two randomly chosen treatment staff members from the same treatment unit.
The intercept-only model is also useful because it provides a baseline measure of the
deviance that will be used to determine how much better models with added
parameters fit the data.
The second step involves analyzing a model that contains all the Level-1
explanatory variables hypothesized to explain (or reduce) variance at the individual
level (i.e., Ry). The following equation represents an initial Level-1 model predicting
medication attitude for one of the three DVs:
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medication attitudey = yoo

+ Xpj (prescriber)
+ X2ij (education)
+ X 3y (education)
+ X4ij (addiction CEUs)
+ X5y (job category)
+ X 6y (psychiatric medications)
+ Ry
+ U0j
Where: (a) yoo is the intercept; (b) Xiy.. .X6ij represent Level-1 predictors; (c) Ry is the
usual Level-1 residual error term; and (d) Uoj is the remaining variance explained by
Level-2 variables. Note that for every Level-1 predictor variable there is a
corresponding overall regression coefficient for the relationship (slope) between a
Level-1 predictor and the DV (i.e., yio - yso). Hox (2002) suggests that this model
include random intercepts and only fixed Level-1 variables (i.e., slopes not allowed to
vary across treatment units and fixed at zero) to allow for a direct comparison with the
intercept-only model.
The third step involves adding the Level-2 variables to the model, and
determining whether they help explain differences between treatment units in the DVs.
Again, explanatory variables at Level-2 are fixed, intercepts are allowed to vary, but
slopes are not allowed to vary in this model. The equation for the Level-2 model is:
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medication attitude^ = yoo + (Level-1 explanatory variables)
+ Zoi (treatment model)
+ Zo2(methadone)
+ Zo3(primary care on-site)
+ Zo4(staff in recovery)
+ Z 05(service setting)
+ Rij

+ Uoj
Where Zoi.. .Z04 represent Level-2 predictor variables. Note that for every Level-2
predictor variable there is a corresponding overall regression coefficient for the
relationship (slope) between a Level-2 predictor and the DV (i.e., yoi - yos). This
equation predicts the D V for the average treatment unit (the intercept yoo) from the five
Level-2 IVs. Notice that the intercept and each of the Level-2 variables do not include
a subscript j , meaning that these parameter estimates are all fixed across treatment
units (i.e., slopes are not allowed to vary). Both of the previous two models are
considered variance component models because they decompose the intercept
variance into different variance components for each level of analysis (Hox, 2002). In
such models, regression slopes for the predictor variables are fixed across treatment
units, but the regression intercepts are assumed to vary across the units. Although such
models have been used widely in research involving hierarchical data, they assume
that the group structure is represented in the explanatory variables (Snijders & Bosker,
1999). When groups vary in size, this is not the case, and random coefficient models
are necessary to account for group differences. Once a model with fixed regression
coefficients at both levels is shown to be superior to the intercept-only model using the
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deviance statistic to test differences, it is then appropriate to investigate and test the
random components of the model.
This step involves development of the random coefficient model by allowing
both the intercepts and the slopes of the Level-2 regression coefficients to vary across
treatment units. The purpose is to assess whether there is significant variance in the
Level-2 predictors between treatment units. Each Level-2 predictor is individually
assessed, and only those that vary significantly between groups are included in the
model. One reason for testing each parameter separately is that when slopes for all
Level-2 predictor variables are allowed to vary, it is possible that the model may not
converge or have serious estimation problems (Hox, 2002). It is also necessary to
consider reassessing any Level-2 variables in the previous step that did not have a
significant average slope across treatment units because such variables could be
significant when slopes are allowed to be random. The general equation may be
written:
medication attitude^ = yoo
+ (level- 1 predictor variables)
+ (level-2 predictor variables)
+ uPj (level- 1 predictor variables)
+ Uoj
+ Rij

Where u pj represent the treatment unit or group level residuals of the slopes of the
Level-1 predictor variables.
The final step is to add the hypothesized cross-level interactions to the model.
The purpose is to assess whether relationships between Level-1 predictors and the
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DVs depend upon the moderating effects of the Level-2 variables. The included
interactions are between the Level-2 variables and those Level-1 variables that had
significant slope variation from the previous step (Hox, 2002). This results in the full
(or final) random coefficient model given in the following equation:
medication attitude^ = yoo
+ (level- 1 predictor variables)
+ (level-2 predictor variables)
+ (level- 1 x level-2 variables)
+ Upj (level- 1 predictor variables)
+ U oj

+ Ry
Where the interaction terms are represented by: “level-1 x level-2” as shown in the
above equation. The overall fit of this final model is again assessed using the deviance
statistic and compared to the previously developed models.
In summary, use of multilevel modeling has a number of advantages over
approaches employed in prior studies, and is most appropriate for the data set used in
the present study. Even though both of these issues were outlined in previous sections
they are summarized here again:
1. Multilevel models are based on assumptions that are more realistic in that
they account for clustering of individuals within higher-level units, such as
treatment units or programs. They do this by not requiring the assumption
o f independence necessary for traditional ordinary least squares (OLS)
regression analysis. Also, they are more realistic in that they allow for the
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examination of variables that interact simultaneously at different levels of
analysis, such as in the present study.
2. Because multilevel models are based on more realistic assumptions, they
utilize more accurate estimated standard errors of parameter estimates and
thus decrease the probability of a Type I error in hypothesis testing.
3. Multilevel models allow for the investigation of cross-level effects by
examining how individual staff attitudes about addiction medication (Level
-1 in the multilevel models) are influenced by contextual factors existing at

the Treatment Unit level (Level-2).
4. Multilevel models partition the variance both within and between groups,
statistically separating the “true” variance of the predictors from the
sampling variance. This improves our ability to understand the degree to
which particular predictors influence individual staff attitudes about
addiction medication.
5. Multilevel models improve estimation of effects in situations with high
intraclass correlation. Such situations occur when there is homogeneity of
observations within groups, relative to between groups (Raudenbush &
Bryk, 2002). This is the case in the current data set, as individual staff in
particular treatment units are assumed to be more alike than staff in other
treatment units. If there were no differences between staff across treatment
units, the intraclass correlation would be zero and use of multilevel
modeling would have no advantages over OLS regression.
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6 . Multilevel models conceptually are an improvement over traditional

regression techniques because they encourage thinking about complex
phenomena systemically.
For all of these advantages, multilevel models are not without their drawbacks.
Perhaps the most significant limitation is that interpretation of the models can be
extremely challenging, particularly when models include multiple predictors at
different levels, and involve cross-level interactions. It is worth noting that of all
published studies that have utilized multilevel models, the majority (perhaps 90%)
have been two-level designs (Newsom, 2006). Although interpretation of fixed effects
is generally straightforward, interpretation of random effects can become more
difficult, particularly in models with multiple variables having moderating effects.
In addition, Kreft and Boon (1996), in an attempt to demystify multilevel
modeling techniques, concluded that no model by itself can advance a field. Multilevel
models may result in increased accuracy of parameter estimates, and allow for the
exploration of complex hierarchical data structures, but in the end, the techniques do
not generate knowledge; that is a function of the researcher. Therefore, model building
is somewhat of an art, and how models are constructed and tested should be driven by
theory and the field in which the models are used. Few studies in the substance abuse
field have utilized multilevel models, but it is hoped that this study will motivate
others to begin using multilevel models when analyzing data appropriate for such
analyses.
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Chapter 6: Results
6.1 Data Preparation and Evaluation of Assumptions
The original data set contained 3,786 treatment staff nested in 348 treatment
units. A limitation of multilevel modeling is the need for no missing data on predictor
or dependent variables. Although a number of sophisticated programs have been
developed to estimate missing data in multilevel data sets, at present, listwise deletion
is considered an acceptable option for handling missing data (Newsom, 2006). Table 1
provides a summary of missing data with no discernable patterns identified by
examining the data and frequency distributions. Two variables, Addiction Minor and
Table 1. Missing data prior to listwise deletion
Variable
Dependent Variables
Naltrexone
Methadone
Buprenorphine
Individual Level-1
Prescriber
Education
Addiction minor
Addiction CEUs
Jobduml - counselor
Jobdum2 - manager
Jobdum3 - support staff
Psychiatric med support
Treatment unit Level-2
Treatment model
Methadone unit
Primary care on-site
Staff in recovery (percent)
Free-standing clinic

Missing
221

90
284
0

137
1177
1357
0
0
0

126
17
5
7
67
0
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Addiction CEUs, were responsible for significantly more missing data than other
variables, but because they produced statistically significant results on two

•

medications they were maintained in the models.
Application of the listwise deletion procedure on the missing data resulted in a
data set containing 1,435 treatment staff nested in 239 treatment units. However, after
final models for each dependent variable were established, all were checked for
distributional assumptions and two multivariate outliers were discovered for
naltrexone.

0

Treatment Unit 196

0.000

50.000

Treatment Unit 309

10,000

50000

Figure 6 . Outliers for treatment units 196 and 309 for dependent variable naltrexone
In Figure 6 , chipct (expected values on the chi-square distribution) is plotted
again mdist (Mahalanobis Distance of the Empirical Bayes coefficients from the fitted
value) to check the normality assumption for Level-2 residuals. Treatment units 196
and 309 were both identified as multivariate outliers. A comparison of means across
predictors showed no obvious reasons why these treatment units were outliers.
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Subsequently, both were deleted from the data set, resulting in a final sample of 1,421
treatment staff nested in 237 treatment units. Descriptive statistics are provided in
Table 2, showing the means and standard deviations for the three dependent variables,
individual Level-1 independent variables, and treatment unit Level-2 independent
variables. Correlations among Level-1 predictors and the dependent variables, and
Level-2 predictors, are shown in Tables 3 and 4 (see next page).

Table 2. Descriptive statistics for dependent, Level-1, and Level-2 variables
Variable
Dependent Variables
Naltrexone
Methadone
Buprenorphine
Individual Level-1
Prescriber
Education
Addiction minor
Addiction CEUs
Jobduml - counselor
Jobdum2 - manager
Jobdum3 - support staff
Psychiatric med support
Treatment unit Level-2
Treatment model
Methadone unit
Primary care on-site
Staff in recovery (percent)
Free-standing clinic

M

SD

3.17
3.03
3.29

.86

1.17
.81

.05
.53
.40

.50
.49

22.12

22.12

.54
.21
.11

.50
.41
.32

3.40

1.01

34.23

13.77
.41
.46
27.01
.48

.22

.30
34.83
.63

.21
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Table 3. Correlations among Level-1 predictors and dependent variables

Variable

1

2

3

4

5

6

7

8

9

1. Prescriber

...

2. Education

.215

3. AOD minor

-.015

-.026

...

4. AOD CEUs

.031

.015

.216

...

-.241

,044

.156

.076

-.038

.171

.010

.081

-.538

-.061

-.210

-.104

-.165

-.400

-.183

.096

.136

.016

.018

-.057

.052

-.053

9. Naltrexone

.101

.122

.008

.048

-.074

.064

-.053

.236

...

10. Methadone

.142

.128

-.030

.014

-.061

.078

-.049

.270

.365

11. Buprenorphine

.191

.139

.040

.096

-.176

.137

-.058

.252

.361

5. Medical vs.
Counselor
6. Medical vs.
Manager
7. Medical vs.
Support
8. Psychiatric med.
support

Table 4. Correlations among Level-2 predictor variables
Variable

1

2

3

4

1. Treatment model

...

2. Methadone Used

-.225

...

3. Primary care on-site

.230

.101

...

4. Staff in recovery

.464

-.280

.004

...

5. Freestanding AOD

.177

-.136

-.088

.292

5

...

-
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Mean levels of support for all addiction medications, measured on a 1 to 5
scale (1 = low support and 5 = high support), were moderate. Treatment staff indicated
the highest mean levels o f support for buprenorphine (3,29), followed by naltrexone
(3.17), and methadone (3.03). It is worth noting that medications with higher levels of
support were more recently approved by the FDA for the treatment of addictive
disorders (i.e., buprenorphine was approved in 2 0 0 2 , naltrexone was approved in
1997, and methadone 1960s).
At Level-1, Prescriber is a dichotomous variable where a mean of .05
indicates there are very few prescribers in the total sample of treatment staff.
Academic Education is also a dichotomous variable where a mean of .53 indicates an
almost even split between graduate-trained counselors and those with a bachelors
degree or less education. In regards to addiction specific education, about 40% of
treatment staff had a minor degree in an addiction related field, and on average
treatment staff had 22.12 CEUs (note: most clinical licenses and certifications require
20 CEUs per year). For the dummy-coded variable Job category, where medical staff
are the reference category, the largest mean difference was between counselors (.54),
followed by managers (.21) and support staff (.11). These numbers represent the mean
difference between medical staff and each job category on a 1 to 5 scale. Mean
treatment staff support for psychiatric medications, measured on a 1 to 5 scale, was
3.40. Note that there was more support for psychiatric medications than for any of the
addiction medications.

f
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At Level-2, treatment model, measured by the SMPS, on average was 34.23 (1
to 100 scale where lower scores equate to a medical model and higher scores indicate
a social model of treatment). There were 22% of treatment units that indicated 10 or
more patients utilized methadone in treatment, and 30% of treatment units that said
primary care was available on-site. About 35% of staff working in treatment units
were in recovery, and 63% of all substance abuse treatment units were free-standing
clinics (i.e., not part of a hospital or other larger behavioral health treatment
organization).
In the results that follow, a linear relationship is assumed for all pairs of
variables. Distributional assumptions for all models were checked in HLM by creating
residual files for the Level-1 and Level-2 models. The files were written in SPSS and
the assumption o f normal distribution of Level-1 and Level-2 residuals were assessed
in Q-Q plots. Graphs for all models indicated no serious deviations from normality or
extreme outliers. The assumption of homogeneity of Level-1 variances (i.e., variance
of the residual errors is the same for all treatment units) for all models was assessed in
HLM utilizing a chi-square test where a significant j?-value indicates a violation of the
assumption. Results for all models found no assumption violations. The three
dependent variables were assessed for normality and produced skewness and kurtosis
statistics that were within the acceptable range (West, Finch, & Curran, 1995).
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6.2 Model Specification
6.2.1 Naltrexone Results
Total variance in staff attitudes towards naltrexone was partitioned into its
within-treatment and between-treatment unit components (random effects). In this
fully unconditional model, there are no predictor variables from any level, and the
analysis is equivalent to conducting a one-way random-effects ANOVA in which
treatment unit is a random factor with varying number of staff members per treatment
unit. Staff attitudes toward naltrexone were measured on a scale from 1 to 5, where
higher values represent greater support for use of naltrexone.
The results indicated that the variance in attitudes toward naltrexone between
staff within treatment units (sigma squared) was .6 8 , and the variance between
treatment units (tau) was .06. The chi-square test statistic of between-treatment unit
variability revealed statistically significant variability existed between treatment units
in staffs’ average naltrexone attitude scores, x2 (236) = 363.56, p < .001. The mean
naltrexone attitude score was significantly greater than zero (yoo = 3.16, t = 108.44,/? <
.001). The intraclass correlation (i.e., the percentage of variance between treatment
units) was .086, indicating that 8 .6 % of the variability in staffs’ attitudes about
naltrexone can be accounted for by differences in treatment units.
Next, a series of multilevel models were analyzed to examine the relationship
between attitudes towards naltrexone and the Level-1 and Level-2 predictors.
Following the steps outlined by Hox (2002) and detailed in Chapter 5, explanatory
variables were first added to the model with fixed slopes, decomposing the intercept
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variance into different variance components at the individual and treatment unit levels.
Predictors with a p-value o f greater than .05 were then deleted from the model,
resulting in the best possible model for the fixed part. Slopes were then allowed to
vary across treatment units, resulting in the final estimated random coefficient model
shown in Table 5. Final model fit was confirmed by examining the reduction in the
deviance statistic across models as discussed in Chapter 5. The initial deviance
statistic for the intercept-only model was 3591.89. After establishing the best possible
fixed model, the deviance dropped to 3504.91. The model fit was further improved by
allowing slopes to vary, resulting in a final deviance statistic of 3480.81.
Table 5. Final HLM model showing Level-1 and Level-2 predictors of attitudes
towards use of naltrexone
Effect
Fixed
Naltrexone attitude mean, yoo
Methadone used, Yoi
Primary care on-site, 702
Education, yio
AOD CEUs, y20
Medical versus Counselor, Y30
Support for psych med, Y40
Random
Variance of adjusted intercepts
across treatment units, Uoj (to2)
Education, Uij (xi2)
AOD CEUs, U2j (x22)
Medical versus Counselor, U 3j (T3 2)
Support for psych med, Uy (T4 2)
* p <.05,

**p<.01,

Coefficient Variance
3.150***
.256 ***
-. 144 **
.180***
.003 *
-.148 **
.157***

.037 *
.074 *
.000
.005
.029 *

***p<.001

Results indicated that the mean naltrexone attitude score was 3.15 at the grandmean o f all Level-1 variables and when Level-2 predictors are zero (t = 89.602, p <
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.001). The fixed effects indicated that variability in naltrexone attitudes is significantly
predicted by education, AOD CEUs, job category (medical versus counselor), and
support for psychiatric medication at Level-1, and use of methadone and primary care
on-site at Level-2.
Considering more specifically the Level-1 predictors, having a graduate degree
(masters degree or higher) was associated with a .180 increase in attitude towards
naltrexone when controlling for other grand-mean centered Level-1 and uncentered
Level-2 predictors (yio = .180, t = 3.744,/? < .001). This suggests that a graduate
education is one important factor associated with greater levels of support for use of
naltrexone. AOD CEUs was marginally significant (720 = -003, t - 2.411, p = .02),
suggesting that clinicians who attend continuing education trainings are more likely to
have greater support for use of naltrexone. For every additional AOD CEU there was a
.003 increase in attitude toward naltrexone when controlling for the other grand-mean
centered Level-1 and uncentered Level-2 predictors in the model. Job category was
dummy coded to reflect differences between medical staff and the other three job
categories (counselor, management, and support staff). In the present model, the only
significant relationship was the comparison between counselors and medical staff.
Specifically, counselors were -.148 less supportive of naltrexone than medical staff
when controlling for other grand-mean centered Level-1 and uncentered Level-2
predictors (730 = -.148, t = -3.637, p = .001). Of all Level-1 predictors, support for
psychiatric medications was most significant (740 = .157, t = 6.157,/? < .001). Results
indicated that a one-unit increase in support for psychiatric medication (e.g., from a 3
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to a 4 on a 1 to 5 scale) was associated with a .157 increase in attitude toward use of
naltrexone when controlling for the other grand-mean centered Level-1 and
uncentered Level-2 predictors in the model.
At Level-2, use of methadone in a treatment unit significantly predicted
increased support for use of naltrexone (yoi = .256, t = 4.758, p < .001). Use of
methadone in a treatment unit was associated with a .256 increase in attitude toward
use of naltrexone when controlling for the other grand-mean centered Level-1 and
uncentered Level-2 predictors in the model. On-site primary care in treatment units
was also a significant predictor of attitudes toward naltrexone (702 = -.144, t = -2.658,
p = .009). Having on-site primary care was associated with a .144 decrease in attitude
toward use of naltrexone when controlling for the other grand-mean centered Level-1
and uncentered level-2 predictors in the model.
The test of random effects indicated that attitudes towards naltrexone, adjusted
for grand-mean centered Level-1 variables and uncentered Level-2 variables varied
significantly across treatment units (to2 = .037, %2 (86 ) = 117.105,/? = .014). O f the
Level-1 predictors, the slope for education varied significantly across treatment units
(t i 2 = .074, x2 (88 ) = 115.144,p = .027), as did the slope for psychiatric
medications^ 2 = .029, X2 ( 88 ) = 116.001, p = .024). Further investigation of
interactions between education and support for psychiatric medications, and other
Level-2 predictors, yielded no significant relationships.
In summary, results for naltrexone provide support for: (a) Hypothesis 2 higher levels of education, specifically a graduate-level education and higher number
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of CEUs, were associated with greater levels of support for naltrexone; (b) Hypothesis
3 - medical staff were more supportive of use of naltrexone than counseling staff, but
other job category comparisons did not produce significant differences; (c) Hypothesis
4 - treatment staff indicating greater levels of support for use of psychiatric
medications were more supportive of naltrexone; and (d) Hypothesis 5 - treatment unit
predictor variables, specifically use of methadone in a treatment unit and having
primary care on-site, both significantly contributed to explaining individual
medication attitudes. No support was found for Hypotheses 1, 6, 7 ox 8 (see Section
7.1 for a more complete recapitulation of research questions and conclusions).
6.2.2 Methadone Results
Total variance in staff attitudes towards methadone was partitioned into its
within-treatment and between-treatment unit components (random effects). In this
fully unconditional model, there are no predictor variables from any level and the
analysis is equivalent to conducting a one-way random-effects ANOVA in which
treatment unit is a random factor with varying number of staff members per treatment
unit. Staff attitudes toward methadone were measured on a scale from 1 to 5, where
higher values represent greater support for use of methadone.
The results indicated that the variance in attitudes toward methadone between
staff within treatment units (sigma squared) was .88, and the variance between

treatment units (tau) was .47. The chi-square test statistic of between-treatment unit
variability revealed that statistically significant variability existed between treatment
units in staffs’ average naltrexone attitude scores, x2 (236) = 1017.87, /? < .001. The
f
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mean methadone attitude score was significantly greater than zero (yoo = 3.03, 1 —
56.208, p < .001). The intraclass correlation (i.e., the percentage of variance between
treatment units) was .345, indicating that 34.5% of the variability in staffs’ attitudes
about methadone can be accounted for by differences in treatment units.
Next, a series of multilevel models were run to examine the relationship
between attitudes towards methadone and the Level-1 and Level-2 predictors.
Following the steps outlined by Hox (2002) and detailed in Chapter 5, explanatory
variables were first added to the model with fixed slopes, decomposing the intercept
variance into different variance components at the individual and treatment unit levels.
Predictors with a p-value of greater than .05 were then deleted from the model,
resulting in the best possible model for the fixed part. Slopes were then allowed to
vary across treatment units, resulting in the final estimated random coefficient model
shown in Table 6 . Final model fit was confirmed by examining the reduction in the
deviance statistic across models. The initial deviance statistic for the intercept-only
model was 4160.80. After establishing the best possible fixed model, the deviance
dropped to 3995.20. The model fit was further improved by allowing slopes to vary,
resulting in a final deviance statistic of 3972.38.
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Table 6 . Final HLM model showing Level-1 and Level-2 predictors of attitudes
towards use of methadone
Effect
Fixed
Methadone attitude mean, yoo
Methadone used, yoi
Primary care on-site, Y02
Staff in recovery (percent), yo3
Prescriber, yio
Education, y2o
Medical versus Manager, y3o
Support for psych med, y4o
Random
Variance of adjusted intercepts
across treatment units, Uoj (to2)
Prescriber, Uy (xi2)
Education, U2j (X22)
Medical versus Manager, U 3j (T32)
Support for psych med, U4j (t 42)
* p <.05,

**p<.01,

Coefficient Variance
2.997***
1.063 * **
-.179*
-.005 **
.484 **
.136*
.209 **
.147 ***

-181 * **
.114
.031
.006
.051 * *

***p<.001

Results indicated that the mean methadone attitude score was 2.997 at the
grand-mean of all Level-1 variables and when Level-2 predictors are zero (t = 36.237,
p < .001). The fixed effects indicated that variability in methadone attitudes is
significantly predicted by professional licensure (prescriber), education, job category
(medical versus managers), and support for psychiatric medication at Level-1, and use
of methadone, primary care on-site, and percent of staff in recovery at Level-2.
More specifically, at Level-1, professional licensure (i.e., the ability to
prescribe medications) significantly predicted attitudes towards methadone (yio = .484,
t = 3.646,/? = .001). The ability to prescribe medications was associated with a .484
increase in attitude toward methadone when controlling for other grand-mean centered
Level-1 and uncentered Level-2 predictors. Further, having a graduate degree (masters
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degree or higher) was associated with a .136 increase in attitude towards methadone
when controlling for other grand-mean centered Level-1 and uncentered Level-2
predictors (720 = .136, t = 2.412,/? = .017). This suggests that a graduate education is
one important factor associated with greater levels of support for use of methadone.
Job category was dummy coded to reflect differences between medical staff and the
other three job categories (counselor, management, and support staff). In the present
model, the only significant relationship was the comparison between counselors and
management. Specifically, management was .209 more supportive of methadone than
medical staff when controlling for other grand-mean centered Level-1 and uncentered
Level-2 predictors (730 = .209, t = 3.563,/? = .001). Support for psychiatric
medications was also a significant predictor of attitude toward methadone
(740 = .147, t - 4.696, p < .001). Results indicated that a one-unit increase in support

for psychiatric medication was associated with a .147 increase in attitude toward use
of methadone when controlling for the other grand-mean centered Level-1 and
uncentered Level-2 predictors in the model.
At Level-2, use of methadone in a treatment unit significantly predicted
increased support for use of methadone as would be expected (yoi = 1.063, t = 9.943,/?
< .001). Use of methadone in a treatment unit was associated with a 1.063 increase in
attitude toward use o f methadone when controlling for the other grand-mean centered
Level-1 and uncentered Level-2 predictors in the model. On-site primary care in
treatment units was also a significant predictor of attitudes toward methadone (702 =
-.179, t = -2.003,/? = .046). Having on-site primary care was associated with a .179
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decrease in attitude toward use of methadone when controlling for the other grandmean centered Level-1 and uncentered Level-2 predictors in the model. Lastly, the
percent of staff in recovery significantly predicted attitude toward methadone (703 =
-.005, t = -2.710,/? = .008). A one-percent increase in the number of treatment staff in
recovery was associated with a .005 decrease in attitude toward methadone.
The test of random effects indicated that attitudes towards methadone, adjusted
for grand-mean centered Level-1 variables and uncentered Level-2 variables varied
significantly across treatment units (to2 = .181, %2 (18) = 70.139, p < .001). Of the
Level-1 predictors, only the slope for support of psychiatric medications varied
significantly across treatment units (X42 = .051, x2 (21) = 39.50, p = .009). Further
investigation of interactions between support for psychiatric medications and other
Level-1 predictors yielded no significant relationships.
In summary, results for methadone provide support for: (a) Hypothesis 1 - the
ability to prescribe methadone was associated with greater levels of support for use of
methadone; (b) Hypothesis 2 - higher levels of education, specifically a graduate-level
education, was associated with greater levels of support for methadone; (c) Hypothesis
4 - treatment staff indicating greater levels of support for use of psychiatric
medications were more supportive of methadone; and (d) Hypothesis 5 - treatment
unit predictor variables, specifically use of methadone in a treatment unit, having
primary care on-site, and the percentage of staff in recovery all significantly
contributed to explaining individual medication attitudes. Opposite to what was
hypothesized about job categories (Hypothesis 3), medical staff were significantly less
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supportive o f methadone than management. No other job category comparisons
produced significant differences, and no support was found for Hypotheses 6, 7 or 8
(see Section 7.1 for a more complete recapitulation of research questions and
conclusions).
6.2.3 Buprenorphine Results
Total variance in staff attitudes towards buprenorphine was partitioned into its
within-treatment and between-treatment unit components (random effects). In this
fully unconditional model, there are no predictor variables from any level and the
analysis is equivalent to conducting a one-way random-effects ANOVA in which
treatment unit is a random factor with varying number of staff members per treatment
unit. Staff attitudes toward buprenorphine were measured on a scale from 1 to 5,
where higher values represent greater support for use of buprenorphine.
The results indicated that the variance in attitudes toward buprenorphine
between staff within treatment units (sigma squared) was .51, and the variance
between treatment units (tau) was .14. The chi-square test statistic of betweentreatment unit variability revealed that statistically significant variability existed
between treatment units in staffs’ average buprenorphine attitude scores, % (236) =
614.143, p < .001. The mean buprenorphine attitude score was significantly greater
than zero (yoo = 3.30, t = 99.908, p < .001). The intraclass correlation (i.e., the
percentage of variance between treatment units) was .215, indicating that 21.5% of the
variability in staffs’ attitudes about buprenorphine can be accounted for by differences
in treatment units.
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Next, a series of multilevel models were run to examine the relationship
between attitudes towards buprenorphine and the Level-1 and Level-2 predictors.
Following the steps outlined by Hox (2002) and detailed in Chapter 5, explanatory
variables were first added to the model with fixed slopes, decomposing the intercept
variance into different variance components at the individual and treatment unit levels.
Predictors with a p-value of greater than .05 were then deleted from the model,
resulting in the best possible model for the fixed part. Slopes were then allowed to
vary across treatment units, resulting in the final estimated random coefficient model
shown in Table 7. Final model fit was confirmed by examining the reduction in the
deviance statistic across models. The initial deviance statistic for the intercept-only
model was 3295.72. After establishing the best possible fixed model, the deviance
dropped to 3144.77. The model fit was further improved by allowing slopes to vary,
resulting in a final deviance statistic of 3116.06.

f
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Table 7. Final HLM model showing Level-1 and Level-2 predictors of attitudes
towards use of buprenorphine
Effect
Fixed
Buprenorphine attitude mean, yoo
Treatment model, yoi
Prescriber, yio
Education, y2o
AOD Minor,
AOD CEUs, y4o
Medical versus Counselor, yso
Support for psych med, y6o
Random
Variance of adjusted intercepts
across treatment units, U o j (xo2)
Prescriber, Uij (xi2)
Education, U 2j (X22)
AOD Minor, U 3j (X
32
)
AOD CEUs, U4j (x42)
Medical versus Counselor, Usj (X
52
)
Support for psych med, U6j (x62)
* p < .05,

** p < .01,

Coefficient Variance
3.528 ***
-.006 **
.463 ***
.162 ***
.090*
004 * * *
- 7 5 7 ***

. 102**

.095
.029
.046
.000
.016
.029

*** p < .001

Results indicated that the mean buprenorphine attitude score was 3.528 at the
grand-mean of all Level-1 variables and when Level-2 predictors are zero (t = 46.093,
p < .001). The fixed effects indicated that variability in buprenorphine attitudes is
significantly predicted by professional licensure (prescriber), education, AOD minor,
AOD CEUs, job category (medical versus counselor), and support for psychiatric
medication at Level-1, and treatment model at Level-2.
More specifically, at Level-1, professional licensure (i.e., the ability to
prescribe medications) significantly predicted attitudes towards buprenorphine (yio =
.463, t = 4.907, p < .001). The ability to prescribe medications was associated with a
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.463 increase in attitude toward buprenorphine when controlling for other grand-mean
centered Level-1 and uncentered Level-2 predictors. Further, having a graduate degree
(masters degree or higher) was associated with a . 162 increase in attitude towards
buprenorphine when controlling for other grand-mean centered Level-1 and
uncentered Level-2 predictors (720 = -162, t = 3.876,/? < .001). This suggests that a
graduate education is one important factor associated with greater levels of support for
use of buprenorphine. Having a minor degree related to addiction was also significant
(730 = .090, t = 2.078,/? = .038) and associated with a .090 increase in attitude toward

buprenorphine when controlling for other grand-mean centered Level-1 and
uncentered Level-2 predictors. Also significantly predictive of attitudes toward
buprenorphine is the number of AOD CEUs (740 = .004, t = 3.861 ,P < .001). For every
additional AOD CEU there was a .004 increase in attitude toward buprenorphine when
controlling for the other grand-mean centered Level-1 and uncentered Level-2
predictors in the model. Job category was dummy coded to reflect differences between
medical staff and the other three job categories (counselor, management, and support
staff). In the present model, the only significant relationship was the comparison
between counselors and medical staff. Specifically, counselors were -.257 less
supportive o f buprenorphine than medical staff when controlling for other grand-mean
centered Level-1 and uncentered Level-2 predictors

(7 5 0

= -.257, t = -6.178,/? < .001).

Finally, support for psychiatric medications was also significant (760 = .155, / = 7.329,
/? < .001). Results indicated that a one-unit increase in support for psychiatric
medication (e.g., from a 3 to a 4 on a 1 to 5 scale) was associated with a .155 increase
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in attitude toward use of buprenorphine when controlling for the other grand-mean
centered Level-1 and uncentered Level-2 predictors in the model.
At the treatment unit level, only treatment model significantly predicted
attitudes towards use of buprenorphine (yoi = -.006, t = -3.137 ,p = .002). A one-unit
increase in the model of treatment (i.e., Kaskutas Scale from 1 to 100) was associated
with a .006 decrease in attitude toward use of buprenorphine when controlling for the
other grand-mean centered Level-1 and uncentered Level-2 predictors in the model.
The test of random effects indicated that attitudes towards buprenorphine,
adjusted for grand-mean centered Level-1 variables and uncentered Level-2 variables
varied significantly across treatment units

( xq2

= .102, x2 (22) = 42.693,p = .005).

However, none of the Level-1 slopes were significant and helped to explain this
treatment unit variance.
In summary, results for buprenorphine provide support for: (a) Hypothesis 1 the ability to prescribe buprenorphine was associated with greater levels of support for
use of buprenorphine; (b) Hypothesis 2 - higher levels of education, both graduate as
well as CEUs, and having a minor degree in an addiction-related field, was associated
with greater levels of support for buprenorphine; (c) Hypothesis 3 - medical staff were
more supportive o f use o f buprenorphine than counseling staff, but other job category
comparisons did not produce significant differences; (d) Hypothesis 4 —treatment staff
indicating greater levels of support for use of psychiatric medications were more
supportive of buprenorphine; and (e) Hypothesis 5 - treatment unit predictor variables,
specifically treatment model, contributed to explaining individual medication
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attitudes. No support was found for Hypotheses 6, 7 or 8 (see Section 7.1 for a more
complete recapitulation of research questions and conclusions).
6.3 Summary Across Medication Models
Table 8 (see next page) provides a summary of the significant predictors in the
final random coefficient models across all three addiction medications. It is worth
noting that education and psychiatric medication support were significant predictors
across all medications. However, the variable, free-standing (i.e., free-standing versus
part of a larger healthcare organization), and the dummy coded variable comparing
medical staff to support staff, were not significant predictors for any of the
medications.
The table also indicates that across all medications, there was significant
variance between treatment units (i.e., random intercept variance). A comparison of
the intraclass correlations revealed that more variability exits at the organizationallevel for methadone (34.5%) and buprenorphine (21.5%) than for naltrexone (8.6%).
Further, although not shown in the table, the random intercept variance was partially
explained by differences in support for psychiatric medications for naltrexone and
methadone, and for differences in education for naltrexone. Additional investigation of
interaction effects with these variables and other Level-2 variables revealed no
significant interactions.
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Table 8. Summary of significant coefficients in final multilevel models across
medications

Level-2
Treatment model
Methadone unit
Primary care on-site
Staff in recovery
Free-standing
Level-1
Prescriber vs. Non-prescriber
Education
AOD minor
AOD CEUs
Medical vs. Counselor
Medical vs. Management
Medical vs. Support Staff
Psychiatric medication support
Random intercept variance
Intraclass Correlation
* p <.05,

* * p < .0 1 ,

Naltrexone

Methadone

.26 ***
-A44 **

1.063 ***
-.179*
-.005 *

Buprenorphir
. 006 ***

.180 ***

.484 **
.136*

.003 *
-.148 **

.463 ***
.162 ***
.090 *
.004 ***
- 257 ***

.209 **
157 ***
Yes
8.6%

147 ***
Yes
34.5%

.155 ***
Yes
21.5%

* * *p < .00 1

An important consideration when evaluating the usefulness of the above
findings is the distinction between statistical and practical significance. Abelson has
said:
A major difficulty with simply using the significance level is that thep value
depends not only on the degree of departure from the null hypothesis, but also
on the sample size. Thus with very large samples, small effects can readily
achieve extreme significance levels (Abelson, 1995, p. 40).
In the present study, a robust sample size contributed to producing some significant
findings that have questionable practical significance. For example, AOD CEUs
significantly predicted medication attitudes towards naltrexone and buprenorphine.
However, the coefficient values, .003 for naltrexone and .004 for buprenorphine, are
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so small that a counselor would have to obtain over a hundred CEUs in one year to
raise an attitude score by even half a point (i.e., score of 3 to 3.5). Since most
professional licensing boards require only 20 CEUs per year, there is little chance that
any counselor would obtain enough CEUs in a given year to significantly influence
medication attitudes.
Although there are additional variables that have questionable practical
significance (treatment model, AOD Minor, staff in recovery), a decision was made to
not eliminate them from the models because: (a) they were statistically significant; (b)
they did influence medication attitudes, although not to the same degree as other
variables in the model; and (c) there is usefulness in understanding the magnitude of
their effects when analyzed within a multilevel design, since they have been shown to
be important predictors in previous research. However, future studies would likely
benefit from examining more parsimonious models.
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Chapter 7: Discussion
There is strong evidence that pharmacotherapy specific to addictive disorders,
when combined with psychosocial interventions, can contribute to positive treatment
outcomes. Yet in spite of this evidence, studies consistently indicate a general lack of
support for use of addiction medications by those working in the addiction treatment
field. The purpose o f this study was to extend previous research on treatment-staff
attitudes towards addiction medications by examining the influence of individual and
organizational factors within a multilevel framework. Although all of the variables
selected for the analysis had been significant predictors in prior studies, none had been
tested within a multilevel design that considers individual and organizational factors
simultaneously.
In the first part of this chapter, findings addressing each of the specific
research questions (hypotheses) are summarized (Aim 1 and Aim 2 from Chapter 5).
The results are then discussed in a more general framework that explores their unique
contribution to the field. The discussion then examines the practical implications for
how support for appropriate use of addiction medications can be increased, utilizing
the systems methodology outlined in Chapter 2 (Aim 3). This chapter also addresses
the possible unintended consequences of promoting and increasing the appropriate use
of addiction medications. Lastly, the limitations of the study and directions for future
research are explored.
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7.1 Recapitulation o f Research Questions and Conclusions
Hypothesis 1. Treatment sta ff members with a professional license to prescribe
addiction medications will be more supportive o f use o f addiction medications than
staff without a license to prescribe addiction medications, when controlling fo r other
individual and organizational factors.
The results indicated that the ability to prescribe addiction medications is a
significant predictor of medication attitudes when controlling for other individual and
organizational factors, but not across all medications. Contrary to studies suggesting
prescriber status is an important predictor of attitudes towards naltrexone (Forman et
al., 2001; Thomas et al., 2003), this study found that it was only predictive for
methadone and buprenorphine. One explanation is that prescribers may view
medications for opiate dependence differently than a medication for alcohol
dependence. Methadone has long been the gold standard for effectively treating opiate
dependence, and has also been used for years as an effective pain analgesic. As a
result, prescribers are likely to be more familiar with methadone, its historical use in
treatment programs (i.e., methadone maintenance programs), and may know that there
are no well-established self-help or psychosocial interventions for opiate dependence
as there are for alcoholism.
To prescribe buprenorphine (also for opiate dependence), physicians are
required to meet specific qualifications outlined in the Drug Addiction Treatment Act
of 2000 aimed at ensuring proper use of the medication. No such requirements exist
for naltrexone, so it is possible that physicians may be less versed in naltrexone’s use
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for alcoholism. But this argument is weak because the physicians surveyed were
working in substance abuse treatment programs and likely were aware of how to
appropriately use it. Perhaps most revealing is that unlike treatment for opiate
dependence, alcoholism has been traditionally treated by programs that emphasize use
of the 12-steps of AA. Such self-help programs have historically not been supportive
of addiction medications. In my own experience as a clinician, I have known at least
three medical directors of alcohol treatment programs that were in recovery
themselves, champions of 12-step ideology, and believed that change was ultimately
related to a spiritual experience and not because of the use of a medication. Although
this study included the percent of staff in recovery as an organizational variable, the
original data did not differentiate recovery status by job category; thus further
exploring its significance for prescribers was not possible. Whether or not personal
recovery status and 12-step ideology help differentiate the effects between different
medications needs to be further explored.
It is also interesting to note that support for psychiatric medications was a
significant individual-level predictor across all medications, but only significantly
explained treatment unit variance for methadone. Thus, prescribers, even in programs
that treat alcohol dependence, are not adverse to supporting use of psychiatric
medications.
Hypothesis 2. Higher levels o f education will be associated with greater levels o f
support fo r use o f addiction medications when controlling fo r other individual and
organizational-level factors.
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Similar to prior research (Forman et al., 2001; Fuller et al., 2005; Knudsen et
al., 2005; Roman & Johnson, 2002), this study found that across all medications,
higher levels of academic education significantly predicted attitudes towards
appropriate use o f addiction medications when controlling for other individual and
organizational factors. The only other variable at either the individual or
organizational-level that was significantly predictive across all medications was
support for psychiatric medications. Thus, this study offers further evidence that
academic education is among the most important of all predictors of addiction
medication attitudes.
Unfortunately, this study did not investigate what specific educational factors
were responsible for increased support for addiction medications. However, an
interesting finding was that having a minor degree related to addiction was only
predictive of attitudes towards buprenorphine, and only at the p < .05 significance
level. This may indicate that the benefits of a graduate-level education may have more
to do with learning how to think about a broad range of issues from multiple
perspectives, critically evaluate research, and become aware of the role of personal
bias, rather than an increased knowledge of addiction-specific content. It is also
possible that those who teach addiction-specific content may have personal biases
towards addiction medications and inadvertently pass on their opinions to students.
Future studies are needed to better understand the role of academic education, and
learn what factors most influence attitudes towards addiction medications.
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As mentioned in Chapter 5, 98% of mental health treatment programs require
incoming clinical staff to have a minimum of a master’s degree, while only 10% of
addiction treatment programs have the same requirement (Kerwin et al., 2006). This
has led to a clinical workforce in the substance abuse treatment field that is much more
academically diverse than in the field of mental health. In the present study, about
60% of workforce staff had a bachelor’s degree or less, 30% had a master’s degree,
and about 5.5% had a medical or doctoral degree (4.5% missing data). Other
workforce surveys have found similar academic diversity (Kaplin, 2005). In the
absence o f knowing what specific educational factors influence medication attitudes,
one obvious implication is that support for appropriate use of addiction medications
can be increased if program managers hire clinicians with a minimum of a master’s
degree.
Alternatively, the present study found that CEUs related to the treatment of
addictive disorders positively influenced attitudes towards naltrexone and
buprenorphine, but not methadone. This finding is similar to those of other studies
(Knudsen et al., 2005; Thomas et al., 2003), and suggests that addiction-specific
education (e.g., trainings, workshops) can influence medication attitudes independent
o f formal academic education. It is also very likely that current CEU trainings and
programs would have a greater emphasis on relatively newer FDA approved
medications like naltrexone and buprenorphine rather than methadone. For program
managers who are limited financially in their ability to hire master’s level counselors,
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increased focus on CEU programs specific to addiction medications may be a costeffective alternative.
Hypothesis 3. Primary job category will predict attitudes about use o f addiction
medication when controlling fo r other individual and organizational-level factors,
such that medical staff will be more supportive o f addiction medications than
managers/supervisors, counselors, and support staff
Primary job category was not a strong predictor of attitudes towards addiction
medications. This study found only three significant differences between medical staff
and other job categories. As hypothesized, medical staff had more favorable attitudes
towards naltrexone and buprenorphine than counselors, but did not differ significantly
in their attitudes towards methadone. This finding provides further evidence that
prescribers have greater levels of support for use of naltrexone and buprenorphine than
clinical treatment staff, but it also reveals that prescribers are not significantly
different from managers and other support staff on these two medications. For
methadone, contrary to what was hypothesized, managers were significantly more
supportive of methadone than prescribers. It is very likely that program managers of
methadone maintenance programs are more supportive of use of methadone than
prescribers because the success of their business relies on the appropriate use of
methadone. It also makes sense that prescribers and counselors would not differ
significantly on their attitudes towards methadone because use of the medication is
ubiquitous within programs.

/
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Collectively, the findings suggest that within substance abuse treatment
programs, medical staff, managers/supervisors and support staff are not so different in
their attitudes towards addiction medications. But counselors, who have the most
patient contact, are the least supportive of use of medications. Findings for hypotheses
1 and 2 suggest that higher levels of education help explain this difference, but support
staff have the least amount of formal academic experience. Thus it appears that the
most significant divide in attitudes within treatment programs is between treatment
staff, and more specifically between counselors and prescribers. In the latest survey on
substance abuse treatment services in the United States (SAMHSA, 2005), only 28%
of the programs said they offered pharmacotherapy, delivered mostly by part-time
prescribers who have little contact with counseling staff (McLellan & Meyers, 2004).
Further, it is worth noting that a large number of program directors worked as
clinicians before moving into managerial positions (McLellan & Meyers, 2004).
Therefore, interventions to increase support for appropriate use of addiction
medications across the entire treatment system must recognize that general counseling
staff should be a primary target population. Even in programs that do not offer
pharmacotherapy, if counselors support the appropriate use of addiction medications,
then they are in a strong position to lobby management to find a way to add this
service. At the very least, programs can develop a system where patients can be
referred to prescribers outside of an agency.
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Hypothesis 4. Treatment sta ff indicating greater levels o f support fo r use o f
psychiatric medications will be more likely to support use o f addiction medications
when controlling fo r other individual and organizational-level factors.
This study contributes further evidence to previous findings that staff who
support use of psychiatric medications are more likely to be supportive of addiction
medications (Forman et al., 2001; Fuller et al., 2005). As mentioned in hypothesis 2,
support for psychiatric medications and academic education were the only two
predictors at both the individual and organizational level that significantly predicted
attitudes towards all three medications. In addition, support for psychiatric
medications significantly explained variance between treatment units, but only for
naltrexone and methadone. Unfortunately, further examination of this random effect
with other Level-2 variables suggested no significant interactions. One possible
explanation for the random effect is that the differences in treatment units are directly
related to which treatment units actively treat psychiatric problems. Additional
research is needed to better understand the role of psychiatric medications in substance
abuse treatment clinics.
Over half of all patients who seek treatment for substance abuse problems have
a significant co-occurring mental health disorder, and that after the severity of the
substance abuse problem, the variable most predictive of successful treatment
outcomes is severity of psychiatric symptoms (Institute of Medicine, 1998; Kessler et
al., 1997; Kessler et al., 1994). Unfortunately, only about 40% of substance abuse
treatment programs in the country conduct any type of psychiatric evaluation, with
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even fewer offering comprehensive treatment services for mental health problems
(McLellan et al., 1993; SAMHSA, 2005). Thus, it appears that one broad challenge of
the current substance abuse treatment system is how best to accommodate individuals
with co-occurring disorders. Although there are a variety of effective psychosocial
interventions for many mental health problems, there is clear evidence that use of
medications (e.g., antidepressants, antipsychotics) can significantly enhance treatment
outcomes for many patients (Institute of Medicine, 2006). Therefore, it appears there
is a dual challenge of how best to go about increasing support for both psychiatric and
addiction medications. It is likely that efforts to increase one will likely have a positive
spillover effect on the other.
Hypothesis 5. Treatment unit predictor variables (Level-2), taken together, will
account fo r a significant amount o f the variance in individual treatment staff attitudes
about the use o f addiction medications.
A primary objective of the present study was to test known predictors of
addiction medication attitudes - both individual and organizational - within a
multilevel framework. Findings suggest that attitudes towards addiction medications
are a function o f both individual and organizational factors, but to varying degrees
across the three medications. The intraclass correlation provides an estimate of the
percentage of variance in individual attitudes that is explained at the organizational
(treatment unit) level. Across the three medications, naltrexone had the least amount
of variance at the organizational-level (8.6%), followed by buprenorphine (21.5%),
and methadone (34.5%). Unlike at the individual-level where academic education and
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support for psychiatric medications were predictive across all medications, no
organizational predictors showed the same consistent outcome. This suggests that
attitudes towards each medication are a unique blend of individual and organizational
factors.
Naltrexone showed the least amount of variability at the organizational-level,
but that variability in part was explained by two factors. Staff working in treatment
units that routinely used methadone (i.e., methadone maintenance programs) were
significantly more supportive of naltrexone for the treatment of alcohol dependence.
This suggests that once staff become comfortable using one addiction medication they
are likely to be supportive of others. Among the most puzzling findings and opposite
to what was hypothesized, was that staff working in treatment units providing on-site
primary care were less likely to be supportive of naltrexone. Although only about a
third of all treatment units offered such services, this finding suggests that primary
care professionals may represent a culture at odds with substance abuse treatment.
Differences in individual characteristics, training, experience, and philosophies of
treatment likely explain such cultural gaps (Thomas & McCarty, 2004). Further, it
may also be that primary care staff working in substance abuse treatment programs are
more likely to be in personal recovery, resulting in less favorable attitudes towards
addiction medications (Thomas et al., 2003).
Organizational factors were most predictive of attitudes towards methadone.
As expected, a significant and positive relationship was found between methadone
maintenance treatment units and attitudes towards use of methadone. Similar to
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naltrexone, staff working in treatment units providing on-site primary care were less
supportive of methadone for likely the same reasons suggested above. It is worth
noting that on-site primary care was not predictive of attitudes towards buprenorphine,
a medication strongly being marketed for use in primary care clinics external to
substance abuse treatment. This suggests even more that primary care staff working in
substance abuse treatment programs may hold unique beliefs and attitudes towards
addiction medications separate from primary care staff not associated with addiction
treatment. Attitudes towards methadone were also significantly predicted by the
percentage of staff in personal recovery. The greater the percentage within a treatment
unit the less supportive staff attitudes were towards methadone. Because this study did
not investigate which personal recovery characteristics most related to medication
attitudes, this finding needs further investigation in light of Knudsen et al. (2005)
suggesting that personal recovery is not synonymous with a 12-step orientation to
treatment.
The only organizational-level factor that significantly predicted attitudes
towards buprenorphine was the model used in treatment (i.e., medical versus social).
Staff adhering more to a social model of care were significantly less supportive of
buprenorphine. This is not surprising since the essence of a social model of care is
based on healing relationships and not use of a medication (Kaskutas et al., 1998).
Although prior studies indicated this factor was important across medications
(Knudsen et al., 2005; Mark, Kranzler, Poole et al., 2003; Ogbome et al., 1998), when
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tested within a multilevel framework, the results suggest that treatment model may
play a less significant role across addiction medications.
In summary, results from this study suggest that organizational factors play a
more significant role in predicting attitudes towards medications to treat opioid
dependence than alcohol dependence. It is worth noting that methadone, which had the
highest degree of organizational variability, also was the only medication for which
management (at the individual-level) were more supportive of its use than prescribers.
Further, when comparing the overall profiles of predictors at both the individual and
organizational levels, attitudes towards buprenorphine were explained by the most
individual-level predictors (six compared to four for naltrexone and methadone) and
the least organizational factors (one compared to two for naltrexone and three for
methadone). Thus when tested in a multilevel framework, attitudes towards each
addiction medication appear to be a unique blend of individual and organizational
factors, suggesting that efforts to increase support for addiction medications would
benefit from medication-specific interventions.
Hypothesis 6. The relationship between staff education and attitudes towards use o f
addiction medications will be moderated by treatment model such that education will
play less o f a role when organizations adhere more to a social model o f care.
No evidence was found to support treatment model as a moderator of the
relationship between staff education and medication attitudes. Only attitudes towards
buprenorphine were predicted by both education and treatment model, but the test for
random effects indicated that treatment unit variance was not related to staff
(
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education. This provides further evidence that education may be among the most
important predictors of medication attitudes, and be independent of the model used in
treatment. As a result, interventions to increase the support for addiction medications
may not have to be as concerned about the organizational culture of treatment units so
much as the degree of education of staff working in those units.
Hypothesis 7. The relationship between support for psychiatric medications and
attitudes towards use o f addiction medications will be moderated by whether a
treatment unit has on-site primary medical care, such that support fo r psychiatric
medications will be greater fo r treatment units offering medical care on-site.
No evidence was found to support on-site primary medical care being a
moderating effect o f the relationship between psychiatric medications and addiction
medication attitudes. As previously noted, support for psychiatric medications was
among the most significant individual-level predictors across all medications, and a
significant random effect for naltrexone and methadone. Yet further investigation of
interaction effects for naltrexone and methadone with on-site primary care revealed no
significant relationships. This may suggest that primary care is not synonymous with
use of all medications, and that medications used for psychiatric and addictive
disorders may represent a class of drugs less known to staff delivering primary care
services. This gap between behavioral health and primary care has been noted by
others (Institute of Medicine, 2006; Thomas & McCarty, 2004), and provides another
opportunity for the development of interventions to increase support for addiction
medications.
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Hypothesis 8. The relationship between primary job and attitudes towards use o f
addiction medications will be moderated by whether a treatment unit is licensed to
dispense methadone, such that across all job categories, support o f addiction
medications will be higher in treatment units that currently use methadone.
Findings suggest that the relationship between primary job category and
medication attitudes is not moderated by the use of methadone in treatment units.
Although some significant differences in attitudes between prescribers and other staff
members across medications was found, none of these produced significant random
effects, suggesting that the differences in attitudes are fairly consistent across
treatment units. This implies that interventions to increase support for addiction
medications specific to job category, may not have to be as concerned about whether a
treatment unit uses methadone or not. However, it is worth noting that only about a
fifth of all treatment units in the present study were considered regular dispensers of
methadone, and that additional multilevel research is needed to more fully characterize
the relationships between treatment staff, use of methadone, and attitudes towards
addiction medications in general.
7.2 Contribution o f the Findings
The primary objective of this dissertation was to develop a better
understanding of why those who deliver substance abuse treatment services are not
more supportive of addiction medications, given the vast evidence that such
medications can significantly contribute to positive treatment outcomes. This is
important because medications have the potential to improve the lives of many who
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struggle with addiction, but only to the extent that such medications are supported by
the treatment community and known to patients. Although numerous studies have
examined the determinants of attitudes towards addiction medications and found that
individual and organizational factors are involved, the present study was the first to
investigate such factors within a multilevel framework. As a result, the findings
advance the current research literature by providing evidence for the following:
1. Individual and organizationalfactors simultaneously influence attitudes
towards addiction medications. Although prior studies have indicated that
attitudes towards addiction medications involve both individual and
organizational determinants, this study provided the first empirical support that
both are involved simultaneously. Further, it showed that attitudes towards
addiction medications are determined primarily by individual characteristics,
but that for some medications, organizational factors are quite important. For
example, attitudes towards naltrexone were least influenced by organizational
determinants (8.6%), while more than a third of the variance of attitudes
towards methadone were explained at the organizational-level (34.5%), with
buprenorphine in the middle (21.5%).
2. Determinants o f medication attitudes are not consistent across medications.
The findings suggest that the determinants of medication attitudes are not
homogeneous across medications. Unlike many of the prior studies that
focused exclusively on one medication, a strength of this study is that it
examined the determinants of attitudes across three different medications. As a
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result, the outcomes provide evidence that a unique blend of individual and
organizational factors exist for each medication, although specific factors are
robust predictors of attitudes across all medications. This suggests that efforts
to increase support for each medication should ideally take into consideration
the unique profile of each medicine.
3. Education and support fo r psychiatric medications are among the most
importantfactors influencing attitudes towards addiction medications. This
study provides further and convincing evidence that higher levels of academic
education (i.e., graduate-level education) and support for use of psychiatric
medications are among the most important determinants of positive attitudes
towards addiction medications. Interestingly, both of these factors are also
critical to substance abuse treatment outcomes in general. As discussed in
Chapter 3, there has been a gap between research and practice that is now
beginning to close as evidence-based practices become more and more
implemented in treatment programs across the country. One of the ways this is
occurring is by recognizing the benefit of hiring professionally trained staff
(i.e., graduate-level education) that have the ability to deliver EBPs, including
those that address mental health disorders. Many payees of addiction treatment
services (e.g., county contracts, HMOs, private health insurance plans) now
require that treatment be delivered by professional counselors, knowing that
their expenditures will be optimized (i.e., best clinical outcomes for the least
expense). Thus, results from this study further support the general shift taking
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place in the field to hire graduate trained clinicians, and integrate substance
abuse treatment with mental health services.
4. Staff attitudes towards addiction medications vary between treatment units.
An advantage of examining the determinants of medication attitudes within a
multilevel framework is that it is possible to explore variance both within and
between treatment units. As a result, this study found that there were
significant differences between treatment units across all medications. Further,
findings pointed to some of the variability between treatment units for
naltrexone and methadone being explained by differences in academic
education and attitudes towards psychiatric medications. Unfortunately, no
significant relationships were found between these predictor variables and the
organizational factors included in the models. This suggests that there are
additional variables influencing attitudes towards addiction medication that
need further investigation.
5. Existing models illustrating the factors and processes involved in the
adoption o f addiction medications (Figure 3 and 4), could be improved by
incorporating factors and processes that more carefully operationalize the
relationships between variables, and take into consideration the unique
attributes o f each medication.The determinants of attitudes towards addiction
medications are a complex blend of individual and organizational factors that
vary across medications. Although the general models of technology diffusion
put forth in the literature go beyond the determinants of attitudes (Simpson,
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2002; Thomas & McCarty, 2004), such models could be refined by
considering: (a) the multilevel nature of the variables (i.e., how do they fit
within a levels framework with emerging properties such as in Figure 1?); (b)
the different roles variables play across medications (i.e., why is treatment
model important for one medication and less important for another?); (c) the
causal relationships between variables (i.e. how are variables specifically
related to each other - what causes what?); (d) the variable of time (i.e., how
do the variables interact and change over time?); and (e) unintended
consequences of the adoption of medication use (i.e., what might be the
negative effects of increased used of addiction medications?).
6. A systems approach offers the bestframework fo r examining the complex
nature o f attitudes towards addiction medications, andfor the development
o f interventions to increase the supportfo r use o f addiction medications. A
significant contribution of this study has been the use of a systems approach
that extends prior research in a number of important ways. First, a system was
explicitly defined that included the relevant environment and context in which
appropriate use of addiction medications occur (Figure 1). Although prior
studies have developed conceptual models related to the adoption of
medications in practice (Figure 3 and 4), the levels approach taken in this study
offers a broader framework for thinking about the system in which use of
addiction medication occurs. This is important because knowledge of a system
is a critical precursor to the development of effective interventions aimed at
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changing attributes of the system. In addition, significant attention was given
to the importance of dynamic complexity, and the potential unintended effects
of increasing medication use when feedback within a complex system is not
well understood.
7.3 Increasing Supportfo r Appropriate Use o f Addiction Medications
The substance abuse treatment infrastructure in this country is not capable of
delivering these emerging “evidence-based practices.” This situation is
particularly worrisome within the addiction field because, unlike other areas of
health care, there is no primary care for substance use disorders. Only the
specialty sector programs provide any care for addiction. The number of these
programs is inadequate and many are on the brink of closing. The clinical
workforce is turning over at the same rate as that in the fast-food industry.
Though very serious in the adult treatment sector, the situation is even worse
within the adolescent treatment sector (McLellan, 2006, p. 290).
It is against the backdrop of a national substance abuse treatment system in
dire need o f change that the topic of how best to increase support for appropriate use
of addiction medications must be examined. Although progress has been made in
recognizing the gap between research and practice (Institute of Medicine, 1998, 2006),
and closing the gap through a number of government sponsored initiatives (e.g., CTN,
PICs, TIPs), there remain many questions as to how to address pervasive systems
problems that threaten to stand in the way of a truly effective treatment enterprise. The
most significant systems problems include:
1) inability of social and health systems to identify and address potential
substance abuse cases; 2) inadequate and difficult access to any type of
substance abuse care for those who are identified; 3) a deteriorating
infrastructure, including the leadership, workforce, and information systems
with the treatment programs. These factors combine to produce inadequate
types, amounts, and quality of substance abuse treatment services for those
who need it (McLellan & Meyers, 2004, p. 764).
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This section does not attempt to offer solutions to the very complex problem of how to
rescue the ailing addiction treatment system, but instead focuses on practical ways to
increase support for appropriate use of addiction medications based on what was
learned from the present study. But clearly, this discussion cannot realistically be
separated from the larger systems problems, because increased use of addiction
medications ultimately requires a treatment system capable of delivering evidencebased practices.
Throughout this dissertation it has been argued that a systems approach is
necessary not only to understand the problem of limited support for addiction
medications, but also as a methodology for exploring how to improve this situation.
Here it is helpful to return to the steps outlined in section 2.3 that provide a useful
framework for exploring how best to increase support for appropriate use of addiction
medications, while at the same time recognizing that such interventions occur within a
challenged treatment system in need of significant changes (Hall, 1989). As previously
noted, the following steps involve taking the knowledge learned from the present
study and utilizing it to explore improved intervention strategies.
(1) Problem definition: Where are we now?
This study has focused primarily on the problem definition, and further
advancing the research literature regarding the limited support for addiction
medications across substance abuse treatment programs. Although prior research has
examined this issue from a number of perspectives, this study utilized a systems
approach to uniquely describe the system in which the problem occurs, its relative
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environment and context, and the specific individual and organizational factors that
simultaneously influence medication attitudes. Thus one answer to where are we now
is found throughout this dissertation, with specific empirical outcomes summarized in
the previous sections.
Another important aspect of this step relates to how a particular treatment
program develops an understanding of its particular intervention needs. Discussed in
section 3.4.2, the TCU Organizational Readiness for Change (ORC) assessment, is an
ideal tool for exploring a programs’ needs specific to staff attributes, available
resources, motivation for change, and organizational climate (Lehman et al., 2002). In
addition, The Change Book: A Blueprint fo r Technology Transfer, provides guidance
on how programs should go about clarifying the problem definition (Addiction
Technology Transfer Centers, 2000).
(2) Value system design: Where do we want to be, what values will guide us in the
process o f getting there, and how do we measure attainment o f the objective(s)?
A blueprint o f the value system design has been meticulously outlined in the
IOM reports briefly reviewed in this dissertation (Institute of Medicine, 1998, 2000,
2001,2005). Although many of the recommendations are aimed at improving the
overall healthcare and substance abuse treatment system, they also provide a clear
framework for answering the above questions specific to addiction medications. Thus,
the six aims of high-quality health care can be adopted for addiction medications as
follows (Institute of Medicine, 2006):
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Safe: All necessary precautions should be taken to avoid causing harm to
patients as a result of appropriate use of addiction medications aimed at
helping them. Among the best approaches for effectively addressing this issue
is considering the unintended consequences of using addiction medications,
detailed in the next section of this chapter.

•

Effective: Appropriate use of addiction medications should be based on solid
empirical evidence that they provide improved clinical outcomes, meet FDA
approval, and not be under or over-utilized in practice.

•

Patient-Centered: Appropriate use of addiction medications should be guided
by individual patient preferences, needs, and values. All decisions related to
use of addiction medications should reside with the patient.

•

Timely: Wait times and delays related to patient access to addiction
medications should be minimized. This also suggests that if patients are
unaware of addiction medications (as is frequently the case), they should be
educated about appropriate medication options in a timely matter (i.e.,
preferably at the time of treatment planning).

•

Efficient: Barriers to efficient use of addiction medications should be identified
and minimized, such as those outlined in the discussion about methadone
(3.2.2).

•

Equitable: Appropriate use of addiction medications should not vary in quality
because of personal characteristics such as gender, ethnicity, geographic
location, or socioeconomic status.
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Further details specific to determining the optimal settings for delivery of addiction
medications, the necessary structural changes needed to dispense medications in
treatment programs, and how best to measure whether use of addiction medications
meets the quality standards set forth in the IOM reports are beyond the scope of this
section. However, many of the answers are well outlined in the IOM reports specific
to substance abuse treatment services (Institute of Medicine, 1998, 2006).
(3) Systems synthesis: What are the possible options fo r solving the problem?
Considering the challenges present in the addiction treatment system, and the
results from the present study, there are a number of practical options for increasing
support for appropriate use of addiction medications that would likely prove useful.
•

Hire graduate trained clinicians: Findings suggest that graduate trained
clinicians have more favorable attitudes towards use of addiction medications,
and have the necessary skills to appropriately treat mental health disorders
common in substance abuse populations. Although most often there are
increased costs associated with hiring professional counselors, payees of
addiction treatment services now recognize that clinical outcomes are
optimized, and costs ultimately reduced, when programs utilize professionally
trained clinicians. This creates an obvious challenge for financially constrained
programs, and will likely be a key determinant in restructuring the future
addiction treatment system.

•

Treat mental health disorders present in substance abuse populations:
Substance abuse programs that do not treat co-occurring mental health
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disorders will likely not remain in business in the future. Payees of addiction
treatment services now recognize the necessity of addressing mental health
problems in optimizing clinical outcomes. Because this study found that
support for psychiatric medications was among the most robust predictors of
attitudes towards addiction medications, efforts by programs to offer
psychiatric services will likely have a positive influence on the appropriate use
of addiction medications.
•

Develop a referral network: In lieu of treatment programs having prescribers
on staff (due to expense), program administrators should establish an outside
network of prescribers that counseling staff can trust and rely upon to prescribe
both psychiatric and addiction medications. Although this may appear a simple
proposition, in all likelihood, developing such a network may require
significant time and energy (although not necessarily money). Optimal referral
networks are based upon relationships between prescribers and treatment staff
that ideally involve face-to-face interactions, regular contact, and mutual
respect for each other’s work. Among the most viable options are linkages with
primary care medicine. A seminar sponsored by NIDA titled Primary care and
drug abuse: A research-setting round table seminar provided evidence for the
need for more collaboration between primary care medicine and substance
abuse treatment, but also delineated some very specific steps that will likely
encourage more linkages in the future (NIDA, 2003).
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Require staff to attend CEU trainings specific to learning evidence-based
interventions that utilize, as one component, addiction medications: This study
found evidence that independent of academic education, CEU trainings and
workshops can play an important role in increasing support for appropriate use
of addiction medications. Because CEUs are required for many treatment staff,
program administrators can encourage and pay for trainings that focus on
evidence-based interventions that combine psychosocial approaches with
addiction medications (Volpicelli, Pettinati, McLellan, & O'Brien, 2001).
Further, research related to attitude-behavior consistency suggests that the
more staff are exposed to information about addiction medications, and are in a
position to effect positive change with patients, the greater the likelihood
addiction medications will be used more in practice (Fazio, 1990).

•

Provide information about addiction medications to clinical staff and patients:
Treatment programs should make available to patients and clinicians
information about addiction medications, their appropriate use in practice, and
possible unintended effects (see next section). Information can be in the form
of popular articles, summary reviews from newsletters like the Harvard Mental
Health Letter, or in some cases, marketing materials from pharmaceutical
companies (bearing in mind the likely bias). Information can be made available
in waiting rooms, counseling offices, group therapy rooms, and in other areas
frequented by patients and/or clinical staff.
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Provide in-house medication services as a routine component of treatment:
This option provides patients with a seamless ability to receive both counselor
and medication services under one roof, further optimizing clinical outcomes.
However, it also requires treatment programs to invest in the infrastructure
necessary to support prescribers, resulting in more significant programmatic
changes that necessitate careful planning and implementation (see Step 7). As
illustrated in Section 2.1, rash policy decisions to implement evidence-based
practices that do not take into consideration the views of all stakeholders in a
change are likely to fail.

(4) Systems analysis: What are the best alternatives or options fo r solving the
problem based on where we want to be?
Every substance abuse treatment program has a unique set of challenges that
must be overcome to successfully achieve the envisioned value system design, and
deliver high-quality care specific to addiction medications. Such challenges are most
often identified and studied during the problem definition phase, so that during this
step, optimal solutions can be matched with specific program needs using the criteria
outlined in Step 2.
During this phase, the TOP approach outlined in Section 2.4 can be useful for
exploring various options from multiple perspectives (Linstone, 1999). For example,
the effects of hiring graduate-trained clinicians can be examined through the lens of
the technical perspective by considering costs and benefits (i.e., higher cost but able to
meet contractual requirements), and the impact on quantitative clinical outcomes
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based on increased ability to deliver evidence-based practices. Alternatively, the
decision to hire professional clinicians can be examined through the organizational
perspective that considers how such an intervention would impact other treatment staff
and the social dynamics existing within a program. Finally, the personal perspective
could be used to examine how hiring one influential clinician supportive of addiction
medications might lead others to follow suit. Final decisions about any particular
interventions would likely benefit from consideration of all three perspectives.
(5) Optimization: How can we optimize the alternative solutions so that each is
the best it can be?
Similar to the previous step, fine-tuning viable intervention options is a process
unique to each treatment program. This step ideally involves administrators, treatment
staff, and expert change agents carefully considering all the possible effects of each
option, and determining which interventions will most likely increase use of addiction
medications while minimizing risks and costs. Key to this step is assessing the
possible unintended consequences that may result from particular interventions (see
next section).
(6) Decision making: What is the ideal solution to the problem?
Optimal interventions to increase support and appropriate use of addiction
medications will vary across treatment programs and service settings. Final decisions
about specific interventions are ideally guided by the criteria established in the value
systems design (Step 2), and result from the collaborative efforts of all stakeholders
involved in the decision-making process.
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(7) Planning fo r action: How best can we implement the solution?
In Section 3.2, the distinction between efficacy and effectiveness research was
introduced to make the point that evidence-based practices developed under carefully
controlled conditions may likely prove challenging to implement in typical substance
abuse treatment programs where diverse patient populations, treatment staff, and
limited resources can all impact clinical outcomes. It has been noted that the
government spends approximately 95 billion dollars a year on research to develop new
treatments across all healthcare related fields, about 1.8 trillion dollars a year on
supports for services to people, and less than 1 billion dollars a year on
implementation research (Fixen, 2006). As a result, there is a tremendous deficit in
knowledge about how best to implement solutions, including interventions to increase
support and appropriate use of addiction medications, into clinical practice. Thus
implementation is the missing link between research and practice.
Fixen (2006) has suggested that there is considerable empirical evidence for
what does not work in terms of implementation, including: (a) dissemination of
information by itself, including practice guidelines, research literature, and mailings;
(b) training alone without additional follow-up and support; (c) implementation
without changing supporting roles and functions; and (d) implementation by edict. As
a result, the options suggested in Step 3 will likely fail as stand-alone interventions,
and must be implemented within a larger framework that considers the stages of
implementation and how best to accomplish the goals and objectives of each stage.
Following a seminal review of the implementation literature, Fixen et al. (2005) put
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forth a conceptual framework for implementation of well-defined programs and
practices, that can be used as a guide for how best to implement interventions specific
to addiction medications. Although the framework initially overlaps with the steps
outlined here, it primarily concerns itself with answering the question: how can we
implement the solution? Although the details of the framework are beyond this section
to review, it is interesting to note that a critical aspect of implementation involves
considering the simultaneous and multilevel nature of the variables involved in a
particular intervention, within a levels paradigm similar to that suggested in Chapter 2.
7.4 Unintended Consequences
This study was motivated by a desire to improve treatment outcomes for
patients with substance abuse disorders, particularly those who consistently relapse
and have relied solely on psychosocial interventions. There is significant evidence that
the majority of patients fall into this category (Hubbard et al., 2001; Institute of
Medicine, 1998; McLellan et al., 2000), and that long-term outcomes may be
improved in many of these patients by combining psychosocial treatment with
addiction medications (Institute of Medicine, 1998, 2006; Volpicelli et al., 2001). But
despite this evidence, few researchers have thought much about how increasing
support for addiction medications might have unintended consequences.
Central to the systems approach is recognizing that any time a change is made
to one part of a system, quite often there are unanticipated effects for the entire
system. Chapter 2 introduced the idea of dynamic complexity, and discussed how the
best intentions to improve a situation can often backfire as a result of not fully
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understanding the role of feedback in a system. When many variables are changing
simultaneously, studies have shown that the ability of humans to make reasonable
inferences about the behavior of a system over time are significantly limited, even
when given complete and perfect knowledge of a system (Sterman, 2000). Given that
most working in the substance abuse treatment field are stressed for time and operate
with limited financial resources, it is not surprising that most change-related decisions
are often based on incomplete information, habits, rote procedures, and simple mental
models that quite often lead to outcomes that are less than desirable.
The previous section (and 3.1) highlighted the dire state of the current
substance abuse treatment system, illustrating that the challenge is not to just increase
support for addiction medications, but to enact entire systems changes that improve
overall levels of addiction care on many fronts. As a result, there are inherent dangers
in going about fixing the current system without significant thought as to how best to
approach such a complex undertaking. The purpose of this section is not to discuss all
the possible outcomes from such system-wide changes, but to highlight the most
probable unintended effects of increasing use of addiction medications, and offer
suggestions on how they may be appropriately addressed.
Over-reliance on use o f addiction medications. A quick-fix mentality
pervades society, fueled by advertising media suggesting that there are simple and fast
solutions to losing weight, quitting smoking, and ending addictions. Even more, many
of these solutions are based solely on the use of a medication. In the forward to the
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book Combining Medication and Psychosocial Treatments fo r Addiction,
Distinguished Professor of Psychology and Psychiatry, William R. Miller states:
I fear that the dispensing of medications for addictions could be thought of
much as the prescription for antibiotics for infections. There are common
features, of course, such as problems with medication adherence, but
addictions center not on an invasive organism, but on a pervasive behavior. A
busy schedule and a mind-set to treating acute illnesses can easily combine to
produce a ‘Just do it!’ approach that frustrates both patient and practitioner,
and becomes a self-perpetuating cycle (Volpicelli et al., 2001, p. xii).
It is not hard to see how counselors and prescribers, given time constraints and
limited resources, might inadvertently scale back psychosocial interventions in lieu of
medications appearing to have a positive effect. Patients may report significant
behavioral change after beginning a medication, unaware they are overstating the
pharmacological benefit and underestimating the need to maintain concurrent
psychosocial recovery activities. Over time, both patient and clinician may fall into the
trap described above, where relapse becomes inevitable.
For clinicians, the solution to a quick-fix mentality is maintaining awareness
that addictive disorders are long-term, chronic medical conditions that require
attention to multiple factors over long periods of time (McLellan et al., 2000;
McLellan, McKay, Forman, Cacciola, & Kemp, 2005). Although addiction
medications can be useful in preventing relapse, they are not panaceas for many of the
problems that co-occur with substance abuse, such as developmental deficits and
constrictions (e.g., self-regulation problems, inability identify and use emotions),
relationship problems, legal issues, and mental health disorders (McLellan et al.,
1993). Thus formal academic education, continuing education trainings, and clinical
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supervision all provide valuable opportunities for educating counselors and prescribers
about the nature o f addiction, the appropriate use of medications, and the most
effective methods for obtaining optimal outcomes.
Policy decisions that lead to adverse outcomes due to lack o f buy-in from
impacted stakeholders. At a time when there is a significant push to incorporate
evidence-based practices into substance abuse treatment, there is also the risk that rash
efforts to do so may have unintended outcomes. An example of how this might happen
was offered in Section 2.1, where a well-meaning program director quickly
implements a policy to increase use of addiction medications, and then scratches his
head months later when counselor turnover doubles and patient dropout rates increase.
As discussed in the previous section of this chapter, there is significant evidence that
implementing evidence-based practices, including appropriate use of addiction
medications, is a complex undertaking that requires a significant amount of time and
effort (Addiction Technology Transfer Centers, 2000; Fixen et al., 2005). Attempts by
program administrators to short-change the implementation process will very likely
lead to a host of unintended consequences that ultimately undermines the use of
medications as an evidence-based treatment. Therefore, efforts to increase appropriate
use of addiction medications in substance abuse treatment programs should include
strong caveats to all counseling staff, administrators and prescribers, that findings
from implementation research should guide programmatic changes.
Unbalanced consideration o f the benefits, risks, and costs. Use of addiction
medications is not without risks and costs. Although the benefits of these medications
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have been reviewed in Section 3.2, little has been said about the potential hazards they
pose to patients and the economic impact of increasing their usage within the
substance abuse treatment system. Although studies reviewed in section 3.2 provided
evidence o f the safety of FDA approved addiction medications, there are numerous
examples of drugs that were long thought to be safe, but later confirmed to actually
cause more harm than good (i.e., Prempro®, Vioxx®, Redux®) (Avorn, 2004).
Although it is not likely that naltrexone, methadone, or buprenorphine will suffer the
same fate, each o f these medications can produce adverse side effects that vary
between patients, and at times, necessitate that a patient stop taking a particular
medication.
Prescribers and patients must always recognize that even mild side effects,
including drowsiness, nausea, and headaches, can influence daily activities like
driving and walking, resulting in consequences beyond the initial side effects o f the
drug (e.g., car accident, fall). Also, patients in treatment for substance abuse
commonly have medical issues that require pharmacotherapy. Although patients,
prescribers and pharmacists are jointly responsible for assessing risks associated with
drug interactions, there is always a chance that such interactions get overlooked. There
is also the issue about how to appropriately address medication risks clinically.
The most commonly consulted source for risk information is the ponderous
Physicians’ Desk Reference, where its depiction may be both overwhelming
and useless. The PDR uses an odd format for describing side effects. Its 3,500
pages of tightly packed small type comprise the FDA sanctioned listings that
each manufacturer provides for its drugs; most descriptions are thousands of
words long. Confusingly, risks can appear under one or more of several
headings: Warnings, Contraindications, Precautions, and Adverse Reactions
(Avorn, 2004, p. 163).
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If addiction medications are to be used more frequently in substance abuse treatment,
counselors and prescribers ideally need tools beyond the PDR that accurately and
concisely characterize side effects as well as benefits, and help patients make informed
decisions about their care. Such tools may include web-based applications that review
benefits and risks, brief publications that can be shared with patients, and in some
cases, marketing materials from pharmaceutical manufacturers. In a recent edition of
the Addiction Professional (2007), the official magazine of the National Association
of Alcohol and Drug Abuse Counselors, an article titled Pharmacotherapy:
Integrating new tools into practice provides an example of where counselors can gain
knowledge of how best to utilize addiction medications in practice.
In addition to balancing benefits and risks, the equation must also include the
economic impact of addiction medications for patients, as well as programs that offer
medication services. Numerous studies have cited cost as a significant barrier to
adoption (Mark, Kranzler, Poole et al., 2003; Mark, Kranzler, & Song, 2003; Thomas
et al., 2003), and for newer medications without generics (e.g., Subutex®, Suboxone®,
Vivitrol®), this is legitimate issue with unintended consequences. One concern
regarding the treatment of opiate addiction is that a two-tier system will develop,
where patients with insurance will receive office-based treatment using
buprenorphine, and those without insurance will have no alternative but to seek help
from methadone maintenance clinics. In a similar manner, I recently had a
conversation (2006) with a sales manager for the company marketing Vivitrol® - the
newly FDA approved, extended-release, injectable naltrexone. Because the medication
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requires a monthly injection, he said patients ideally would have the cost covered by
insurance not under their medication formularies, but as a surgery. Without insurance
he estimated the cost around $600 per month. With a significant population of
substance abusing patients having no insurance, or means for paying for addiction
medications, the issue of cost has no simple solutions.
Another concern related to increasing use of addiction medications in
substance abuse treatment programs is the ability of program administrators to
effectively manage the costs associated with having prescribers on staff. As McLellan
and Meyers (2004) have pointed out, most program administrators have minimal
graduate business education, have commonly worked as counselors before taking on
administrative roles, and often work second jobs as a way of improving their salaries.
As a result, the development of an infrastructure to support medications services,
given that many programs are already financially unstable, may present challenges
beyond the capabilities of many administrators. For many programs, the best solution
is to invest resources into a referral network of prescribers that are willing to work
closely with counseling staff.
In summary, efforts to increase appropriate use of addiction medications
should also include the development of a framework that patients, prescribers, and
counseling staff can use to appropriately balance the benefits, risks and costs.
Although there is no simple formula that can be followed in all cases, such a
framework would optimally provide guidelines as to when addiction medications are a
realistic treatment option for a particular patient. Such a framework would likely
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consider a patient’s substance abuse history, treatment experiences, relapse rate,
insurance coverage, motivation for pharmacotherapy, and any contraindications.
Learning how to assess such factors and determine the best course of action in regards
to medication, ideally should begin during graduate training, and then be reinforced in
continuing education programs and clinical supervision. Substance abuse treatment
programs should also provide information to patients about the benefits, risks, and
costs of medication in literature describing treatment services and options.
Abuse and diversion o f opioid medications. An unintended consequence of
efforts to increase the use of medications to treat opioid dependence is a likely
increase in abuse and diversion of these medications. As reviewed in Section 3.2.2,
when used appropriately, methadone and buprenorphine can be effective treatments
for those struggling with addiction. But studies indicate that these medications are not
immune to problems of abuse and diversion (Cicero & Inciardi, 2005a, 2005b; Cicero
et al., 2005). Although much of this research has focused on the abuse and diversion
liability of these medications in pain patients, there is evidence that some abuse and
diversion may also occur among patients in substance abuse treatment. In one of the
only reported studies on the abuse potential of buprenorphine in office-based treatment
of opioid dependence, Cicero and Inciardi (2005) reported that a year after the launch
of Subutex® and Suboxone®, very little abuse was found, and much less than that for
methadone. Nevertheless, there is some indication that when methadone and
buprenorphine are diverted or abused, such behaviors are related to patients attempting

(
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to self-treat addiction symptoms outside the scope of formal treatment, particularly in
situations where there is limited treatment available.
With reports indicating a significant and growing problem with abuse of opioid
analgesics in general (SAMHSA, 2004), mechanisms to better understand the
prevalence, scope, and problem of abuse and diversion specifically in patients using
methadone and buprenorphine for addiction treatment purposes is needed. Joranson
and Gilson (2006) have argued that a public health approach provides the best
mechanism to collect such information. There is a significant need for better data
sources that investigate the motivations of abusers, the sources and ways in which
diversion occurs and the ethnographic variability in abuse and diversion across
different geographic locales.
Complex dosing may lead to non-adherence and increased likelihood o f
relapse. Although medications to treat substance abuse disorders can improve clinical
outcomes, prescribers and counselors may take for granted that patients take the
medications exactly as prescribed. Because addiction medications are commonly used
for many months or years, and can involve multiple or complicated dosing schedules,
patient adherence to treatment can suffer over time, particularly if the effects of the
medication are not obvious. Thus far, no specific studies have examined addiction
medication compliance, but there is evidence that for other chronic medical
conditions, patients’ ability to adhere to a specific pharmacotherapy regimen is
limited.
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Hypertension, diabetes, and asthma are also chronic disorders, requiring
continuing care throughout a patient’s life. Treatments for these illnesses are
effective but heavily dependent on adherence to the medical regimen for that
effectiveness. Unfortunately, studies have shown that less than 60% of adult
patients with type 1 diabetes mellitus fully adhere to their medication
schedule, and less than 40% of patients with hypertension or asthma adhere
fully to their medication regimens (McLellan et al., 2000, p. 1693).
The authors of the previous statement also make the point that low adherence to
medication regimens is associated with low socioeconomic status, lack of social
support, and significant psychiatric comorbidity - the same issues that plague patients
in substance abuse treatment. This suggests that when addiction medications are
utilized in such patient populations, both prescribers and counselors should become
acutely aware o f adherence issues, and develop strategies to improve medication
compliance.
In summary, addiction medications can play an important role in improving
treatment outcomes for many patients, but also can be responsible for a number of
unintended consequences. Hopefully by now, this dissertation has illustrated that the
addiction treatment enterprise is dynamically complex, involving many different
stakeholders, technologies, and treatments. Efforts to successfully incorporate
appropriate use o f addictiontmedications into such a complex system will likely fail if
the above factors are not taken into consideration. Perhaps the best mechanism for
addressing such issues is that outlined throughout this study: a systems approach.
7.5 Limitations and Directions fo r Future Research
There are several limitations with regard to findings presented in this
dissertation. First, the study was based on a secondary analysis of workforce surveys
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designed to gain general knowledge of workforce characteristics within the CTN, and
not on a random sample of substance abuse treatment programs throughout the
country. Participants in the CTN were selected because of their capacity and
willingness to become involved in research, and likely represent programs and staff
with a greater interest in research, medicine, and the incorporation of evidence-based
practices. Thus, generalizing findings from the present study to the entire treatment
industry should be done with caution, as programs outside of the CTN are likely to
have even greater resistance to use of addiction medications. Future research should
investigate workforce attitudes about addiction medications in such treatment settings,
particularly those that would most likely be resistant to pharmacotherapy.
A second limitation of this study is that only one independent variable
{Treatment Model) was measured using a standardized and validated assessment
measure (i.e., the Social Model Philosophy Scale). As discussed in Section 5.1, items
in the surveys were primarily constructed from the National Survey of Substance
Abuse Treatment Services, prior literature, or developed specifically for the surveys to
assess beliefs and opinions about practices and treatment interventions being tested or
potentially tested in the CTN. Future research on medication attitudes could benefit
from the inclusion of additional standardized measures.
A third limitation is the reduction in sample size from the original data set due
to missing data. The initial sample included more than 3,700 workforce staff nested in
348 treatment units, but dropped to 1,421 staff working in 237 treatment units
following listwise deletion. A limitation of multilevel modeling is that there can be no
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missing data on any of the predictors or dependent variables. Although a number of
software programs exist for estimating missing values in multilevel data sets, at
present, the reliability and validity of such imputation options is questionable;
therefore, listwise deletion is presently considered the safest option for addressing
missing data. However, it should be noted that despite the reduction in sample size, the
analyzed data set met sample size requirements for a multilevel analysis, and provided
robust estimates of predictors without any convergence problems. Although it would
have been useful to investigate whether significant differences existed between staff
members included in the present study and those with missing data, in practice this is
extremely hard to do because data are missing on multiple variables and at different
levels, often in complex ways that makes detection of relationships very difficult.
A fourth limitation of this study is that the results are based on measuring
treatment staff attitudes towards addiction medications, and not directly behavior.
Although there is significant evidence in the research literature that attitudes play a
crucial role in determining behavior, attitudes and behavior are not synonymous, and
there are likely to be discrepancies between what treatment staff say about addiction
medications and what they actually would do in practice. Such discrepancies should be
the focus of future research. Studies should also investigate how the determinants of
behavior differ from those found in the present study.
The findings are also limited by a number of constraints imposed on the
multilevel models. Because this was the first study to investigate both individual and
organizational factors within a multilevel framework, a decision was made to include

Chapter 7: Discussion

182

only those factors that had been shown in prior studies to consistently explain
medication attitudes. This provided a useful way to pare down the many possible
predictor choices and establish useful baseline multilevel models upon which future
studies could build. At the same time, this approach limited the explanatory power of
the models by the selected variables. Because models for methadone and
buprenorphine both produced significant random effects, and tests of interactions to
explain these effects proved non-significant, there is a clear need for additional
research to investigate other individual and organizational factors within a multilevel
framework.
Another factor that limits the findings is the lack of any interaction variables in
the models. Such variables are commonly used in multilevel analyses to account for
complex real-world relationships between multilevel predictors. But the downside of
interaction variables is that their inclusion can quickly result in models that become
extremely challenging to interpret. Because no prior studies provided clear evidence
for particular interactions among the chosen predictors, none were modeled in this
study. As a result, a strength of the findings is that they are based on the simplest of
multilevel models, and can be understood by a wide audience. However, even results
from this study indicate that attitudes towards addiction medications are a complex
blend of factors. Future studies based on more sophisticated multilevel models will
likely show that the determinants of attitudes are even more complex.
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